Interferons, interferon-like cytokines, and their receptors
Recombinant interferon‐α (IFN‐α) was approved by regulatory agencies in many countries in 1986. As the first biotherapeutic approved, IFN‐α paved the way for the development of many other cytokines and growth factors. Nevertheless, understanding the functions of the multitude of human IFNs and IFN‐l...
Saved in:
| Published in | Immunological reviews Vol. 202; no. 1; pp. 8 - 32 |
|---|---|
| Main Authors | , , |
| Format | Journal Article |
| Language | English |
| Published |
Oxford, UK; Malden, USA
Munksgaard International Publishers
01.12.2004
|
| Subjects | |
| Online Access | Get full text |
Cover
Loading…
| Abstract | Recombinant interferon‐α (IFN‐α) was approved by regulatory agencies in many countries in 1986. As the first biotherapeutic approved, IFN‐α paved the way for the development of many other cytokines and growth factors. Nevertheless, understanding the functions of the multitude of human IFNs and IFN‐like cytokines has just touched the surface. This review summarizes the history of the purification of human IFNs and the key aspects of our current state of knowledge of human IFN genes, proteins, and receptors. All the known IFNs and IFN‐like cytokines are described [IFN‐α, IFN‐β, IFN‐ε, IFN‐κ, IFN‐ω, IFN‐δ, IFN‐τ, IFN‐γ, limitin, interleukin‐28A (IL‐28A), IL‐28B, and IL‐29] as well as their receptors and signal transduction pathways. The biological activities and clinical applications of the proteins are discussed. An extensive section on the evolution of these molecules provides some new insights into the development of these proteins as major elements of innate immunity. The overall structure of the IFNs is put into perspective in relation to their receptors and functions. |
|---|---|
| AbstractList | Recombinant interferon‐α (IFN‐α) was approved by regulatory agencies in many countries in 1986. As the first biotherapeutic approved, IFN‐α paved the way for the development of many other cytokines and growth factors. Nevertheless, understanding the functions of the multitude of human IFNs and IFN‐like cytokines has just touched the surface. This review summarizes the history of the purification of human IFNs and the key aspects of our current state of knowledge of human IFN genes, proteins, and receptors. All the known IFNs and IFN‐like cytokines are described [IFN‐α, IFN‐β, IFN‐ε, IFN‐κ, IFN‐ω, IFN‐δ, IFN‐τ, IFN‐γ, limitin, interleukin‐28A (IL‐28A), IL‐28B, and IL‐29] as well as their receptors and signal transduction pathways. The biological activities and clinical applications of the proteins are discussed. An extensive section on the evolution of these molecules provides some new insights into the development of these proteins as major elements of innate immunity. The overall structure of the IFNs is put into perspective in relation to their receptors and functions. Recombinant interferon-alpha (IFN-alpha) was approved by regulatory agencies in many countries in 1986. As the first biotherapeutic approved, IFN-alpha paved the way for the development of many other cytokines and growth factors. Nevertheless, understanding the functions of the multitude of human IFNs and IFN-like cytokines has just touched the surface. This review summarizes the history of the purification of human IFNs and the key aspects of our current state of knowledge of human IFN genes, proteins, and receptors. All the known IFNs and IFN-like cytokines are described [IFN-alpha, IFN-beta, IFN-epsilon, IFN-kappa, IFN-omega, IFN-delta, IFN-tau, IFN-gamma, limitin, interleukin-28A (IL-28A), IL-28B, and IL-29] as well as their receptors and signal transduction pathways. The biological activities and clinical applications of the proteins are discussed. An extensive section on the evolution of these molecules provides some new insights into the development of these proteins as major elements of innate immunity. The overall structure of the IFNs is put into perspective in relation to their receptors and functions. Recombinant interferon-alpha (IFN-alpha) was approved by regulatory agencies in many countries in 1986. As the first biotherapeutic approved, IFN-alpha paved the way for the development of many other cytokines and growth factors. Nevertheless, understanding the functions of the multitude of human IFNs and IFN-like cytokines has just touched the surface. This review summarizes the history of the purification of human IFNs and the key aspects of our current state of knowledge of human IFN genes, proteins, and receptors. All the known IFNs and IFN-like cytokines are described [IFN-alpha, IFN-beta, IFN-epsilon, IFN-kappa, IFN-omega, IFN-delta, IFN-tau, IFN-gamma, limitin, interleukin-28A (IL-28A), IL-28B, and IL-29] as well as their receptors and signal transduction pathways. The biological activities and clinical applications of the proteins are discussed. An extensive section on the evolution of these molecules provides some new insights into the development of these proteins as major elements of innate immunity. The overall structure of the IFNs is put into perspective in relation to their receptors and functions.Recombinant interferon-alpha (IFN-alpha) was approved by regulatory agencies in many countries in 1986. As the first biotherapeutic approved, IFN-alpha paved the way for the development of many other cytokines and growth factors. Nevertheless, understanding the functions of the multitude of human IFNs and IFN-like cytokines has just touched the surface. This review summarizes the history of the purification of human IFNs and the key aspects of our current state of knowledge of human IFN genes, proteins, and receptors. All the known IFNs and IFN-like cytokines are described [IFN-alpha, IFN-beta, IFN-epsilon, IFN-kappa, IFN-omega, IFN-delta, IFN-tau, IFN-gamma, limitin, interleukin-28A (IL-28A), IL-28B, and IL-29] as well as their receptors and signal transduction pathways. The biological activities and clinical applications of the proteins are discussed. An extensive section on the evolution of these molecules provides some new insights into the development of these proteins as major elements of innate immunity. The overall structure of the IFNs is put into perspective in relation to their receptors and functions. Recombinant interferon- (IFN-) was approved by regulatory agencies in many countries in 1986. As the first biotherapeutic approved, IFN- paved the way for the development of many other cytokines and growth factors. Nevertheless, understanding the functions of the multitude of human IFNs and IFN-like cytokines has just touched the surface. This review summarizes the history of the purification of human IFNs and the key aspects of our current state of knowledge of human IFN genes, proteins, and receptors. All the known IFNs and IFN-like cytokines are described [IFN-, IFN-, IFN-, IFN-, IFN-, IFN-, IFN-, IFN-, limitin, interleukin-28A (IL-28A), IL-28B, and IL-29] as well as their receptors and signal transduction pathways. The biological activities and clinical applications of the proteins are discussed. An extensive section on the evolution of these molecules provides some new insights into the development of these proteins as major elements of innate immunity. The overall structure of the IFNs is put into perspective in relation to their receptors and functions. |
| Author | Walter, Mark R. Pestka, Sidney Krause, Christopher D. |
| Author_xml | – sequence: 1 givenname: Sidney surname: Pestka fullname: Pestka, Sidney email: pestka@waksman.rutgers.edu organization: Department of Molecular Genetics, Microbiology, and Immunology, Robert Wood Johnson Medical School, University of Medicine and Dentistry of New Jersey, Piscataway, NJ, USA – sequence: 2 givenname: Christopher D. surname: Krause fullname: Krause, Christopher D. organization: Department of Molecular Genetics, Microbiology, and Immunology, Robert Wood Johnson Medical School, University of Medicine and Dentistry of New Jersey, Piscataway, NJ, USA – sequence: 3 givenname: Mark R. surname: Walter fullname: Walter, Mark R. organization: Department of Molecular Genetics, Microbiology, and Immunology, Robert Wood Johnson Medical School, University of Medicine and Dentistry of New Jersey, Piscataway, NJ, USA |
| BackLink | https://www.ncbi.nlm.nih.gov/pubmed/15546383$$D View this record in MEDLINE/PubMed |
| BookMark | eNqNUV1v0zAUtdAQ67r9BZSnPZHsOnbiVExIo4KusA9pKoI3y0muhds0KbYr2n-PQ0qReGF-sH3lc451zjkjJ23XIiERhYSGdbVMgEIWp8UkT1IAngCkYd-9ICOaA8SQZ99OyOgIOiVnzi0BqGApf0VOaZbxnBVsRN7OW49Wo-1a9yYyxyFuzAqjau-7lWkxPKm2jvx3NDayWOHGd9adk5daNQ4vDueYfPn4YTG9je8eZ_PpzV1cccZ4zLQCyNlEU81zkVVQYJgKLUBzRaEsSpGXGcvqUlHO6hJSOhFpxemk1AwEZ2NyOehubPdji87LtXEVNo1qsds6mQsoWBrs_A8Y7AtBg_MxeX0Abss11nJjzVrZvfyTSwAUA6CynXMW9V8IyL4CuZR9urJPV_YVyN8VyF2gvvuHWhmvvOlab5VpniNwPQj8NA3un_2xnN8_hUugxwPdOI-7I13ZVQiKiUx-fZhJkX76vIDZe8nZLwgMrE8 |
| CitedBy_id | crossref_primary_10_3390_v12091009 crossref_primary_10_4049_jimmunol_180_3_1592 crossref_primary_10_3389_fimmu_2020_00526 crossref_primary_10_1038_srep32259 crossref_primary_10_1016_j_fsi_2022_03_035 crossref_primary_10_1371_journal_pone_0190334 crossref_primary_10_1016_j_dci_2020_103877 crossref_primary_10_1073_pnas_0610352104 crossref_primary_10_1371_journal_pone_0179781 crossref_primary_10_1016_j_cyto_2010_03_019 crossref_primary_10_1084_jem_20140280 crossref_primary_10_1016_j_cyto_2007_03_002 crossref_primary_10_1038_nri3344 crossref_primary_10_1128_JVI_01913_17 crossref_primary_10_1016_j_anireprosci_2024_107452 crossref_primary_10_1371_journal_pone_0018543 crossref_primary_10_1016_j_cytogfr_2007_06_009 crossref_primary_10_3390_vaccines12060583 crossref_primary_10_1186_s12884_023_05562_0 crossref_primary_10_1186_s12985_020_01478_9 crossref_primary_10_1016_j_domaniend_2013_12_003 crossref_primary_10_1016_j_prp_2023_155064 crossref_primary_10_21518_2079_701X_2022_16_8_79_87 crossref_primary_10_26508_lsa_201900447 crossref_primary_10_1016_j_aqrep_2021_100749 crossref_primary_10_1016_j_gene_2008_11_026 crossref_primary_10_4049_jimmunol_1401056 crossref_primary_10_3390_ani11020262 crossref_primary_10_3390_ijms241311086 crossref_primary_10_1016_j_antiviral_2019_104703 crossref_primary_10_3389_fimmu_2019_01711 crossref_primary_10_1007_s00262_010_0831_3 crossref_primary_10_1016_j_carbpol_2018_09_032 crossref_primary_10_1016_j_cytogfr_2013_04_002 crossref_primary_10_1016_j_brainres_2011_09_061 crossref_primary_10_1016_j_aquaculture_2008_11_015 crossref_primary_10_1089_jir_2007_9990 crossref_primary_10_3390_pharmaceutics16020180 crossref_primary_10_3390_v13030519 crossref_primary_10_1021_es304886y crossref_primary_10_1016_j_micpath_2024_106633 crossref_primary_10_3389_fimmu_2017_00304 crossref_primary_10_1016_j_micpath_2024_106873 crossref_primary_10_3390_curroncol31110536 crossref_primary_10_1016_j_scr_2013_09_010 crossref_primary_10_21518_2079_701X_2021_4_96_102 crossref_primary_10_3390_life13061310 crossref_primary_10_1038_nri3133 crossref_primary_10_3390_cancers13051037 crossref_primary_10_3390_cells8090963 crossref_primary_10_1016_j_fsi_2016_05_003 crossref_primary_10_1002_art_30399 crossref_primary_10_1021_acsami_7b18277 crossref_primary_10_1016_j_fsi_2013_07_012 crossref_primary_10_1016_j_molimm_2022_12_003 crossref_primary_10_1016_j_ygeno_2020_08_029 crossref_primary_10_4049_jimmunol_1502192 crossref_primary_10_1111_j_1365_2893_2008_01040_x crossref_primary_10_3390_ani11113306 crossref_primary_10_1007_s11739_013_1036_5 crossref_primary_10_1155_2010_706825 crossref_primary_10_1186_1471_2156_9_80 crossref_primary_10_1371_journal_ppat_1012612 crossref_primary_10_2334_josnusd_53_147 crossref_primary_10_1128_JVI_01571_06 crossref_primary_10_1016_j_fsi_2008_12_002 crossref_primary_10_1128_JVI_00279_18 crossref_primary_10_3389_fimmu_2022_812148 crossref_primary_10_1155_2012_734865 crossref_primary_10_3390_s20174776 crossref_primary_10_1128_JVI_02471_16 crossref_primary_10_1093_infdis_jit600 crossref_primary_10_1016_j_imlet_2024_106938 crossref_primary_10_1016_j_molimm_2020_01_020 crossref_primary_10_1128_JVI_80_9_4501_4509_2006 crossref_primary_10_1038_s41467_022_28645_6 crossref_primary_10_3389_fimmu_2017_01617 crossref_primary_10_1007_s13365_011_0031_8 crossref_primary_10_1111_bpa_12955 crossref_primary_10_1371_journal_pone_0033732 crossref_primary_10_1038_s41556_020_0545_5 crossref_primary_10_1089_jir_2014_0091 crossref_primary_10_1016_j_fsi_2011_02_003 crossref_primary_10_1007_s12016_009_8192_4 crossref_primary_10_1016_j_ctrv_2009_11_004 crossref_primary_10_3389_fcimb_2020_00225 crossref_primary_10_5582_irdr_2017_01066 crossref_primary_10_4161_jkst_23820 crossref_primary_10_1002_JLB_3MR0717_307R crossref_primary_10_1016_j_fsi_2023_109274 crossref_primary_10_2174_1381612826666200707121636 crossref_primary_10_1016_j_cyto_2013_06_309 crossref_primary_10_1128_jvi_01204_23 crossref_primary_10_1038_sj_icb_7100159 crossref_primary_10_1111_1348_0421_13205 crossref_primary_10_3390_ijms24043919 crossref_primary_10_4049_jimmunol_0902028 crossref_primary_10_1089_jir_2014_0083 crossref_primary_10_3389_fmicb_2021_692069 crossref_primary_10_1002_humu_21484 crossref_primary_10_3389_fviro_2021_759655 crossref_primary_10_1258_ebm_2011_011004 crossref_primary_10_3389_fnins_2014_00455 crossref_primary_10_1128_JVI_00303_10 crossref_primary_10_1111_asj_12807 crossref_primary_10_1093_bioinformatics_btn400 crossref_primary_10_1111_j_1582_4934_2005_tb00353_x crossref_primary_10_18821_0507_4088_2018_63_1_10_18 crossref_primary_10_1074_jbc_C800030200 crossref_primary_10_1016_j_pharmthera_2018_07_003 crossref_primary_10_3390_ijms19123879 crossref_primary_10_1095_biolreprod_108_073353 crossref_primary_10_3390_vaccines7040160 crossref_primary_10_4049_jimmunol_1402794 crossref_primary_10_15252_embr_202051252 crossref_primary_10_1016_j_dci_2014_08_007 crossref_primary_10_1016_j_addr_2007_07_002 crossref_primary_10_1038_bjc_2011_379 crossref_primary_10_1007_s00251_006_0081_x crossref_primary_10_1371_journal_pone_0106392 crossref_primary_10_1080_1744666X_2018_1519396 crossref_primary_10_1016_j_canlet_2017_04_005 crossref_primary_10_1002_eji_200635854 crossref_primary_10_1016_j_bcp_2016_09_029 crossref_primary_10_1097_MD_0000000000007288 crossref_primary_10_1016_j_aqrep_2022_101080 crossref_primary_10_1016_j_mad_2008_11_004 crossref_primary_10_1155_2013_148725 crossref_primary_10_1016_j_brainres_2021_147368 crossref_primary_10_1186_s12967_024_04881_w crossref_primary_10_1038_icb_2011_109 crossref_primary_10_1016_j_xcrm_2020_100019 crossref_primary_10_3389_fimmu_2020_580412 crossref_primary_10_3109_08916930903510971 crossref_primary_10_1016_j_cyto_2012_06_015 crossref_primary_10_1111_j_1398_9995_2010_02349_x crossref_primary_10_1073_pnas_2203760119 crossref_primary_10_1186_1743_422X_10_299 crossref_primary_10_1371_journal_ppat_1005040 crossref_primary_10_1007_s11033_014_3155_0 crossref_primary_10_1016_j_jaci_2011_01_023 crossref_primary_10_1016_j_rcreue_2017_11_002 crossref_primary_10_1016_j_dci_2021_103997 crossref_primary_10_2478_v10006_008_0013_z crossref_primary_10_1111_prd_12603 crossref_primary_10_1155_2016_5032051 crossref_primary_10_1016_j_fsi_2024_109510 crossref_primary_10_1016_j_pep_2015_07_007 crossref_primary_10_1016_j_immuni_2005_09_016 crossref_primary_10_1055_s_0042_1749646 crossref_primary_10_1038_s41419_023_05836_7 crossref_primary_10_1084_jem_20180325 crossref_primary_10_3109_08830185_2011_567361 crossref_primary_10_1016_j_cyto_2021_155777 crossref_primary_10_1016_j_gene_2015_09_058 crossref_primary_10_1177_15598276221123005 crossref_primary_10_1016_j_immuni_2008_07_016 crossref_primary_10_1016_j_jhep_2011_01_013 crossref_primary_10_1111_j_1399_3089_2005_00227_x crossref_primary_10_4049_jimmunol_0902065 crossref_primary_10_1189_jlb_1208761 crossref_primary_10_1016_j_ncrna_2024_01_013 crossref_primary_10_3109_08820139_2013_822766 crossref_primary_10_3389_fimmu_2019_01558 crossref_primary_10_3389_fimmu_2019_00229 crossref_primary_10_1039_C5MB00728C crossref_primary_10_1007_s00005_015_0365_7 crossref_primary_10_3389_fimmu_2022_888427 crossref_primary_10_1007_s12032_024_02416_3 crossref_primary_10_1016_j_immuni_2012_01_011 crossref_primary_10_1530_JOE_16_0490 crossref_primary_10_3390_cancers16081600 crossref_primary_10_4049_jimmunol_177_6_4055 crossref_primary_10_1155_2015_537637 crossref_primary_10_1074_jbc_M114_602474 crossref_primary_10_1080_13543784_2022_2022120 crossref_primary_10_1128_JVI_03117_13 crossref_primary_10_3389_fmolb_2022_813637 crossref_primary_10_1152_ajpgi_00470_2006 crossref_primary_10_3389_fimmu_2017_01232 crossref_primary_10_18231_j_ijcaap_2024_003 crossref_primary_10_1186_1743_422X_2_59 crossref_primary_10_1111_j_1600_065X_2008_00643_x crossref_primary_10_1038_s41564_019_0421_x crossref_primary_10_1016_j_bioelechem_2006_10_006 crossref_primary_10_1016_j_fsi_2017_01_033 crossref_primary_10_3389_fimmu_2023_1117760 crossref_primary_10_4049_jimmunol_0903374 crossref_primary_10_1016_j_abb_2012_03_001 crossref_primary_10_3390_jcm10030532 crossref_primary_10_1016_j_cyto_2018_10_023 crossref_primary_10_1074_jbc_M806019200 crossref_primary_10_1016_j_fsi_2024_109742 crossref_primary_10_1089_jir_2006_26_40 crossref_primary_10_1089_jir_2014_0227 crossref_primary_10_1007_s00018_022_04219_z crossref_primary_10_1007_s10753_016_0477_1 crossref_primary_10_1016_j_jneuroim_2010_03_018 crossref_primary_10_3389_fimmu_2017_01006 crossref_primary_10_3389_fmicb_2017_01635 crossref_primary_10_3389_fendo_2017_00232 crossref_primary_10_1111_pcmr_12620 crossref_primary_10_1038_s41467_024_53060_4 crossref_primary_10_1038_s41598_017_01695_3 crossref_primary_10_1038_s41598_024_77957_8 crossref_primary_10_1016_j_intimp_2016_10_012 crossref_primary_10_1016_j_aca_2014_10_009 crossref_primary_10_1016_j_drudis_2015_10_021 crossref_primary_10_1159_000508379 crossref_primary_10_1038_gene_2009_22 crossref_primary_10_1016_j_vaccine_2008_12_048 crossref_primary_10_1016_S1642_431X_12_60012_6 crossref_primary_10_1016_j_virol_2007_10_025 crossref_primary_10_1111_raq_12349 crossref_primary_10_1128_MCB_02256_06 crossref_primary_10_1080_14728222_2020_1762176 crossref_primary_10_1016_j_imlet_2008_11_002 crossref_primary_10_4049_jimmunol_177_1_383 crossref_primary_10_1038_nri3787 crossref_primary_10_4049_jimmunol_176_10_5995 crossref_primary_10_1016_j_fsi_2021_07_012 crossref_primary_10_1111_j_1365_2567_2008_02837_x crossref_primary_10_18632_oncotarget_18781 crossref_primary_10_1074_jbc_M109_021915 crossref_primary_10_1016_j_jaut_2019_02_003 crossref_primary_10_1111_j_1600_0463_2005_apm_386_x crossref_primary_10_1016_j_fsi_2024_109718 crossref_primary_10_1016_j_jped_2020_12_005 crossref_primary_10_21518_ms2023_379 crossref_primary_10_1016_j_dci_2017_02_005 crossref_primary_10_1016_j_humimm_2013_09_004 crossref_primary_10_1038_s41598_021_03067_4 crossref_primary_10_3389_fimmu_2020_01494 crossref_primary_10_3389_fimmu_2017_01224 crossref_primary_10_4049_jimmunol_179_1_463 crossref_primary_10_1016_j_soc_2007_07_011 crossref_primary_10_1111_j_1600_065X_2008_00698_x crossref_primary_10_1002_ijc_30159 crossref_primary_10_2217_nnm_2016_0058 crossref_primary_10_4049_jimmunol_182_3_1296 crossref_primary_10_1371_journal_pmed_0030289 crossref_primary_10_1016_j_fsi_2015_07_008 crossref_primary_10_1083_jcb_201412049 crossref_primary_10_1051_jbio_2018023 crossref_primary_10_1002_jgm_1493 crossref_primary_10_1016_j_heliyon_2023_e22597 crossref_primary_10_1051_medsci_20122812020 crossref_primary_10_3347_kjp_2017_55_6_587 crossref_primary_10_1016_j_clim_2020_108513 crossref_primary_10_1242_jcs_185421 crossref_primary_10_1093_femspd_ftab014 crossref_primary_10_1007_s00262_008_0579_1 crossref_primary_10_3389_fimmu_2018_00590 crossref_primary_10_1016_j_jhep_2014_11_020 crossref_primary_10_1016_j_vetimm_2009_09_007 crossref_primary_10_1146_annurev_immunol_032713_120211 crossref_primary_10_1128_JVI_02246_17 crossref_primary_10_1016_j_antiviral_2016_12_013 crossref_primary_10_1038_nri3581 crossref_primary_10_1089_jir_2014_0021 crossref_primary_10_1038_s41598_018_32549_1 crossref_primary_10_3390_vaccines9020164 crossref_primary_10_1016_j_jconrel_2016_06_033 crossref_primary_10_3390_biomedicines12081811 crossref_primary_10_3390_ijms241210115 crossref_primary_10_1111_raq_12333 crossref_primary_10_3390_ph3020406 crossref_primary_10_1051_e3sconf_202129203095 crossref_primary_10_4049_jimmunol_180_9_5991 crossref_primary_10_1016_j_humimm_2014_01_007 crossref_primary_10_3389_fimmu_2017_00354 crossref_primary_10_1073_pnas_1518240113 crossref_primary_10_1007_s00395_018_0709_7 crossref_primary_10_1016_j_cyto_2013_05_026 crossref_primary_10_3389_fimmu_2016_00598 crossref_primary_10_1016_j_pep_2013_10_019 crossref_primary_10_1016_j_vaccine_2013_02_016 crossref_primary_10_1016_j_str_2016_03_023 crossref_primary_10_1016_j_cytogfr_2014_10_011 crossref_primary_10_3390_polym11111862 crossref_primary_10_1038_nri1961 crossref_primary_10_3389_fimmu_2018_00777 crossref_primary_10_1186_s12985_016_0677_1 crossref_primary_10_1016_j_cyto_2009_03_005 crossref_primary_10_1111_febs_15961 crossref_primary_10_1371_journal_pone_0128636 crossref_primary_10_1089_jir_2007_0014 crossref_primary_10_1007_s00705_019_04438_z crossref_primary_10_1155_2012_534929 crossref_primary_10_1002_eji_202250307 crossref_primary_10_36290_vnl_2019_121 crossref_primary_10_4049_jimmunol_178_12_7540 crossref_primary_10_5713_ab_24_0257 crossref_primary_10_1146_annurev_immunol_032713_120231 crossref_primary_10_1002_pauz_201100402 crossref_primary_10_1016_j_bbrc_2006_04_043 crossref_primary_10_1002_jez_b_21102 crossref_primary_10_1007_s10875_011_9617_4 crossref_primary_10_3389_fimmu_2021_788368 crossref_primary_10_1128_MCB_05251_11 crossref_primary_10_1016_j_biochi_2007_05_001 crossref_primary_10_3390_cancers3043856 crossref_primary_10_1080_09273948_2017_1298822 crossref_primary_10_1080_14760584_2021_1927724 crossref_primary_10_1016_j_ijid_2012_08_004 crossref_primary_10_1371_journal_pone_0059307 crossref_primary_10_1016_j_jaci_2017_07_035 crossref_primary_10_1186_1743_422X_9_171 crossref_primary_10_1074_jbc_M114_591966 crossref_primary_10_1080_2162402X_2022_2054758 crossref_primary_10_3390_biom11020251 crossref_primary_10_1002_jgm_1174 crossref_primary_10_3390_ph3040795 crossref_primary_10_1016_j_cell_2011_06_048 crossref_primary_10_3390_v11020172 crossref_primary_10_4049_jimmunol_1800553 crossref_primary_10_1101_cshperspect_a028423 crossref_primary_10_3389_fimmu_2023_1273604 crossref_primary_10_1371_journal_ppat_1006867 crossref_primary_10_3892_mmr_2015_4277 crossref_primary_10_4049_jimmunol_2300651 crossref_primary_10_1016_j_postharvbio_2025_113404 crossref_primary_10_1074_jbc_M111_229120 crossref_primary_10_1016_j_atherosclerosis_2013_12_043 crossref_primary_10_1016_j_cyto_2017_04_012 crossref_primary_10_12688_f1000research_74758_2 crossref_primary_10_1016_j_fsi_2020_04_069 crossref_primary_10_3390_microorganisms11071817 crossref_primary_10_3109_03009734_2011_624649 crossref_primary_10_1016_j_jmb_2013_09_033 crossref_primary_10_3389_fvets_2022_972433 crossref_primary_10_3389_fimmu_2019_02263 crossref_primary_10_1016_j_jaci_2009_05_019 crossref_primary_10_3389_fimmu_2019_01176 crossref_primary_10_1016_j_antiviral_2020_104811 crossref_primary_10_1016_j_fsi_2017_12_049 crossref_primary_10_1186_s40168_019_0691_9 crossref_primary_10_1634_theoncologist_2015_0380 crossref_primary_10_1128_JVI_00319_11 crossref_primary_10_4049_jimmunol_177_2_822 crossref_primary_10_1016_j_dci_2025_105321 crossref_primary_10_1089_vim_2020_0085 crossref_primary_10_1111_febs_12666 crossref_primary_10_1002_advs_202308890 crossref_primary_10_1016_j_ces_2018_02_003 crossref_primary_10_1016_j_jmb_2006_11_053 crossref_primary_10_1016_j_aqrep_2022_101442 crossref_primary_10_1016_j_fsi_2005_01_010 crossref_primary_10_12688_f1000research_74758_1 crossref_primary_10_1016_j_dci_2014_04_004 crossref_primary_10_1177_1753425915575078 crossref_primary_10_17816_RCF192145_174 crossref_primary_10_1002_eji_201040668 crossref_primary_10_3390_v10040196 crossref_primary_10_3390_ijms241814101 crossref_primary_10_3390_v14040719 crossref_primary_10_1016_j_tim_2013_10_003 crossref_primary_10_1128_JVI_00744_16 crossref_primary_10_1208_s12248_012_9423_9 crossref_primary_10_1016_j_dci_2025_105338 crossref_primary_10_1038_nri2851 crossref_primary_10_1016_j_cyto_2011_10_011 crossref_primary_10_3389_fimmu_2024_1385473 crossref_primary_10_1128_AAC_02427_15 crossref_primary_10_1016_j_immuni_2007_06_009 crossref_primary_10_1128_JVI_07147_11 crossref_primary_10_1016_j_cytogfr_2010_08_003 crossref_primary_10_1016_j_fsi_2020_04_044 crossref_primary_10_1158_0008_5472_CAN_05_3653 crossref_primary_10_3389_fcvm_2024_1357343 crossref_primary_10_1016_j_crviro_2021_100014 crossref_primary_10_1038_nri2623 crossref_primary_10_3892_ol_2022_13355 crossref_primary_10_7554_eLife_65109 crossref_primary_10_1007_s00213_019_05253_9 crossref_primary_10_3390_v14071456 crossref_primary_10_1016_j_bcp_2022_115246 crossref_primary_10_1186_s12967_020_02219_w crossref_primary_10_1111_cea_13082 crossref_primary_10_1016_j_cyto_2025_156888 crossref_primary_10_1111_iji_12055 crossref_primary_10_3389_fimmu_2022_971674 crossref_primary_10_1093_intimm_dxh318 crossref_primary_10_1371_journal_pone_0215062 crossref_primary_10_3389_fimmu_2021_783725 crossref_primary_10_1016_j_jhep_2008_07_034 crossref_primary_10_1155_2011_235142 crossref_primary_10_1007_s00281_018_0700_2 crossref_primary_10_1016_j_cyto_2015_07_019 crossref_primary_10_3389_fonc_2021_769628 crossref_primary_10_1007_s11010_012_1360_5 crossref_primary_10_1016_j_biocel_2022_106187 crossref_primary_10_1016_j_semcancer_2022_02_017 crossref_primary_10_1089_vim_2020_0295 crossref_primary_10_3182_20090812_3_DK_2006_0101 crossref_primary_10_1080_13543784_2020_1797677 crossref_primary_10_1016_j_pharmthera_2004_12_002 crossref_primary_10_3390_ijms22094942 crossref_primary_10_18632_oncotarget_12512 crossref_primary_10_1089_jir_2012_0130 crossref_primary_10_3389_fcimb_2022_804011 crossref_primary_10_1016_j_cytogfr_2014_11_003 crossref_primary_10_4049_jimmunol_177_9_5920 crossref_primary_10_1089_jir_2021_0148 crossref_primary_10_3389_fimmu_2025_1496613 crossref_primary_10_1016_j_dci_2022_104614 crossref_primary_10_1186_s13567_022_01046_9 crossref_primary_10_3390_ncrna5010029 crossref_primary_10_4049_jimmunol_2100092 crossref_primary_10_1002_eji_200526258 crossref_primary_10_1021_bi901313x crossref_primary_10_1371_journal_ppat_1010072 crossref_primary_10_1007_s00705_021_05036_8 crossref_primary_10_1007_s00018_025_05625_9 crossref_primary_10_1038_s41420_022_01122_1 crossref_primary_10_1074_jbc_M109_002923 crossref_primary_10_1016_j_cytogfr_2024_08_005 crossref_primary_10_1002_adtp_202100035 crossref_primary_10_3389_fimmu_2021_742542 crossref_primary_10_3389_fimmu_2022_1013322 crossref_primary_10_1016_j_vaccine_2006_04_059 crossref_primary_10_3390_biomedicines12112559 crossref_primary_10_1016_j_dci_2023_104725 crossref_primary_10_3390_ijms232214394 crossref_primary_10_1080_1744666X_2021_1939686 crossref_primary_10_1093_nar_gks1215 crossref_primary_10_3389_fimmu_2022_873701 crossref_primary_10_1002_hep_24189 crossref_primary_10_1016_j_fsi_2023_108935 crossref_primary_10_1016_j_aquaculture_2013_01_017 crossref_primary_10_1038_cgt_2016_29 crossref_primary_10_1016_j_heliyon_2022_e11724 crossref_primary_10_1007_s00449_020_02457_8 crossref_primary_10_1007_s11926_018_0748_y crossref_primary_10_1007_s13277_015_3829_9 crossref_primary_10_1089_dna_2009_0963 crossref_primary_10_3390_ijms25010202 crossref_primary_10_1111_j_1462_5822_2007_01114_x crossref_primary_10_1146_annurev_virology_100114_055249 crossref_primary_10_1016_j_biochi_2007_03_001 crossref_primary_10_1016_j_ebiom_2022_104291 crossref_primary_10_1186_1471_2105_8_56 crossref_primary_10_2353_ajpath_2009_090328 crossref_primary_10_1002_biof_19 crossref_primary_10_1016_j_ymthe_2006_02_015 crossref_primary_10_3389_fimmu_2024_1439371 crossref_primary_10_1016_j_fsi_2023_108927 crossref_primary_10_1002_JLB_MR0318_122RR crossref_primary_10_3389_fcimb_2021_624094 crossref_primary_10_3851_IMP2106 crossref_primary_10_1016_j_jaut_2020_102486 crossref_primary_10_1016_j_jiph_2020_12_023 crossref_primary_10_1186_s12957_021_02272_9 crossref_primary_10_1016_j_molimm_2005_05_009 crossref_primary_10_1371_journal_ppat_1000017 crossref_primary_10_1111_j_1365_2567_2011_03412_x crossref_primary_10_1016_j_fsi_2007_07_008 crossref_primary_10_1038_gene_2014_18 crossref_primary_10_1016_j_imlet_2017_10_011 crossref_primary_10_1016_j_trecan_2015_10_004 crossref_primary_10_1111_j_1365_2893_2008_01011_x crossref_primary_10_1530_REP_17_0292 crossref_primary_10_1128_JVI_00231_09 crossref_primary_10_1134_S0026893311020178 crossref_primary_10_1016_j_spinee_2024_09_002 crossref_primary_10_1186_s12917_022_03178_8 crossref_primary_10_3389_fcimb_2014_00050 crossref_primary_10_1016_j_coi_2006_09_014 crossref_primary_10_1016_j_virusres_2023_199040 crossref_primary_10_2174_2666796701999201211205557 crossref_primary_10_1016_j_jaut_2018_10_015 crossref_primary_10_1038_s41698_021_00181_4 crossref_primary_10_1053_j_seminoncol_2014_08_002 crossref_primary_10_1155_2012_347141 crossref_primary_10_1016_j_cytogfr_2016_03_002 crossref_primary_10_1016_j_cytogfr_2016_03_005 crossref_primary_10_1016_j_mib_2013_04_009 crossref_primary_10_1111_j_1348_0421_2012_00419_x crossref_primary_10_1007_s00705_023_05792_9 crossref_primary_10_3390_ijms23169415 crossref_primary_10_1016_j_jim_2022_113313 crossref_primary_10_1158_1078_0432_CCR_16_1386 crossref_primary_10_3390_life13081672 crossref_primary_10_1128_MMBR_00027_06 crossref_primary_10_1007_s11684_024_1075_5 crossref_primary_10_1016_j_imlet_2019_01_013 crossref_primary_10_1038_mi_2012_35 crossref_primary_10_1080_02713683_2020_1817490 crossref_primary_10_3389_fimmu_2025_1533038 crossref_primary_10_1016_j_cytogfr_2016_03_008 crossref_primary_10_1136_lupus_2018_000270 crossref_primary_10_3389_fneur_2018_00458 crossref_primary_10_1002_cbi3_10009 crossref_primary_10_1248_bpb_b23_00741 crossref_primary_10_1016_j_dci_2013_07_002 crossref_primary_10_1016_j_ijbiomac_2020_05_134 crossref_primary_10_15204_jkobgy_2013_26_2_017 crossref_primary_10_1093_bioinformatics_btu659 crossref_primary_10_1016_j_biochi_2007_04_016 crossref_primary_10_1042_BJ20140644 crossref_primary_10_1074_jbc_M115_665943 crossref_primary_10_1155_2015_186274 crossref_primary_10_47456_bjpe_v9i1_39945 crossref_primary_10_1186_s12576_021_00805_1 crossref_primary_10_1111_j_0105_2896_2010_00909_x crossref_primary_10_1038_icb_2012_7 crossref_primary_10_1042_BA20060211 crossref_primary_10_1038_s41577_020_0288_3 crossref_primary_10_1371_journal_ppat_1003727 crossref_primary_10_1038_icb_2012_9 crossref_primary_10_1007_s10571_010_9593_x crossref_primary_10_1038_srep17577 crossref_primary_10_2217_fnl_15_6 crossref_primary_10_1016_j_immuni_2007_08_012 crossref_primary_10_1586_edm_11_64 crossref_primary_10_1165_rcmb_2016_0174OC crossref_primary_10_1016_j_fsi_2020_02_031 crossref_primary_10_3390_ph11030073 crossref_primary_10_3390_v13040584 crossref_primary_10_18632_aging_204098 crossref_primary_10_1016_j_pep_2014_08_010 crossref_primary_10_1097_QAI_0b013e31829c6de0 crossref_primary_10_59807_jlsar_v1i2_15 crossref_primary_10_1590_S0074_0276108042013003 crossref_primary_10_1016_j_micpath_2018_11_040 crossref_primary_10_1016_j_dci_2013_08_017 crossref_primary_10_1016_j_jprot_2021_104352 crossref_primary_10_1371_journal_ppat_1003721 crossref_primary_10_1089_jir_2023_0066 crossref_primary_10_1007_s10875_022_01339_w crossref_primary_10_1007_s12017_010_8112_z crossref_primary_10_4049_jimmunol_0804277 crossref_primary_10_1016_j_critrevonc_2016_06_013 crossref_primary_10_3390_v13122478 crossref_primary_10_1016_j_bbadis_2014_04_016 crossref_primary_10_1016_j_cellimm_2021_104411 crossref_primary_10_1128_mbio_02357_23 crossref_primary_10_1073_pnas_2316104121 crossref_primary_10_2220_biomedres_35_9 crossref_primary_10_3390_ijms24076426 crossref_primary_10_1016_j_it_2016_01_006 crossref_primary_10_1089_vim_2014_0028 crossref_primary_10_1016_j_it_2012_10_004 crossref_primary_10_3390_vaccines10020235 crossref_primary_10_1089_jir_2023_0037 crossref_primary_10_1007_s00018_017_2652_4 crossref_primary_10_1007_s11596_013_1130_y crossref_primary_10_1097_BOR_0b013e32832e089e crossref_primary_10_1016_j_jmb_2005_05_008 crossref_primary_10_1186_s11658_017_0057_x crossref_primary_10_3390_life13010009 crossref_primary_10_1016_j_jaut_2013_12_016 crossref_primary_10_1111_imm_12509 crossref_primary_10_1084_jem_20090222 crossref_primary_10_3390_vaccines11020480 crossref_primary_10_1016_j_vetmic_2023_109678 crossref_primary_10_1111_j_1574_695X_2007_00266_x crossref_primary_10_4103_mj_mj_26_21 crossref_primary_10_1016_j_dci_2022_104461 crossref_primary_10_1155_2016_5153184 crossref_primary_10_1016_j_dci_2014_01_001 crossref_primary_10_1111_j_1442_9071_2010_02457_x crossref_primary_10_1007_s12079_018_0486_y crossref_primary_10_1177_17448069231222403 crossref_primary_10_3390_cancers11101472 crossref_primary_10_1161_ATVBAHA_115_305464 crossref_primary_10_1016_j_biologicals_2012_07_006 crossref_primary_10_3389_fimmu_2020_606489 crossref_primary_10_1016_j_ijbiomac_2024_138242 crossref_primary_10_1002_jez_2108 crossref_primary_10_1155_2022_7137900 crossref_primary_10_1016_j_virusres_2016_05_015 crossref_primary_10_1165_rcmb_2013_0003OC crossref_primary_10_3390_pr6090138 crossref_primary_10_1111_febs_16420 crossref_primary_10_1371_journal_ppat_1009241 crossref_primary_10_4049_jimmunol_181_9_6467 crossref_primary_10_1182_blood_2008_03_144634 crossref_primary_10_3390_vaccines9040328 crossref_primary_10_1111_cei_12024 crossref_primary_10_1016_j_coviro_2011_10_016 crossref_primary_10_1371_journal_pntd_0003010 crossref_primary_10_1016_j_dci_2013_05_009 crossref_primary_10_1093_abt_tbab014 crossref_primary_10_1002_adtp_202200020 crossref_primary_10_1016_j_fsi_2015_03_015 crossref_primary_10_1189_jlb_0311166 crossref_primary_10_1111_j_1863_2378_2012_01528_x crossref_primary_10_1586_1744666X_3_4_579 crossref_primary_10_1016_j_psj_2022_102398 crossref_primary_10_1007_s13555_021_00583_z crossref_primary_10_3390_ijms21239249 crossref_primary_10_1161_JAHA_121_020754 crossref_primary_10_1155_2020_1372494 crossref_primary_10_1038_nmeth1068 crossref_primary_10_1196_annals_1373_014 crossref_primary_10_4049_jimmunol_1301796 crossref_primary_10_2478_v10006_010_0060_0 crossref_primary_10_1016_j_coviro_2011_10_026 crossref_primary_10_1093_jmcb_mjw042 crossref_primary_10_3390_cells14060400 crossref_primary_10_1186_s12967_023_04732_0 crossref_primary_10_1371_journal_pone_0089869 crossref_primary_10_3390_ijms19051379 crossref_primary_10_4049_jimmunol_0902346 crossref_primary_10_1074_jbc_M113_485847 crossref_primary_10_1038_mt_2008_113 crossref_primary_10_1016_j_bbadis_2009_10_004 crossref_primary_10_3389_fimmu_2021_696803 crossref_primary_10_1111_aor_14924 crossref_primary_10_1016_j_xcrm_2024_101569 crossref_primary_10_1074_jbc_M110_197921 crossref_primary_10_1089_jir_2018_0066 crossref_primary_10_1093_nsr_nwaa037 crossref_primary_10_3390_v10010046 crossref_primary_10_4049_jimmunol_180_4_2158 crossref_primary_10_4110_in_2025_25_e8 crossref_primary_10_1016_j_cytogfr_2016_09_001 crossref_primary_10_1016_j_immuni_2010_11_020 crossref_primary_10_2119_2008_00028_Chen crossref_primary_10_3389_fimmu_2017_01758 crossref_primary_10_1155_2022_2054431 crossref_primary_10_1016_j_fsi_2007_10_004 crossref_primary_10_1089_jir_2006_26_373 crossref_primary_10_4049_jimmunol_1201925 crossref_primary_10_1089_jir_2022_0158 crossref_primary_10_1016_j_dci_2013_05_020 crossref_primary_10_1002_art_34632 crossref_primary_10_1016_j_dci_2008_10_001 crossref_primary_10_1172_JCI139980 crossref_primary_10_1155_2023_2949008 crossref_primary_10_4049_jimmunol_1001473 crossref_primary_10_3390_ijms18071530 crossref_primary_10_1038_onc_2010_635 crossref_primary_10_1016_j_fsi_2017_08_046 crossref_primary_10_3390_ijerph192215050 crossref_primary_10_1016_j_gene_2015_04_087 crossref_primary_10_1007_s11262_017_1434_2 crossref_primary_10_1128_mBio_00799_19 crossref_primary_10_1089_dna_2011_1384 crossref_primary_10_1080_10428194_2021_1901092 crossref_primary_10_1089_jir_2018_0046 crossref_primary_10_1111_j_1600_065X_2011_01049_x crossref_primary_10_4049_jimmunol_2300081 crossref_primary_10_3390_ijms22084282 crossref_primary_10_1016_j_biochi_2007_02_009 crossref_primary_10_1016_j_cellimm_2016_09_003 crossref_primary_10_1111_j_1462_5822_2006_00716_x crossref_primary_10_1016_j_virol_2010_07_027 crossref_primary_10_17656_jsmc_10053 crossref_primary_10_1007_s11033_010_0087_1 crossref_primary_10_1016_j_febslet_2008_08_013 crossref_primary_10_1016_j_nbd_2021_105272 crossref_primary_10_1124_jpet_108_138263 crossref_primary_10_3390_genes13071250 crossref_primary_10_1110_ps_062283006 crossref_primary_10_3389_fimmu_2018_00299 crossref_primary_10_1016_j_molimm_2015_12_004 crossref_primary_10_3390_vaccines9040364 crossref_primary_10_1016_j_immuni_2006_08_014 crossref_primary_10_4049_jimmunol_2100622 crossref_primary_10_1128_JVI_01122_06 crossref_primary_10_1186_s13567_017_0456_z crossref_primary_10_21518_ms2022_047 crossref_primary_10_1002_pmic_200700020 crossref_primary_10_1089_jir_2013_0118 crossref_primary_10_1016_j_bihy_2008_06_004 crossref_primary_10_3390_v6124999 crossref_primary_10_1111_jfd_13755 crossref_primary_10_1371_journal_pone_0024291 crossref_primary_10_1002_hep_21312 crossref_primary_10_3389_fimmu_2014_00526 crossref_primary_10_1038_mt_2008_88 crossref_primary_10_1111_jvh_12817 crossref_primary_10_1016_j_bbcan_2012_04_007 crossref_primary_10_3109_08916930903510872 crossref_primary_10_1274_jmor_30_2 crossref_primary_10_1080_2162402X_2017_1314424 crossref_primary_10_3389_fimmu_2022_935800 crossref_primary_10_1016_j_cytogfr_2012_01_001 crossref_primary_10_1155_2011_479013 crossref_primary_10_3109_08820139_2013_804836 crossref_primary_10_1016_j_fsi_2018_02_024 crossref_primary_10_1007_s11926_005_0053_4 crossref_primary_10_1515_hsz_2016_0345 crossref_primary_10_3390_ph4101295 crossref_primary_10_1128_JVI_03051_13 crossref_primary_10_3389_fphys_2015_00129 crossref_primary_10_1016_j_immuni_2006_08_009 crossref_primary_10_1089_jir_2010_0078 crossref_primary_10_1016_j_dci_2016_03_020 crossref_primary_10_1093_molbev_msp074 crossref_primary_10_1038_s41423_019_0341_y crossref_primary_10_3390_ijms232415998 crossref_primary_10_1016_j_cytogfr_2014_05_002 crossref_primary_10_1111_j_1398_9995_2008_01826_x crossref_primary_10_1111_pim_12448 crossref_primary_10_1128_mbio_02415_22 crossref_primary_10_3389_fimmu_2020_606874 crossref_primary_10_3390_v1030383 crossref_primary_10_3390_ijms22168660 crossref_primary_10_7124_bc_000775 crossref_primary_10_1016_j_dci_2011_03_012 crossref_primary_10_1007_s42977_023_00153_8 crossref_primary_10_1016_j_archoralbio_2014_09_002 crossref_primary_10_3389_fimmu_2019_00732 crossref_primary_10_3390_vaccines12050477 crossref_primary_10_3390_v14020218 crossref_primary_10_1111_jdv_13303 crossref_primary_10_1089_jir_2022_0117 crossref_primary_10_1038_s41467_024_53039_1 crossref_primary_10_1016_j_semarthrit_2012_12_026 crossref_primary_10_4161_cc_23717 crossref_primary_10_3389_fimmu_2022_862764 crossref_primary_10_1371_journal_pgen_0020131 crossref_primary_10_1128_mBio_00422_18 crossref_primary_10_3389_fnbeh_2022_1006065 crossref_primary_10_1016_j_brainres_2010_07_077 crossref_primary_10_1016_j_vetmic_2023_109718 crossref_primary_10_1016_j_aquaculture_2024_741316 crossref_primary_10_1203_PDR_0b013e31819dc55c crossref_primary_10_1128_JVI_79_21_13778_13793_2005 crossref_primary_10_1371_journal_pone_0117397 crossref_primary_10_1128_JVI_01365_10 crossref_primary_10_1007_s11033_011_1227_y crossref_primary_10_1016_j_it_2009_06_003 crossref_primary_10_1038_s41598_019_40503_y crossref_primary_10_1093_infdis_jiq018 crossref_primary_10_2217_17460816_3_3_269 crossref_primary_10_1038_s41598_021_02522_6 crossref_primary_10_1038_sj_clpt_6100081 crossref_primary_10_1186_s12879_019_4654_3 crossref_primary_10_1089_jir_2010_0054 crossref_primary_10_1038_labinvest_3700444 crossref_primary_10_1042_BST20200900 crossref_primary_10_1099_jgv_0_001616 crossref_primary_10_1089_jir_2017_0076 crossref_primary_10_1016_j_beem_2015_09_004 crossref_primary_10_1099_jgv_0_000522 crossref_primary_10_1038_nri1684 crossref_primary_10_1002_art_24449 crossref_primary_10_1111_liv_12244 crossref_primary_10_1177_17448069211045211 crossref_primary_10_1016_j_clim_2013_02_013 crossref_primary_10_1074_mcp_M115_048413 crossref_primary_10_1155_2011_275617 crossref_primary_10_1093_noajnl_vdaa043 crossref_primary_10_1158_1078_0432_CCR_10_1114 crossref_primary_10_1016_j_virol_2013_02_015 crossref_primary_10_1074_jbc_M507788200 crossref_primary_10_3892_etm_2014_1868 crossref_primary_10_1016_j_actbio_2015_03_002 crossref_primary_10_1159_000493316 crossref_primary_10_3109_15476910903286733 crossref_primary_10_1371_journal_pone_0024252 crossref_primary_10_1002_iub_2222 crossref_primary_10_1016_j_cytogfr_2016_07_005 crossref_primary_10_1111_pcmr_12315 crossref_primary_10_1007_s13238_013_3021_1 crossref_primary_10_4049_jimmunol_180_6_3789 crossref_primary_10_1038_leu_2008_263 crossref_primary_10_1073_pnas_0804956105 crossref_primary_10_1016_j_antiviral_2010_10_005 crossref_primary_10_1016_j_fsi_2007_11_008 crossref_primary_10_1016_j_fsi_2024_109402 crossref_primary_10_1089_adt_2009_0228 crossref_primary_10_1016_j_ajpath_2021_03_006 crossref_primary_10_1016_j_jaut_2017_07_012 crossref_primary_10_1016_j_vetmic_2009_09_038 crossref_primary_10_1038_s41598_018_31301_z crossref_primary_10_1038_jid_2008_253 crossref_primary_10_1016_j_critrevonc_2020_103204 crossref_primary_10_1016_j_jim_2018_06_007 crossref_primary_10_1128_JVI_00489_06 crossref_primary_10_1074_jbc_M111_255570 crossref_primary_10_3389_fimmu_2017_00029 crossref_primary_10_4049_jimmunol_1101044 crossref_primary_10_1093_jac_dkp092 crossref_primary_10_3389_fimmu_2022_904875 crossref_primary_10_1016_j_canlet_2024_216988 crossref_primary_10_1186_s12931_022_02035_4 crossref_primary_10_1007_s12013_014_0199_7 crossref_primary_10_1042_BJ20060272 crossref_primary_10_1152_ajpendo_00659_2013 crossref_primary_10_1007_s00281_015_0539_8 crossref_primary_10_1016_j_cyto_2020_155359 crossref_primary_10_1016_j_virusres_2013_10_027 crossref_primary_10_1016_j_fsi_2015_12_002 crossref_primary_10_1016_j_micpath_2022_105452 crossref_primary_10_1038_leu_2008_280 crossref_primary_10_1016_j_aquaculture_2018_12_083 crossref_primary_10_1371_journal_pone_0108410 crossref_primary_10_3389_fimmu_2022_821816 crossref_primary_10_1128_JVI_79_24_15405_15416_2005 crossref_primary_10_1007_s00335_018_9772_5 crossref_primary_10_22328_2077_9828_2020_12_4_7_22 crossref_primary_10_1146_annurev_immunol_083122_043545 crossref_primary_10_1089_jir_2010_0091 crossref_primary_10_1016_j_trsl_2014_10_005 crossref_primary_10_1016_j_trsl_2011_01_006 crossref_primary_10_1111_j_1872_034X_2009_00602_x crossref_primary_10_1016_j_autrev_2022_103135 crossref_primary_10_1016_j_cyto_2020_155172 crossref_primary_10_3851_IMP2099 crossref_primary_10_1371_journal_ppat_1007778 crossref_primary_10_1155_2018_5906819 crossref_primary_10_1016_j_celrep_2016_12_047 crossref_primary_10_1016_j_jim_2007_08_012 crossref_primary_10_1016_j_bcmd_2010_05_009 crossref_primary_10_4049_jimmunol_1800576 crossref_primary_10_1586_14737140_7_1_79 crossref_primary_10_1128_JVI_01703_09 crossref_primary_10_1371_journal_pone_0175413 crossref_primary_10_1016_j_fsi_2020_06_036 crossref_primary_10_1016_j_antiviral_2006_07_011 crossref_primary_10_1007_s00705_016_3081_7 crossref_primary_10_3390_pathogens12020319 crossref_primary_10_1021_bi801588g crossref_primary_10_1084_jem_20190449 crossref_primary_10_1016_j_dci_2016_01_023 crossref_primary_10_1016_j_fsi_2016_01_037 crossref_primary_10_1203_01_pdr_0000219860_96732_09 crossref_primary_10_3390_v2112541 crossref_primary_10_1158_1078_0432_CCR_20_2564 crossref_primary_10_1016_j_coi_2024_102425 crossref_primary_10_1016_j_coi_2024_102427 crossref_primary_10_1007_s10528_010_9365_9 crossref_primary_10_1084_jem_20062545 crossref_primary_10_1089_jir_2012_0067 crossref_primary_10_4049_jimmunol_0800596 crossref_primary_10_1016_j_fsi_2018_04_012 crossref_primary_10_3389_fmicb_2019_00344 crossref_primary_10_3390_ijms151121045 crossref_primary_10_1089_jir_2009_0093 crossref_primary_10_1097_BOR_0000000000000653 crossref_primary_10_3389_fped_2024_1295133 crossref_primary_10_1155_2019_5370706 crossref_primary_10_4049_jimmunol_179_4_2134 crossref_primary_10_2147_JIR_S267280 crossref_primary_10_1016_j_cyto_2012_10_032 crossref_primary_10_1128_JVI_01093_12 crossref_primary_10_1002_cti2_1304 crossref_primary_10_1038_sj_emboj_7601149 crossref_primary_10_1517_17460441_1_1_69 crossref_primary_10_1016_j_jneuroim_2007_09_032 crossref_primary_10_3390_pathogens12020303 crossref_primary_10_1007_s13258_023_01421_6 crossref_primary_10_4049_jimmunol_1800598 crossref_primary_10_1016_j_semcancer_2008_09_003 crossref_primary_10_1128_JVI_01015_06 crossref_primary_10_3724_SP_J_1005_2008_00788 crossref_primary_10_1016_j_bbadis_2006_05_001 crossref_primary_10_1016_j_intimp_2014_08_010 crossref_primary_10_3390_ijms21176447 crossref_primary_10_3390_v1030545 crossref_primary_10_1038_srep37815 crossref_primary_10_1089_jir_2006_0107 crossref_primary_10_1111_jfd_13335 crossref_primary_10_1016_j_jcv_2017_12_016 crossref_primary_10_1038_gene_2008_87 crossref_primary_10_1016_j_micpath_2019_103919 crossref_primary_10_1089_jir_2009_0067 crossref_primary_10_1016_j_fsi_2018_10_038 crossref_primary_10_1084_jem_20111680 crossref_primary_10_1089_jir_2019_0051 crossref_primary_10_1111_odi_12390 crossref_primary_10_3389_fimmu_2019_02989 crossref_primary_10_1016_j_dci_2008_11_005 crossref_primary_10_1096_fj_06_6616com crossref_primary_10_1155_2014_315470 crossref_primary_10_1007_s00705_008_0232_5 crossref_primary_10_1016_j_cyto_2010_09_006 crossref_primary_10_1089_jir_2012_0080 crossref_primary_10_1038_s44319_024_00346_9 crossref_primary_10_1039_C4AN01305K crossref_primary_10_1016_j_smim_2006_12_006 crossref_primary_10_18632_oncotarget_19531 crossref_primary_10_1002_eji_202350384 crossref_primary_10_1016_j_gene_2018_05_041 crossref_primary_10_2139_ssrn_4106535 crossref_primary_10_1002_msj_20225 crossref_primary_10_1038_nri1604 crossref_primary_10_1038_s41392_024_01934_w crossref_primary_10_1089_vim_2022_0200 crossref_primary_10_3389_fimmu_2023_1279245 crossref_primary_10_1111_j_1468_1331_2012_03721_x crossref_primary_10_1089_jir_2005_25_749 crossref_primary_10_1016_j_seppur_2013_09_038 crossref_primary_10_1152_ajprenal_00487_2012 crossref_primary_10_1016_j_canlet_2017_08_037 crossref_primary_10_1111_j_1365_2826_2009_01821_x crossref_primary_10_1007_s41048_018_0070_2 crossref_primary_10_3390_ph8040793 crossref_primary_10_1016_j_molimm_2008_09_016 crossref_primary_10_1038_s41586_023_06816_9 crossref_primary_10_1089_jamp_2020_1628 crossref_primary_10_1016_j_antiviral_2009_04_004 crossref_primary_10_1007_s00432_010_0900_1 crossref_primary_10_2478_jvetres_2021_0011 crossref_primary_10_1074_jbc_M115_652156 crossref_primary_10_1038_s41467_021_26112_2 crossref_primary_10_1016_j_ijmm_2021_151491 crossref_primary_10_1093_jleuko_qiac011 crossref_primary_10_1016_j_dci_2018_03_011 crossref_primary_10_1074_jbc_M706816200 crossref_primary_10_1016_j_dci_2021_104211 crossref_primary_10_1053_j_seminoncol_2014_02_002 crossref_primary_10_1111_imm_12273 crossref_primary_10_2119_2008_00035_Gribar crossref_primary_10_1073_pnas_0609001104 crossref_primary_10_1074_jbc_RA118_007161 crossref_primary_10_2217_bmm_12_9 crossref_primary_10_1007_s00281_018_0710_0 crossref_primary_10_3389_fimmu_2024_1512353 crossref_primary_10_3390_pathogens12030437 crossref_primary_10_1016_j_cyto_2008_01_008 crossref_primary_10_1371_journal_ppat_1002159 crossref_primary_10_1002_jez_b_22559 crossref_primary_10_1152_ajpendo_90770_2008 crossref_primary_10_3389_fimmu_2022_963923 crossref_primary_10_1111_j_1365_2184_2008_00558_x crossref_primary_10_2217_fmb_10_105 crossref_primary_10_1111_j_1365_2249_2006_03253_x crossref_primary_10_1038_s41423_019_0237_x crossref_primary_10_1016_j_fsi_2015_07_020 crossref_primary_10_2174_1566523220666201127114845 crossref_primary_10_1016_j_it_2015_01_004 crossref_primary_10_1111_j_0105_2896_2009_00881_x crossref_primary_10_3390_cancers12071954 crossref_primary_10_4049_jimmunol_178_7_4576 crossref_primary_10_3389_fimmu_2022_1008072 crossref_primary_10_1016_j_micinf_2010_01_008 crossref_primary_10_1016_j_virol_2008_04_014 crossref_primary_10_17816_CI627301 crossref_primary_10_1111_j_1365_2249_2008_03739_x crossref_primary_10_1155_2020_6876920 crossref_primary_10_1016_j_jmb_2020_08_016 crossref_primary_10_1089_jir_2012_0052 crossref_primary_10_1038_nrd2422 crossref_primary_10_1080_14712598_2021_1933940 crossref_primary_10_1007_s00431_006_0339_1 crossref_primary_10_1128_IAI_00275_10 crossref_primary_10_1177_1744806916644927 crossref_primary_10_1089_jir_2006_26_804 crossref_primary_10_1016_j_theriogenology_2009_01_017 crossref_primary_10_1016_j_psychres_2009_10_012 crossref_primary_10_1128_JVI_79_21_13350_13361_2005 crossref_primary_10_1371_journal_ppat_1006980 crossref_primary_10_1038_cmi_2016_25 crossref_primary_10_1038_nri3806 crossref_primary_10_1016_j_ejca_2009_10_013 crossref_primary_10_1016_j_vetimm_2011_06_008 crossref_primary_10_4239_wjd_v12_i7_939 crossref_primary_10_1007_s00011_020_01382_6 crossref_primary_10_1016_j_lfs_2024_123301 crossref_primary_10_1074_jbc_M117_800755 crossref_primary_10_1016_j_chom_2014_11_004 crossref_primary_10_3389_fimmu_2022_951937 crossref_primary_10_3389_fphys_2014_00279 crossref_primary_10_3892_ijmm_2015_2213 crossref_primary_10_1158_2767_9764_CRC_24_0024 crossref_primary_10_1016_j_molimm_2015_02_015 crossref_primary_10_1684_ecn_2020_0443 crossref_primary_10_2217_imt_2015_0021 crossref_primary_10_1007_s12250_019_00085_5 crossref_primary_10_3389_fimmu_2024_1285411 crossref_primary_10_1128_JVI_01347_07 crossref_primary_10_1371_journal_ppat_1000196 crossref_primary_10_3390_v10090505 crossref_primary_10_32706_tusbid_1395894 crossref_primary_10_1055_s_0041_1735301 crossref_primary_10_1016_j_bmc_2020_115552 crossref_primary_10_1128_mBio_01223_19 crossref_primary_10_1016_j_addr_2007_12_002 crossref_primary_10_18632_oncotarget_23504 crossref_primary_10_3851_IMP1720 crossref_primary_10_1016_j_fsi_2020_09_018 crossref_primary_10_1016_j_intimp_2007_04_006 crossref_primary_10_1038_cmi_2017_1 crossref_primary_10_1002_eji_201646725 crossref_primary_10_1097_MCG_0b013e3180381584 crossref_primary_10_3390_fishes7010003 crossref_primary_10_3109_08923973_2012_672425 crossref_primary_10_3389_fimmu_2019_01009 crossref_primary_10_1371_journal_pone_0063940 crossref_primary_10_3389_fimmu_2021_613145 crossref_primary_10_1016_j_ejmech_2019_111686 crossref_primary_10_1111_j_1365_2249_2012_04638_x crossref_primary_10_1016_j_rvsc_2012_09_025 crossref_primary_10_3109_10409238_2012_729561 crossref_primary_10_4049_jimmunol_2101042 crossref_primary_10_1042_BST0340461 crossref_primary_10_3892_etm_2018_6227 crossref_primary_10_1038_s41467_021_24982_0 crossref_primary_10_1073_pnas_1921484117 crossref_primary_10_1111_j_1742_4658_2006_05176_x crossref_primary_10_1371_journal_pone_0029060 crossref_primary_10_1016_j_cyto_2011_09_003 crossref_primary_10_1128_mbio_02582_24 crossref_primary_10_1186_s12864_017_3641_6 crossref_primary_10_1097_TP_0b013e3181874989 crossref_primary_10_1002_ijc_24669 crossref_primary_10_1016_j_devcel_2024_02_005 crossref_primary_10_1111_jvh_12494 crossref_primary_10_1099_vir_0_81919_0 crossref_primary_10_4049_jimmunol_2400265 crossref_primary_10_1016_j_vaccine_2009_10_016 crossref_primary_10_1039_c0ib00099j crossref_primary_10_1007_s00277_010_1114_y crossref_primary_10_1016_j_vetmic_2018_11_017 crossref_primary_10_1158_0008_5472_CAN_05_1123 crossref_primary_10_1002_JLB_2MR0420_152R crossref_primary_10_3390_vaccines8030490 crossref_primary_10_3390_cells10081864 crossref_primary_10_1111_liv_12421 crossref_primary_10_3390_jcm10061164 crossref_primary_10_3390_ijms25105320 crossref_primary_10_1038_s41392_023_01434_3 crossref_primary_10_4049_jimmunol_177_5_3235 crossref_primary_10_1016_j_physbeh_2021_113593 crossref_primary_10_1038_emboj_2008_126 crossref_primary_10_1053_j_gastro_2006_10_028 crossref_primary_10_3389_fvets_2020_00045 crossref_primary_10_3389_fmolb_2019_00148 crossref_primary_10_1016_j_canlet_2009_05_020 crossref_primary_10_3389_fimmu_2024_1397117 crossref_primary_10_1371_journal_pone_0186105 crossref_primary_10_3390_biology10090856 crossref_primary_10_1089_dna_2012_1950 crossref_primary_10_1017_erm_2017_11 crossref_primary_10_21518_2079_701X_2022_16_23_126_135 crossref_primary_10_1016_j_imbio_2007_09_011 crossref_primary_10_1126_scitranslmed_abd8179 crossref_primary_10_18632_genesandcancer_37 crossref_primary_10_3233_JND_170294 crossref_primary_10_1371_journal_ppat_1000151 crossref_primary_10_2485_jhtb_31_23 crossref_primary_10_3389_fimmu_2021_624919 crossref_primary_10_1038_nrrheum_2018_31 crossref_primary_10_1038_s41392_022_01174_w crossref_primary_10_1186_ar2883 crossref_primary_10_3109_09513590_2012_743011 crossref_primary_10_1111_imr_12195 crossref_primary_10_1186_ar2884 crossref_primary_10_1016_j_ics_2005_09_010 crossref_primary_10_1016_j_kint_2022_02_031 crossref_primary_10_1016_j_bbcan_2013_11_003 crossref_primary_10_1097_CJI_0b013e3181d32e59 crossref_primary_10_4049_jimmunol_181_10_6757 crossref_primary_10_1016_j_heliyon_2024_e36220 crossref_primary_10_1021_bi100041f crossref_primary_10_1089_jir_2011_0034 crossref_primary_10_1016_j_rcreu_2017_04_002 crossref_primary_10_11118_actaun200654040111 crossref_primary_10_1186_1471_2164_7_254 crossref_primary_10_1371_journal_ppat_1003648 crossref_primary_10_1186_s13104_019_4562_z crossref_primary_10_1097_MPG_0b013e3181fb0cb9 crossref_primary_10_1016_j_virol_2016_04_022 crossref_primary_10_1111_imm_13779 crossref_primary_10_1186_s12943_025_02243_8 crossref_primary_10_1007_s12185_012_1116_8 crossref_primary_10_1371_journal_pone_0093396 crossref_primary_10_1007_s11864_014_0317_1 crossref_primary_10_1007_s12250_020_00208_3 crossref_primary_10_1016_j_dci_2017_07_017 crossref_primary_10_3390_bios11030094 crossref_primary_10_1038_bjc_2015_255 crossref_primary_10_1074_jbc_RA118_003617 crossref_primary_10_1111_aji_13320 crossref_primary_10_3389_fmicb_2025_1515241 crossref_primary_10_3390_cells11111767 crossref_primary_10_3389_fgene_2014_00418 crossref_primary_10_1099_vir_0_80904_0 crossref_primary_10_1016_j_gene_2007_03_018 crossref_primary_10_1038_s41598_019_45800_0 crossref_primary_10_1089_jir_2011_0048 crossref_primary_10_17650_2313_805X_2024_11_4_23_40 crossref_primary_10_1016_j_jinf_2013_09_024 crossref_primary_10_1002_glia_22608 crossref_primary_10_3389_fimmu_2016_00629 crossref_primary_10_1038_nrrheum_2009_237 crossref_primary_10_34133_research_0007 crossref_primary_10_1110_ps_073178108 crossref_primary_10_1210_endocr_bqab235 crossref_primary_10_31548_dopovidi2018_01_005 crossref_primary_10_1016_j_jri_2025_104453 crossref_primary_10_1089_jir_2013_0148 crossref_primary_10_3389_fcimb_2020_594621 crossref_primary_10_1155_2012_582716 crossref_primary_10_1016_j_onehlt_2023_100506 crossref_primary_10_1165_rcmb_2013_0013OC crossref_primary_10_1038_s41392_021_00604_5 crossref_primary_10_1016_j_bbrc_2007_12_137 crossref_primary_10_1134_S0026893315020077 crossref_primary_10_1158_1541_7786_MCR_08_0344 crossref_primary_10_3389_fimmu_2022_986840 crossref_primary_10_1016_j_ejphar_2022_175051 crossref_primary_10_1016_j_hoc_2014_02_001 crossref_primary_10_1021_acschembio_9b00912 crossref_primary_10_4049_jimmunol_0800621 crossref_primary_10_1172_JCI65180 crossref_primary_10_1074_jbc_M502586200 crossref_primary_10_3389_fimmu_2022_901913 crossref_primary_10_1016_j_tranon_2023_101742 crossref_primary_10_1074_jbc_M110_165936 crossref_primary_10_1016_j_pep_2006_12_013 crossref_primary_10_1016_j_biopha_2023_115603 crossref_primary_10_1007_s12016_020_08798_2 crossref_primary_10_1111_cen3_12827 crossref_primary_10_1371_journal_ppat_1000355 crossref_primary_10_3390_biomedicines10102628 crossref_primary_10_4049_jimmunol_2200787 crossref_primary_10_1016_j_ijbiomac_2025_141622 crossref_primary_10_1016_j_biopha_2017_12_041 crossref_primary_10_1002_eji_201243288 crossref_primary_10_3389_fimmu_2016_00609 crossref_primary_10_1016_j_jsps_2020_08_024 crossref_primary_10_1016_j_intimp_2018_03_022 crossref_primary_10_1016_j_bbrc_2011_05_014 crossref_primary_10_3389_frph_2021_702929 crossref_primary_10_4049_jimmunol_0902314 crossref_primary_10_1371_journal_ppat_1010384 crossref_primary_10_1089_jir_2011_0075 crossref_primary_10_4049_jimmunol_1003115 crossref_primary_10_1128_IAI_00829_06 crossref_primary_10_1186_s13578_023_01188_z crossref_primary_10_1016_j_bbih_2021_100392 crossref_primary_10_1016_j_cyto_2015_10_015 crossref_primary_10_1093_intimm_dxm075 crossref_primary_10_2174_1381612826666200109181238 crossref_primary_10_1038_s41467_023_37129_0 crossref_primary_10_1371_journal_pone_0011704 crossref_primary_10_52420_2071_5943_2021_20_4_12_17 crossref_primary_10_1089_jir_2011_0071 crossref_primary_10_3389_fimmu_2018_03047 crossref_primary_10_1042_BJ20070605 crossref_primary_10_1016_j_fsi_2024_109396 crossref_primary_10_1177_0961203320935976 crossref_primary_10_3390_v13122362 crossref_primary_10_12688_f1000research_9356_1 crossref_primary_10_18632_oncotarget_10272 crossref_primary_10_1016_S1359_6446_05_03721_9 crossref_primary_10_1007_s00253_020_10676_y crossref_primary_10_1016_j_virol_2022_04_004 crossref_primary_10_1111_j_1582_4934_2008_00372_x crossref_primary_10_1111_liv_12859 crossref_primary_10_1007_s12010_015_1804_y crossref_primary_10_1016_j_antiviral_2011_01_004 crossref_primary_10_1126_science_abd4585 crossref_primary_10_3389_fcell_2023_1122408 crossref_primary_10_1002_art_22732 crossref_primary_10_1073_pnas_0904477106 crossref_primary_10_1016_j_clim_2008_07_002 crossref_primary_10_1089_jir_2008_0082 crossref_primary_10_1128_JVI_02438_06 crossref_primary_10_1158_1078_0432_CCR_11_0482 crossref_primary_10_1016_j_dci_2016_10_007 crossref_primary_10_3389_fnins_2016_00193 crossref_primary_10_1186_1743_422X_6_70 crossref_primary_10_1089_jir_2008_0075 crossref_primary_10_1038_s41374_018_0102_z crossref_primary_10_1089_jir_2005_25_780 crossref_primary_10_1016_j_devcel_2014_11_007 crossref_primary_10_1128_JVI_01649_07 crossref_primary_10_1186_s40104_018_0256_y crossref_primary_10_3390_v14051107 crossref_primary_10_1016_j_dci_2022_104589 crossref_primary_10_1089_jir_2011_0095 crossref_primary_10_3390_cancers14225495 crossref_primary_10_3390_v1031073 crossref_primary_10_1016_j_smim_2022_101632 crossref_primary_10_1074_jbc_R700004200 crossref_primary_10_3390_biology11010109 crossref_primary_10_1002_JLB_3MR0821_147R crossref_primary_10_1016_j_smim_2019_101299 crossref_primary_10_1089_jir_2005_25_770 crossref_primary_10_1128_AAC_01584_21 crossref_primary_10_1089_jir_2005_25_511 crossref_primary_10_1016_j_ijbiomac_2024_131721 crossref_primary_10_1016_j_fsi_2012_07_018 crossref_primary_10_4161_cbt_20990 crossref_primary_10_1111_j_1600_065X_2012_01131_x crossref_primary_10_1016_j_biopha_2017_07_160 crossref_primary_10_1007_s10499_022_00889_5 crossref_primary_10_1128_mBio_00903_16 crossref_primary_10_3389_fneur_2022_1026449 crossref_primary_10_1007_s10142_024_01427_7 crossref_primary_10_1007_s11154_008_9083_3 crossref_primary_10_3389_fimmu_2022_1001070 crossref_primary_10_3390_ijms25031681 crossref_primary_10_3389_fimmu_2021_638479 crossref_primary_10_1371_journal_pone_0038149 crossref_primary_10_3390_antib11010019 crossref_primary_10_1016_j_heliyon_2024_e37103 crossref_primary_10_3347_kjp_2017_55_3_295 crossref_primary_10_1089_jir_2018_0087 |
| Cites_doi | 10.4049/jimmunol.166.12.7136 10.1016/0022-2836(85)90401-2 10.1073/pnas.83.2.384 10.1007/BF01535312 10.1016/S1359-6101(02)00012-6 10.1006/jmbi.1995.0544 10.1073/pnas.89.24.11706 10.1111/j.1749-6632.1980.tb20641.x 10.1016/S0192-0561(00)00074-6 10.1016/S0021-9258(19)39901-6 10.1073/pnas.77.10.5716 10.1073/pnas.84.12.4151 10.1074/jbc.M011006200 10.1038/ni873 10.1006/jmbi.1998.2480 10.1073/pnas.111163898 10.1038/416744a 10.1146/annurev.bi.56.070187.003455 10.1101/sqb.1999.64.465 10.1002/1097-0142(19870201)59:3 <664::AID-CNCR2820591316>3.0.CO;2-Y 10.1016/S0021-9258(17)43764-1 10.1007/s004120050298 10.1081/PRG-120016788 10.1006/viro.1995.1522 10.1016/0003-9861(81)90194-6 10.1056/NEJM198601093140202 10.1073/pnas.89.16.7836 10.1074/jbc.273.5.3021 10.1038/287401a0 10.1016/0003-9861(83)90118-2 10.1016/0092-8674(94)90354-9 10.1002/ijc.2910310306 10.1074/jbc.271.13.7635 10.1089/107999003766628124 10.1089/107999099314018 10.1016/0006-291X(84)91625-5 10.1002/ana.410400606 10.1126/science.273.5282.1717 10.1073/pnas.79.10.3265 10.1016/0092-8674(88)90050-5 10.1073/pnas.91.13.5818 10.1016/S0021-9258(18)45950-9 10.1074/jbc.271.51.32659 10.1016/j.ygeno.2004.03.003 10.1098/rspb.1957.0048 10.1016/S0300-9084(99)80030-3 10.1016/0008-8749(82)90208-8 10.1007/s001090100206 10.1016/0192-0561(91)90128-T 10.1016/S0968-0004(02)02085-6 10.1016/S0140-6736(82)91031-5 10.1016/0163-7258(91)90064-S 10.1172/JCI118025 10.1023/A:1008335318764 10.1073/pnas.77.12.7010 10.1042/BJ20021935 10.1093/emboj/16.19.5894 10.1073/pnas.74.10.4415 10.1038/376230a0 10.1111/j.1572-0241.1999.01300.x 10.1007/BF01946357 10.1128/jvi.50.2.445-450.1984 10.1038/sj.onc.1203524 10.1136/gut.50.2.191 10.1038/ni875 10.1016/S1359-6101(97)00009-9 10.1046/j.1440-1746.2000.02082.x 10.4049/jimmunol.167.4.2060 10.1089/jir.1985.5.11 10.2144/Oct0207 10.1016/j.exphem.2003.08.011 10.1016/S0021-9258(19)84735-X 10.1016/S0021-9258(17)32423-7 10.1128/JVI.77.17.9622-9631.2003 10.1016/S0079-6603(08)61004-1 10.1016/S0092-8674(00)81289-1 10.1089/107999001317205123 10.1073/pnas.87.18.6934 10.1007/BF02987765 10.1073/pnas.94.22.11813 10.1016/S1074-7613(00)00077-7 10.1101/gr.9.3.242 10.1038/scientificamerican0883-36 10.1074/jbc.M304531200 10.1016/S0969-2126(96)00152-9 10.1016/S1043-4666(03)00029-2 10.1002/mrd.1080260205 10.1146/annurev.bi.64.070195.003201 10.1111/j.1432-1033.1992.tb17248.x 10.1016/S0952-7915(01)00305-3 10.1212/WNL.58.8_suppl_4.S40 10.1073/pnas.111164198 10.1016/0092-8674(94)90355-7 10.1006/jmbi.1997.1396 10.1016/S0969-2126(01)00567-6 10.1128/JVI.77.3.1992-2002.2003 10.1073/pnas.81.15.4926 10.1038/nrc905 10.1006/viro.1997.8493 10.1074/jbc.M105070200 10.1002/j.1460-2075.1995.tb00192.x 10.1007/s00251-003-0580-y 10.1074/jbc.275.17.12661 10.1126/science.278.5344.1803 10.1200/JCO.2004.10.952 10.1006/geno.1993.1199 10.1002/hep.1840210307 10.1073/pnas.92.12.5401 10.1016/S0092-8674(02)00616-5 10.1126/science.725605 10.1099/0022-1317-77-6-1163 10.1006/jmbi.2000.3734 10.1038/76233 10.1074/jbc.271.8.4134 10.1089/jir.1992.12.363 10.1146/annurev.biochem.67.1.227 10.1016/S0171-2985(11)80562-0 10.1016/S0165-2427(97)00019-6 10.1385/MO:18:3:209 10.1099/0022-1317-28-2-259 10.1200/JCO.2002.20.5.1429 10.1016/0003-9861(81)90195-8 10.1002/1097-0282(2000)55:4<254::AID-BIP1001>3.0.CO;2-1 10.1073/pnas.76.2.640 10.1038/sj.embor.7400005 10.1006/geno.1994.1427 10.1016/S1359-6101(01)00009-0 10.1093/emboj/16.2.260 10.1126/science.1902591 10.1006/scbi.2000.0315 10.1007/BF01215180 10.1016/S0378-1119(97)00600-8 10.1007/BF02678212 10.2144/Oct0208 10.1126/science.3580039 10.1517/14712598.1.4.641 10.1146/annurev.immunol.22.012703.104622 10.1074/jbc.M909607199 10.4049/jimmunol.171.1.285 10.1016/S0092-8674(00)81288-X 10.1074/jbc.270.37.21606 10.1126/science.1281555 10.1016/S0021-9258(17)44554-6 10.1016/S0021-9258(17)32231-7 10.1016/S0021-9258(18)33788-8 10.1038/ni1032 10.1159/000050075 10.1073/pnas.77.7.4099 10.1016/S0140-6736(88)92723-7 10.1007/BF03402135 10.1007/s11864-001-0033-5 10.1089/jir.1994.14.197 10.1126/science.1074900 10.1074/jbc.271.14.8057 10.1074/mcp.M200065-MCP200 10.1073/pnas.89.16.7840 10.1073/pnas.89.23.11317 10.1016/S0969-2126(03)00120-5 10.1016/0163-7258(85)90023-3 10.1099/0022-1317-73-3-673 10.1016/S0021-9673(00)88614-8 10.1177/019459988409200403 10.1073/pnas.90.18.8737 10.1016/S0969-2126(00)00184-2 10.1016/S1535-6108(03)00193-4 10.1074/jbc.271.23.13448 10.1126/science.7690989 10.1016/0076-6879(86)19074-4 10.1146/annurev.immunol.15.1.563 10.1107/S0907444999014304 10.1016/S0140-6736(02)08001-7 10.1128/MCB.17.7.3833 10.1016/0163-7258(94)00063-9 10.1084/jem.181.3.839 10.1002/j.1460-2075.1982.tb01277.x 10.1159/000057631 10.1074/jbc.M102502200 10.1126/science.8197455 10.1186/1471-2164-4-29 10.1089/107999003322485107 10.1128/jvi.69.12.8159-8163.1995 10.1016/0092-8674(90)90738-Z 10.1358/dof.1992.017.10.195933 10.1126/science.277.5332.1630 10.1074/jbc.274.44.31531 10.1046/j.1365-2141.2003.04650.x 10.1089/jir.1995.15.625 10.1128/iai.40.1.172-176.1983 10.1016/S0092-8674(85)80022-2 10.1038/298859a0 10.1016/0092-8674(94)90154-6 10.1038/nature01850 |
| ContentType | Journal Article |
| DBID | BSCLL AAYXX CITATION CGR CUY CVF ECM EIF NPM 7T5 H94 7X8 |
| DOI | 10.1111/j.0105-2896.2004.00204.x |
| DatabaseName | Istex CrossRef Medline MEDLINE MEDLINE (Ovid) MEDLINE MEDLINE PubMed Immunology Abstracts AIDS and Cancer Research Abstracts MEDLINE - Academic |
| DatabaseTitle | CrossRef MEDLINE Medline Complete MEDLINE with Full Text PubMed MEDLINE (Ovid) AIDS and Cancer Research Abstracts Immunology Abstracts MEDLINE - Academic |
| DatabaseTitleList | CrossRef MEDLINE MEDLINE - Academic AIDS and Cancer Research Abstracts |
| Database_xml | – sequence: 1 dbid: NPM name: PubMed url: https://proxy.k.utb.cz/login?url=http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed sourceTypes: Index Database – sequence: 2 dbid: EIF name: MEDLINE url: https://proxy.k.utb.cz/login?url=https://www.webofscience.com/wos/medline/basic-search sourceTypes: Index Database |
| DeliveryMethod | fulltext_linktorsrc |
| Discipline | Biology |
| EISSN | 1600-065X |
| EndPage | 32 |
| ExternalDocumentID | 15546383 10_1111_j_0105_2896_2004_00204_x IMR204 ark_67375_WNG_72JKT0GB_4 |
| Genre | reviewArticle Research Support, U.S. Gov't, P.H.S Journal Article Review |
| GrantInformation_xml | – fundername: NIAID NIH HHS grantid: AI36450 – fundername: NIAID NIH HHS grantid: AI47300 – fundername: NIAID NIH HHS grantid: AI43369 – fundername: NCI NIH HHS grantid: CA46465 |
| GroupedDBID | --- .3N .GA .GJ .Y3 05W 0R~ 10A 1OB 1OC 29I 31~ 33P 36B 3O- 3SF 4.4 50Y 50Z 51W 51X 52M 52N 52O 52P 52R 52S 52T 52U 52V 52W 52X 53G 5GY 5HH 5LA 5RE 5VS 66C 702 7PT 8-0 8-1 8-3 8-4 8-5 8F7 8UM 930 A01 A03 AAESR AAEVG AAHHS AAKAS AANLZ AAONW AASGY AAXRX AAZKR ABCQN ABCUV ABDBF ABEML ABJNI ABLJU ABPVW ABQWH ABXGK ACAHQ ACBWZ ACCFJ ACCZN ACFBH ACGFO ACGFS ACGOF ACMXC ACPOU ACPRK ACSCC ACXBN ACXQS ADBBV ADBTR ADEOM ADIZJ ADKYN ADMGS ADOZA ADXAS ADZCM ADZMN ADZOD AEEZP AEGXH AEIGN AEIMD AENEX AEQDE AEUQT AEUYR AFBPY AFEBI AFFNX AFFPM AFGKR AFPWT AFRAH AFZJQ AHBTC AHEFC AI. AIACR AIAGR AITYG AIURR AIWBW AJBDE ALAGY ALMA_UNASSIGNED_HOLDINGS ALUQN AMBMR AMYDB AOETA ASPBG ATUGU AVWKF AZBYB AZFZN AZVAB BAFTC BDRZF BFHJK BHBCM BMXJE BROTX BRXPI BSCLL BY8 C45 CAG COF CS3 D-6 D-7 D-E D-F DC6 DCZOG DPXWK DR2 DRFUL DRMAN DRSTM DU5 E3Z EAD EAP EAS EBB EBC EBD EBS EBX EJD EMB EMK EMOBN ESX EX3 F00 F01 F04 F5P FEDTE FUBAC FZ0 G-S G.N GODZA H.X HF~ HGLYW HVGLF HZI HZ~ IH2 IHE IX1 J0M K48 KBYEO L7B LATKE LC2 LC3 LEEKS LH4 LITHE LOXES LP6 LP7 LUTES LW6 LYRES MEWTI MK4 MRFUL MRMAN MRSTM MSFUL MSMAN MSSTM MVM MXFUL MXMAN MXSTM N04 N05 N9A NF~ O66 O9- OBC OBS OEB OIG OVD P2P P2W P2X P2Z P4B P4D PALCI Q.N Q11 QB0 R.K RIWAO RJQFR ROL RWI RX1 SAMSI SUPJJ SV3 TEORI TUS UB1 V8K VH1 W8V W99 WBKPD WHWMO WIH WIJ WIK WOHZO WOW WQJ WRC WUP WVDHM WXI WXSBR X7N XG1 XV2 YFH YOC YUY YYP ZGI ZXP ZZTAW ~IA ~KM ~WT AAHQN AAIPD AAMNL AANHP AAYCA ACRPL ACUHS ACYXJ ADNMO AFWVQ ALVPJ AAYXX AETEA AEYWJ AGHNM AGQPQ AGYGG CITATION CGR CUY CVF ECM EIF NPM PKN 7T5 AAMMB AEFGJ AGXDD AIDQK AIDYY H94 7X8 |
| ID | FETCH-LOGICAL-c4334-3fa00639f1f4675c08e6398f70f4a10b8b76b535dba143db021972c419bf30743 |
| IEDL.DBID | DR2 |
| ISSN | 0105-2896 |
| IngestDate | Fri Jul 11 03:35:55 EDT 2025 Fri Jul 11 06:29:01 EDT 2025 Wed Feb 19 01:37:43 EST 2025 Thu Apr 24 23:05:42 EDT 2025 Tue Jul 01 03:22:53 EDT 2025 Wed Jan 22 16:44:18 EST 2025 Wed Oct 30 09:53:37 EDT 2024 |
| IsPeerReviewed | true |
| IsScholarly | true |
| Issue | 1 |
| Language | English |
| License | http://onlinelibrary.wiley.com/termsAndConditions#vor |
| LinkModel | DirectLink |
| MergedId | FETCHMERGED-LOGICAL-c4334-3fa00639f1f4675c08e6398f70f4a10b8b76b535dba143db021972c419bf30743 |
| Notes | ArticleID:IMR204 istex:8DD6E6854B168E2B703B323EA99B1039D16C1515 ark:/67375/WNG-72JKT0GB-4 ObjectType-Article-2 SourceType-Scholarly Journals-1 ObjectType-Feature-3 content type line 23 ObjectType-Review-1 ObjectType-Article-1 ObjectType-Feature-2 ObjectType-Review-3 |
| PMID | 15546383 |
| PQID | 17377146 |
| PQPubID | 23462 |
| PageCount | 25 |
| ParticipantIDs | proquest_miscellaneous_67083238 proquest_miscellaneous_17377146 pubmed_primary_15546383 crossref_primary_10_1111_j_0105_2896_2004_00204_x crossref_citationtrail_10_1111_j_0105_2896_2004_00204_x wiley_primary_10_1111_j_0105_2896_2004_00204_x_IMR204 istex_primary_ark_67375_WNG_72JKT0GB_4 |
| ProviderPackageCode | CITATION AAYXX |
| PublicationCentury | 2000 |
| PublicationDate | 2004-12 December 2004 2004-12-00 2004-Dec 20041201 |
| PublicationDateYYYYMMDD | 2004-12-01 |
| PublicationDate_xml | – month: 12 year: 2004 text: 2004-12 |
| PublicationDecade | 2000 |
| PublicationPlace | Oxford, UK; Malden, USA |
| PublicationPlace_xml | – name: Oxford, UK; Malden, USA – name: England |
| PublicationTitle | Immunological reviews |
| PublicationTitleAlternate | Immunol Rev |
| PublicationYear | 2004 |
| Publisher | Munksgaard International Publishers |
| Publisher_xml | – name: Munksgaard International Publishers |
| References | Pestka S, Krause CD, Sarkar D, Walter MR, Shi Y, Fisher PB. Interleukin-10 related cytokines receptors. Annu Rev Immunol 2004;22: 929-979. Pestka S. The human interferons - from protein purification and sequence to cloning and expression in bacteria: before, between, beyond. Arch Biochem Biophys 1983;221: 1-37. Maniatis T. Mechanisms of human beta-interferon gene regulation. Harvey Lect 1986;82: 71-104. Basham TY, Bourgeade MF, Creasey AA, Merigan TC. Interferon increases HLA synthesis in melanoma cells: interferon-resistant and -sensitive cell lines. Proc Natl Acad Sci USA 1982;79: 3265-3269. Eilers A, Decker T. Activity of Stat family transcription factors is developmentally controlled in cells of the macrophage lineage. Immunobiology 1995;193: 328-333. Kile BT, Schulman BA, Alexander WS, Nicola NA, Martin HM, Hilton DJ. The SOCS box: a tale of destruction and degradation. Trends Biochem Sci 2002;27: 235-241. Fountoulakis M, Zulauf M, Lusting A, Garotta G. Stoichiometry of interaction between interferon gamma and its receptor. Eur J Biochem 1992;208: 781-787. Gil MP, et al. Biologic consequences of Stat1-independent IFN signaling. Proc Natl Acad Sci USA 2001;98: 6680-6685. Sakatsume M, et al. Interferon gamma activation of Raf-1 is Jak1-dependent and p21ras-independent. J Biol Chem 1998;273: 3021-3026. Fisher PB, Hermo H Jr, Prignoli DR, Weinstein IB, Pestka S. Hybrid recombinant human leukocyte interferon inhibits differentiation in murine B-16 melanoma cells. Biochem Biophys Res Commun 1984;119: 108-115. Kotenko SV, et al. IFN-λs mediate antiviral protection through a distinct class II cytokine receptor complex. Nat Immunol 2003;4: 69-77. Hayden FG, Albrecht JK, Kaiser DL, Gwaltney JM Jr. Prevention of natural colds by contact prophylaxis with intranasal alpha 2-interferon. N Engl J Med 1986; 314: 71-75. Oritani K, Kincade PW, Tomiyama Y. Limitin: an interferon-like cytokine without myeloerythroid suppressive properties. J Mol Med 2001;79: 168-174. Klein ML, Bartley TD, Lai PH, Lu HS. Structural characterization of recombinant consensus interferon-α. J Chromatogr 1988;454: 205-215. Greiner JW, et al. Recombinant interferon enhances monoclonal antibody-targeting carcinoma lesions in vivo. Science 1987;235: 895-898. Isaacs A, Lindenmann J. Virus interference. I. The interferon. Proc R Soc Lond Ser B Biol Sci 1957;147: 258-267. Lundquist PG, Haglund S, Carlsoo B, Strander H, Lundgren E. Interferon therapy in juvenile laryngeal papillomatosis. Otolaryngol Head Neck Surg 1984;92: 386-391. Kim TK, Maniatis T. Regulation of interferon-gamma-activated STAT1 by the ubiquitin-proteasome pathway. Science 1996;273: 1717-1719. Roberts RM, Ezashi T, Rosenfeld CS, Ealy AD, Kubisch HM. Evolution of the interferon τ genes and their promoters, and maternal-trophoblast interactions in control of their expression. Reprod Suppl 2003;61: 239-251. Duc-Goiran P, Chany C, Doly J. Unusually large interferon-alpha-like mRNAs and high expression of interleukin-6 in human fetal annexes. J Biol Chem 1989;264: 16507-16511. Kirkwood JM, Ibrahim JG, Sondak VK, Ernstoff MS, Ross M. Interferon alfa-2a for melanoma metastases. Lancet 2002;359: 978-979. Hemmi S, Bohni R, Stark G, Di Marco F, Aguet M. A novel member of the interferon receptor family complements functionality of the murine interferon γ receptor in human cells. Cell 1994;76: 803-810. Talpaz M, Kantarjian H, McCredie K, Trujillo J, Keating M, Gutterman JU. Therapy of chronic myelogenous leukemia. Cancer 1987;59: 664-667. Einhorn S, Strander H. Interferon treatment of human malignancies - a short review. Med Oncol Tumor Pharmacother 1993;10: 25-29. Park YB, Lee SK, Kim DS, Lee J, Lee CH, Song CH. Elevated interleukin-10 levels correlated with disease activity in systemic lupus erythematosus. Clin Exp Rheumatol 1998;16: 283-288. Masihi KN. Immunomodulators in infectious diseases: panoply of possibilities. Int J Immunopharmacol 2000;22: 1083-1091. Touitou R, Cochet C, Joab I. Transcriptional analysis of the Epstein-Barr virus interleukin-10 homologue during the lytic cycle. J Gen Virol 1996;77: 1163-1168. Ortaldo JR, et al. Effects of recombinant and hybrid recombinant human leukocyte interferons on cytotoxic activity of natural killer cells. J Biol Chem 1983;258: 15011-15015. Sperber SJ, Gocke DJ, Haberzettl C, Kuk R, Schwartz B, Pestka S. Anti-HIV-1 activity of recombinant and hybrid species of interferon-alpha. J Interferon Res 1992;12: 363-368. Reboul J, Gardiner K, Monneron D, Uze G, Lutfalla G. Comparative genomic analysis of the interferon/interleukin-10 receptor gene cluster. Genome Res 1999;9: 242-250. Keay S, Grossberg SE. Interferon inhibits the conversion of 3T3-L1 mouse fibroblasts into adipocytes. Proc Natl Acad Sci USA 1980;77: 4099-4103. Pestka S, Kelder B, Familletti PC, Moschera JA, Crowl R, Kempner ES. Molecular weight of the functional unit of human leukocyte, fibroblast, and immune interferons. J Biol Chem 1983;258: 9706-9709. Hochkeppel HK, Gruetter M, Horisberger MA, Lazdins JK. Human IFN-alpha hybrids. Drugs Future 1992;17: 899-914. Yamamoto H, Hayashi E, Nakamura H, Kimura Y, Ito H, Kambe H. Interferon therapy for non-A, non-B hepatitis: a pilot study and review of the literature. Hepatogastroenterology 1992;39: 377-380. Antonelli G, et al. Interferon antibodies in patients with infectious diseases. Anti-interferon antibodies. Biotherapy 1997;10: 7-14. Rockley PF, Tyring SK. Interferons alpha, beta and gamma therapy of anogenital human papillomavirus infections. Pharmacol Ther 1995;65: 265-287. Von Wussow P, Hochkeppel HK, Jakschies D, Rapp U, Franke M, Deicher H. Phase I study of a new recombinant hybrid IFN (alpha1/alpha2). Proc Am Soc Clin Oncol 1991;32: 1532[Abstract]. Silberberg DH. Specific treatment of multiple sclerosis. Clin Neurosci 1994;2: 271-274. Dianzani F, Pestka S. A review of interferon immunogenicity. J Interferon Cytokine Res 1997;17: S1-55. Lander A, et al. Design, characterization, and structure of a biologically active single-chain mutant of human IFN-gamma. J Mol Biol 2000;299: 169-179. Viscomi GC, et al. Antigenic characterization of recombinant, lymphoblastoid, and leukocyte IFN-alpha by monoclonal antibodies. J Interferon Cytokine Res 1999;19: 319-326. Berg K. Purification and characterization of murine and human interferons. A review of the literature of the 1970s. Acta Pathol Microbiol Immunol Scand Suppl 1982;279: 1-136. Yang CH, Murti A, Pfeffer SR, Kim JG, Donner DB, Pfeffer LM. Interferon alpha/beta promotes cell survival by activating nuclear factor kappa B through phosphatidylinositol 3-kinase and Akt. J Biol Chem 2001;276: 13756-13761. Greiner JW, et al. Modulation of tumor associated antigen expression and shedding by recombinant human leukocyte and fibroblast interferons. Pharmacol Ther 1985;31: 209-236. Kaempfer R. RNA sensors: novel regulators of gene expression. EMBO Rep 2003;4: 1043-1047. Pestka S. The interferon receptors. Semin Oncol 1997;24: S9. Duc-Goiran P, Lebon P, Chany C. Measurement of interferon in human amniotic fluid and placental blood extract. Methods Enzymol 1986;119: 541-551. Glezerman M, et al. Placebo-controlled trial of topical interferon in labial and genital herpes. Lancet 1988;1: 150-152. Pestka S. A dance between interferon-alpha/beta and p53 demonstrates collaborations in tumor suppression and antiviral activities. Cancer Cell 2003;4: 85-87. Nomenclature Committee. ISICR Committee Minutes. ISICR Newsletter 2004;11: 25-26. Galabov A, Petrunova S, Savov Z. Molecular weight of virus-induced tortoise interferon in cell cultures. Experientia 1973;29: 900-901. Galabov AS, Velichikova EH. Interferon production in tortoise peritoneal cells. J Gen Virol 1975;28: 259-263. Nardelli B, et al. IFN-κ, a novel type I interferon. Eur Cytokine Netw 2000;11: 39[Abstract]. Yang CH, et al. Direct association of STAT3 with the IFNAR-1 chain of the human type I interferon receptor. J Biol Chem 1996;271: 8057-8061. Kato K, et al. Intracellular signal transduction of interferon on the suppression of haematopoietic progenitor cell growth. Br J Haematol 2003;123: 528-535. Su L, David M. Distinct mechanisms of STAT phosphorylation via the interferon-alpha/beta receptor. Selective inhibition of STAT3 and STAT5 by piceatannol. J Biol Chem 2000;275: 12661-12666. Harrison GA, Young LJ, Watson CM, Miska KB, Miller RD, Deane EM. A survey of type I interferons from a marsupial and monotreme: implications for the evolution of the type I interferon gene family in mammals. Cytokine 2003;21: 105-119. Cook JR, Cleary CM, Mariano TM, Izotova L, Pestka S. Differential responsiveness of a splice variant of the human type I interferon receptor to interferons. J Biol Chem 1996;271: 13448-13453. Jung V, Jones C, Kumar CS, Stefanos S, O'Connell S, Pestka S. Expression and reconstitution of a biologically active human interferon-gamma receptor in hamster cells. J Biol Chem 1990;265: 1827-1830. Stein S, Kenny C, Friesen HJ, Shively J, Del Valle U, Pestka S. NH2-terminal amino acid sequence of human fibroblast interferon. Proc Natl Acad Sci USA 1980;77: 5716-5719. Greiner JW, Hand PH, Noguchi P, Fisher PB, Pestka S, Schlom J. Enhanced expression of surface tumor-associated antigens on human breast and colon tumor cells after recombinant human leukocyte α-interferon treatment. Cancer Res 1984;44: 3208-3214. Taniguchi T, Takaoka A. The interferon-alpha/beta system in antiviral responses: a multimodal machinery of gene regulation by the IRF family of transcription factors. Curr Opin Immunol 2002;14: 111-116. Lutfalla G, et al. Mutant U5A cells are complemented by an interferon-αβ receptor subunit generated by alternative processing of a new member of a cytokine receptor gene cluster. EMBO J 1995;14: 5100-5108. Pollack BP, Kotenko SV, He W, Izotova LS, Barnoski BL, Pestka S. The human homologue of the yeast proteins Skb1 and Hsl7p interacts with Jak kinases and contains protein methyltransferase activity. J Biol Chem 1999;274: 31531-31542. Senda T, Saitoh S, Mitsui Y. Refined crystal structure of recombinant 1997; 278 2004; 22 2002; 14 1991; 13 1997; 274 2002; 13 1973; 17 1997; 277 1999; 286 2004; 5 1998; 80 1995; 376 2001; 44 1995; 253 2003; 278 1990; 60 2003; 55 1997; 8 1998; 273 1996; 77 1982; 67 1984; 50 1998; 16 11 1994; 264 1986; 82 2000; 19 1986; 83 1994; 269 2000; 15 1987; 235 2000; 13 2000; 10 2000; 11 1997; 57 1997; 56 1995; 21 1998; 207 1986 1988; 454 1994; 77 1983 1982 1981 1980 1982; 257 1994; 76 2001; 166 1983; 258 1987; 56 1986; 119 2001; 167 1988; 14 1984; 44 1992; 267 1997; 24 2002; 1 1992; 39 2002; 2 2003; 171 2002; 416 1980; 350 1998; 67 2003; 31 1995; 6 1995; 270 1987; 59 2001; 21 2001; 276 1983; 249 1995; 41 1990; 26 1975; 28 1981; 210 1992; 258 1973; 29 1994; 14 1996; 84 1982; 279 1978; 202 1994; 91 2003; 21 2003; 22 2003; 23 2002; 58 2000; 6 1957; 147 2002; 50 1997; 230 2000; 8 1991; 51 1992; 17 2002; 359 1994; 22 1992; 208 1995; 212 2000; 299 1992; 11 1979; 76 1992; 12 1990; 265 1995; 64 1990; 87 1997; 94 1983; 221 1987; 84 1984; 92 2001 1982; 1 1982; 2 1997; 10 1999; 19 2000; 56 1995; 69 1997; 15 2000; 55 1989; 264 1980; 77 1995; 65 1982; 298 2002; 107 2003; 4 1997; 17 1977; 74 1997; 16 1984; 119 2002; 108 2001; 18 1999; 94 1996; 4 2001; 12 1992; 89 2003; 123 1990; 252 2001; 98 1982; 79 1995; 96 2004; 84 1995; 92 1984; 81 1986; 314 1985; 5 2002; 297 1991; 32 1995; 15 1995; 14 2000; 22 1983; 31 2003; 370 1988; 55 1993; 261 1999; 64 1985; 41 2000; 275 1993; 90 2002 1999; 5 1985; 185 1995; 193 2003; 77 1992; 73 1999; 9 2002; 27 1988; 1 2004; 11 2003; 424 1993; 16 2002; 20 1993; 10 2001; 9 1999; 274 1996; 271 1998; 107 1983; 40 1996; 40 1985; 30 2001; 2 2001; 1 1996; 273 2003; 61 1985; 31 2001; 79 1994; 2 1980; 287 1995; 181 e_1_2_10_109_2 e_1_2_10_40_2 Cleary CM (e_1_2_10_69_2) 1994; 269 e_1_2_10_158_2 e_1_2_10_207_2 e_1_2_10_74_2 e_1_2_10_112_2 e_1_2_10_135_2 e_1_2_10_150_2 e_1_2_10_173_2 e_1_2_10_37_2 e_1_2_10_97_2 e_1_2_10_6_2 e_1_2_10_14_2 Pestka S (e_1_2_10_62_2) 1983; 258 e_1_2_10_222_2 Yamamoto H (e_1_2_10_148_2) 1992; 39 e_1_2_10_147_2 e_1_2_10_219_2 e_1_2_10_101_2 e_1_2_10_162_2 e_1_2_10_185_2 e_1_2_10_86_2 e_1_2_10_25_2 Reboul J (e_1_2_10_187_2) 1999; 9 e_1_2_10_41_2 Greiner JW (e_1_2_10_124_2) 1984; 44 e_1_2_10_211_2 e_1_2_10_90_2 e_1_2_10_159_2 e_1_2_10_208_2 e_1_2_10_52_2 e_1_2_10_136_2 e_1_2_10_15_2 e_1_2_10_75_2 e_1_2_10_98_2 e_1_2_10_113_2 e_1_2_10_151_2 e_1_2_10_197_2 e_1_2_10_7_2 e_1_2_10_174_2 Ortaldo JR (e_1_2_10_61_2) 1983 Sen GC (e_1_2_10_161_2) 1984; 50 e_1_2_10_200_2 e_1_2_10_223_2 Pestka S (e_1_2_10_38_2) 1997; 24 Ozato K (e_1_2_10_13_2) 2002 e_1_2_10_125_2 e_1_2_10_26_2 e_1_2_10_49_2 e_1_2_10_64_2 e_1_2_10_87_2 Lutfalla G (e_1_2_10_192_2) 1992; 267 Berg K (e_1_2_10_28_2) 1982; 279 e_1_2_10_102_2 e_1_2_10_140_2 e_1_2_10_186_2 Pestka S (e_1_2_10_143_2) Dianzani F (e_1_2_10_171_2) 1997; 17 e_1_2_10_42_2 Pestka S (e_1_2_10_48_2) 1980 e_1_2_10_212_2 e_1_2_10_198_2 Pestka S (e_1_2_10_5_2) 1986 e_1_2_10_91_2 e_1_2_10_209_2 e_1_2_10_114_2 e_1_2_10_137_2 e_1_2_10_190_2 e_1_2_10_39_2 e_1_2_10_53_2 e_1_2_10_16_2 e_1_2_10_76_2 e_1_2_10_152_2 e_1_2_10_175_2 e_1_2_10_99_2 Silberberg DH (e_1_2_10_163_2) 1994; 2 e_1_2_10_30_2 e_1_2_10_224_2 e_1_2_10_201_2 Jung V (e_1_2_10_210_2) 1990; 265 e_1_2_10_149_2 e_1_2_10_80_2 e_1_2_10_103_2 e_1_2_10_126_2 e_1_2_10_27_2 e_1_2_10_65_2 e_1_2_10_141_2 e_1_2_10_164_2 Friesen H‐J (e_1_2_10_33_2) 1981 e_1_2_10_88_2 e_1_2_10_43_2 Galabov A (e_1_2_10_196_2) 1973; 17 e_1_2_10_213_2 e_1_2_10_130_2 e_1_2_10_176_2 Pestka S (e_1_2_10_66_2) 1997; 24 e_1_2_10_92_2 e_1_2_10_138_2 e_1_2_10_17_2 e_1_2_10_115_2 e_1_2_10_191_2 e_1_2_10_77_2 e_1_2_10_153_2 e_1_2_10_31_2 e_1_2_10_202_2 e_1_2_10_225_2 Nomenclature Committee. (e_1_2_10_199_2) 2004; 11 e_1_2_10_165_2 e_1_2_10_81_2 e_1_2_10_127_2 e_1_2_10_104_2 e_1_2_10_180_2 e_1_2_10_89_2 e_1_2_10_44_2 e_1_2_10_21_2 Rehberg E (e_1_2_10_54_2) 1982; 257 e_1_2_10_214_2 e_1_2_10_131_2 e_1_2_10_154_2 e_1_2_10_177_2 e_1_2_10_70_2 e_1_2_10_116_2 e_1_2_10_139_2 e_1_2_10_93_2 e_1_2_10_2_2 e_1_2_10_18_2 e_1_2_10_55_2 e_1_2_10_78_2 e_1_2_10_79_2 e_1_2_10_32_2 e_1_2_10_203_2 e_1_2_10_226_2 Roberts RM (e_1_2_10_183_2) 2003; 61 e_1_2_10_120_2 e_1_2_10_166_2 e_1_2_10_189_2 Duc‐Goiran P (e_1_2_10_20_2) 1989; 264 Maniatis T (e_1_2_10_24_2) 1986; 82 Kempner ES (e_1_2_10_63_2) 1986 e_1_2_10_105_2 e_1_2_10_181_2 e_1_2_10_82_2 e_1_2_10_29_2 e_1_2_10_67_2 e_1_2_10_22_2 e_1_2_10_45_2 e_1_2_10_68_2 Einhorn S (e_1_2_10_142_2) 1993; 10 Pestka S (e_1_2_10_47_2) 1980 e_1_2_10_215_2 e_1_2_10_155_2 Ritch PS (e_1_2_10_59_2) 1992; 11 e_1_2_10_178_2 e_1_2_10_71_2 e_1_2_10_94_2 Ortaldo JR (e_1_2_10_56_2) 1982 e_1_2_10_117_2 e_1_2_10_193_2 e_1_2_10_3_2 e_1_2_10_170_2 e_1_2_10_132_2 e_1_2_10_57_2 e_1_2_10_10_2 e_1_2_10_118_2 Suresh M (e_1_2_10_188_2) 1995; 69 e_1_2_10_204_2 e_1_2_10_227_2 Ozzello L (e_1_2_10_129_2) 1995; 6 e_1_2_10_144_2 e_1_2_10_167_2 e_1_2_10_60_2 e_1_2_10_83_2 e_1_2_10_106_2 e_1_2_10_182_2 Evinger M (e_1_2_10_51_2) 1981 Von Wussow P (e_1_2_10_58_2) 1991; 32 Nardelli B (e_1_2_10_184_2) 2000; 11 e_1_2_10_121_2 e_1_2_10_23_2 e_1_2_10_107_2 e_1_2_10_216_2 e_1_2_10_156_2 e_1_2_10_179_2 e_1_2_10_228_2 e_1_2_10_72_2 e_1_2_10_95_2 Fidler IJ (e_1_2_10_134_2) 2001 e_1_2_10_110_2 e_1_2_10_133_2 e_1_2_10_194_2 e_1_2_10_35_2 e_1_2_10_11_2 e_1_2_10_34_2 e_1_2_10_8_2 e_1_2_10_119_2 e_1_2_10_205_2 Bakhutashvili VI (e_1_2_10_19_2) 1985; 30 e_1_2_10_145_2 e_1_2_10_168_2 e_1_2_10_217_2 Chill JH (e_1_2_10_230_2); 11 e_1_2_10_160_2 e_1_2_10_84_2 e_1_2_10_122_2 e_1_2_10_46_2 e_1_2_10_108_2 e_1_2_10_157_2 e_1_2_10_206_2 e_1_2_10_229_2 e_1_2_10_73_2 e_1_2_10_96_2 e_1_2_10_172_2 e_1_2_10_36_2 Dolei A (e_1_2_10_128_2) 1983; 40 e_1_2_10_111_2 e_1_2_10_195_2 e_1_2_10_9_2 e_1_2_10_12_2 Park YB (e_1_2_10_220_2) 1998; 16 e_1_2_10_50_2 e_1_2_10_221_2 e_1_2_10_146_2 e_1_2_10_218_2 e_1_2_10_169_2 Pestka S (e_1_2_10_4_2) 1981 e_1_2_10_85_2 e_1_2_10_123_2 e_1_2_10_100_2 |
| References_xml | – reference: Ophir J, Brenner S, Bali R, Kriss-Leventon S, Smetana Z, Revel M. Effect of topical interferon-beta on recurrence rates in genital herpes: a double-blind, placebo-controlled, randomized study. J Interferon Cytokine Res 1995;15: 625-631. – reference: Radhakrishnan R, et al. Zinc mediated dimer of human interferon-α2b revealed by X-ray crystallography. Structure 1996;4: 1453-1463. – reference: Kotenko SV. The family of IL-10-related cytokines and their receptors: related, but to what extent? Cytokine Growth Factor Rev 2002;13: 223-240. – reference: Darnell JE Jr. STATs and gene regulation. Science 1997;277: 1630-1635. – reference: Kaiser P, Wain HM, Rothwell L. Structure of the chicken interferon-γ gene, and comparison to mammalian homologues. Gene 1998;207: 25-32. – reference: Lutfalla G, McInnis MG, Antonarakis SE, Uze G. Structure of the human CRFB4 gene: comparison with its IFNAR neighbor. J Mol Evol 1995;41: 338-344. – reference: Kotenko SV, et al. IFN-λs mediate antiviral protection through a distinct class II cytokine receptor complex. Nat Immunol 2003;4: 69-77. – reference: Takaoka A, et al. Integration of interferon-alpha/beta signalling to p53 responses in tumour suppression and antiviral defence. Nature 2003;424: 516-523. – reference: Nomenclature Committee. ISICR Committee Minutes. ISICR Newsletter 2004;11: 25-26. – reference: Walter MR, et al. Crystal structure of a complex between interferon-γ and its soluble high-affinity receptor. Nature 1995;376: 230-235. – reference: Meraz MA, et al. Targeted disruption of the Stat1 gene in mice reveals unexpected physiologic specificity in the JAK-STAT signaling pathway. Cell 1996;84: 431-442. – reference: Yang CH, Murti A, Pfeffer SR, Kim JG, Donner DB, Pfeffer LM. Interferon alpha/beta promotes cell survival by activating nuclear factor kappa B through phosphatidylinositol 3-kinase and Akt. J Biol Chem 2001;276: 13756-13761. – reference: Pestka S. A dance between interferon-alpha/beta and p53 demonstrates collaborations in tumor suppression and antiviral activities. Cancer Cell 2003;4: 85-87. – reference: Nanda I, et al. Sex chromosome linkage of chicken and duck type I interferon genes: further evidence of evolutionary conservation of the Z chromosome in birds. Chromosoma 1998;107: 204-210. – reference: Rockley PF, Tyring SK. Interferons alpha, beta and gamma therapy of anogenital human papillomavirus infections. Pharmacol Ther 1995;65: 265-287. – reference: Talpaz M, Kantarjian H, McCredie K, Trujillo J, Keating M, Gutterman JU. Therapy of chronic myelogenous leukemia. Cancer 1987;59: 664-667. – reference: Henco K, et al. Structural relationship of human interferon alpha genes and pseudogenes. J Mol Biol 1985;185: 227-260. – reference: Kato K, et al. Intracellular signal transduction of interferon on the suppression of haematopoietic progenitor cell growth. Br J Haematol 2003;123: 528-535. – reference: Ben Asouli Y, Banai Y, Pel-Or Y, Shir A, Kaempfer R. Human interferon-gamma mRNA autoregulates its translation through a pseudoknot that activates the interferon-inducible protein kinase PKR. Cell 2002;108: 221-232. – reference: Pestka S, Langer JA, Zoon KC, Samuel CE. Interferons and their actions. Annu Rev Biochem 1987;56: 727-777. – reference: Klein ML, Bartley TD, Lai PH, Lu HS. Structural characterization of recombinant consensus interferon-α. J Chromatogr 1988;454: 205-215. – reference: Pestka S. The human interferon-α species and hybrid proteins. Semin Oncol 1997;24: S9. – reference: Gray PW, Goeddel DV. Structure of the human immune interferon gene. Nature 1982;298: 859-863. – reference: Cook JR, Cleary CM, Mariano TM, Izotova L, Pestka S. Differential responsiveness of a splice variant of the human type I interferon receptor to interferons. J Biol Chem 1996;271: 13448-13453. – reference: Pestka S. The human interferon α species and receptors. Biopolymers 2000;55: 254-287. – reference: Evinger M, Rubinstein M, Pestka S. Antiproliferative and antiviral activities of human leukocyte interferons. Arch Biochem Biophys 1981;210: 319-329. – reference: Aoki K, et al. Limitin, an interferon-like cytokine, transduces inhibitory signals on B-cell growth through activation of Tyk2, but not Stat1, followed by induction and nuclear translocation of Daxx. Exp Hematol 2003;31: 1317-1322. – reference: Clemens MJ. Interferons and apoptosis. J Interferon Cytokine Res 2003;23: 277-292. – reference: Pollack BP, Kotenko SV, He W, Izotova LS, Barnoski BL, Pestka S. The human homologue of the yeast proteins Skb1 and Hsl7p interacts with Jak kinases and contains protein methyltransferase activity. J Biol Chem 1999;274: 31531-31542. – reference: Antonelli G, et al. Interferon antibodies in patients with infectious diseases. Anti-interferon antibodies. Biotherapy 1997;10: 7-14. – reference: Nguyen KB, et al. Critical role for STAT4 activation by type 1 interferons in the interferon-gamma response to viral infection. Science 2002;297: 2063-2066. – reference: Pestka S, Kelder B, Familletti PC, Moschera JA, Crowl R, Kempner ES. Molecular weight of the functional unit of human leukocyte, fibroblast, and immune interferons. J Biol Chem 1983;258: 9706-9709. – reference: Dianzani F, Pestka S. A review of interferon immunogenicity. J Interferon Cytokine Res 1997;17: S1-55. – reference: Rehberg E, Kelder B, Hoal EG, Pestka S. Specific molecular activities of recombinant and hybrid leukocyte interferons. J Biol Chem 1982;257: 11497-11502. – reference: Pestka S, Krause CD, Sarkar D, Walter MR, Shi Y, Fisher PB. Interleukin-10 related cytokines receptors. Annu Rev Immunol 2004;22: 929-979. – reference: Kim TK, Maniatis T. Regulation of interferon-gamma-activated STAT1 by the ubiquitin-proteasome pathway. Science 1996;273: 1717-1719. – reference: Oritani K, et al. Limitin: an interferon-like cytokine that preferentially influences B-lymphocyte precursors. Nat Med 2000;6: 659-666. – reference: Fujita T, Ohno S, Yasumitsu H, Taniguchi T. Delimitation and properties of DNA sequences required for the regulated expression of human interferon-beta gene. Cell 1985;41: 489-496. – reference: Aguet M, Dembic Z, Merlin G. Molecular cloning and expression of the human interferon-γ receptor. Cell 1988;55: 273-280. – reference: Sick C, Schultz U, Staeheli P. A family of genes coding for two serologically distinct chicken interferons. J Biol Chem 1996;271: 7635-7639. – reference: Durbin JE, Hackenmiller R, Simon MC, Levy DE. Targeted disruption of the mouse Stat1 gene results in compromised innate immunity to viral disease. Cell 1996;84: 443-450. – reference: Isaacs A, Lindenmann J. Virus interference. I. The interferon. Proc R Soc Lond Ser B Biol Sci 1957;147: 258-267. – reference: Krause CD, et al. Seeing the light: preassembly and ligand-induced changes of the interferon γ receptor complex in cells. Mol Cell Proteomics 2002;1: 805-815. – reference: Ealick SE, et al. Three dimensional structure of recombinant human initerferon-γ. Science 1990;252: 698-702. – reference: Von Wussow P, Hochkeppel HK, Jakschies D, Rapp U, Franke M, Deicher H. Phase I study of a new recombinant hybrid IFN (alpha1/alpha2). Proc Am Soc Clin Oncol 1991;32: 1532[Abstract]. – reference: Duc-Goiran P, Chany C, Doly J. Unusually large interferon-alpha-like mRNAs and high expression of interleukin-6 in human fetal annexes. J Biol Chem 1989;264: 16507-16511. – reference: Darnell JE Jr, Kerr IM, Stark GR. Jak-STAT pathways and transcriptional activation in response to IFNs and other extracellular signaling proteins. Science 1994;264: 1415-1421. – reference: Kotenko SV, Pestka S. Jak-Stat signal transduction pathway through the eyes of cytokine class II receptor complexes. Oncogene 2000;19: 2557-2565. – reference: Heller ED, Levy AM, Vaiman R, Schwartsburd B. Chicken-embryo fibroblasts produce two types of interferon upon stimulation with Newcastle disease virus. Vet Immunol Immunopathol 1997;57: 289-303. – reference: Jung V, Rashidbaigi A, Jones C, Tischfield JA, Shows TB, Pestka S. Human chromosomes 6 and 21 are required for sensitivity to human interferon gamma. Proc Natl Acad Sci USA 1987;84: 4151-4155. – reference: Taya Y, Devos R, Tavernier J, Cheroutre H, Engler G, Fiers W. Cloning and structure of the human immune interferon-γ chromosomal gene. EMBO J 1982;1: 953-958. – reference: Yamamoto H, Hayashi E, Nakamura H, Kimura Y, Ito H, Kambe H. Interferon therapy for non-A, non-B hepatitis: a pilot study and review of the literature. Hepatogastroenterology 1992;39: 377-380. – reference: Sperber SJ, Gocke DJ, Haberzettl C, Kuk R, Schwartz B, Pestka S. Anti-HIV-1 activity of recombinant and hybrid species of interferon-alpha. J Interferon Res 1992;12: 363-368. – reference: Nardelli B, et al. IFN-κ, a novel type I interferon. Eur Cytokine Netw 2000;11: 39[Abstract]. – reference: Ramana CV, Gil MP, Han Y, Ransohoff RM, Schreiber RD, Stark GR. Stat1-independent regulation of gene expression in response to IFN-gamma. Proc Natl Acad Sci USA 2001;98: 6674-6679. – reference: LaFleur DW, et al. Interferon-κ, a novel type I interferon expressed in human keratinocytes. J Biol Chem 2001;276: 39765-39771. – reference: David M. Signal transduction by type I interferons. Biotechniques 2002; 58-65. – reference: Domanski P, et al. Cloning and expression of a long form of the β subunit of the interferon αβ receptor that is required for signaling. J Biol Chem 1995;270: 21606-21611. – reference: Hochkeppel HK, Gruetter M, Horisberger MA, Lazdins JK. Human IFN-alpha hybrids. Drugs Future 1992;17: 899-914. – reference: Wingerchuk DM, Noseworthy JH. Randomized controlled trails to assess therapies for multiple sclerosis. Neurology 2002;58: S40-S48. – reference: Stark GR, Kerr IM, Williams BR, Silverman RH, Schreiber RD. How cells respond to interferons. Annu Rev Biochem 1998;67: 227-264. – reference: Leppert D, Waubant E, Burk MR, Oksenberg JR, Hauser SL. Interferon beta-1b inhibits gelatinase secretion and in vitro migration of human T cells: a possible mechanism for treatment efficacy in multiple sclerosis. Ann Neurol 1996;40: 846-852. – reference: Klaus W, Gsell B, Labhardt AM, Wipf B, Senn H. The three-dimensional high resolution structure of human interferon α-2a determined by heteronuclear NMR spectroscopy in solution. J Mol Biol 1997;274: 661-675. – reference: Ziegler-Heitbrock L, Lotzerich M, Schaefer A, Werner T, Frankenberger M, Benkhart E. IFN-alpha induces the human IL-10 gene by recruiting both IFN regulatory factor 1 and Stat3. J Immunol 2003;171: 285-290. – reference: Lundquist PG, Haglund S, Carlsoo B, Strander H, Lundgren E. Interferon therapy in juvenile laryngeal papillomatosis. Otolaryngol Head Neck Surg 1984;92: 386-391. – reference: Pestka S, Kotenko SV, Muthukumaran G, Izotova LS, Cook JR, Garotta G. The interferon γ (IFN-γ) receptor: a paradigm for the multichain cytokine receptor. Cytokine Growth Factor Rev 1997;8: 189-206. – reference: Gil MP, et al. Biologic consequences of Stat1-independent IFN signaling. Proc Natl Acad Sci USA 2001;98: 6680-6685. – reference: Ritch PS, et al. Phase I study IFN alpha BDBB hybrid. Proc Am Soc Clin Oncol 1992;11: 252. – reference: Rashidbaigi A, et al. The gene for the human immune interferon receptor is located on chromosome 6. Proc Natl Acad Sci USA 1986;83: 384-388. – reference: Pestka S. The interferon receptors. Semin Oncol 1997;24: S9. – reference: Roberts RM, Ezashi T, Rosenfeld CS, Ealy AD, Kubisch HM. Evolution of the interferon τ genes and their promoters, and maternal-trophoblast interactions in control of their expression. Reprod Suppl 2003;61: 239-251. – reference: Moschos SJ, Kirkwood JM, Konstantinopoulos PA. Present status and future prospects for adjuvant therapy of melanoma: time to build upon the foundation of high-dose interferon alfa-2b. J Clin Oncol 2004;22: 11-14. – reference: Young HA, Ghosh P. Molecular regulation of cytokine gene expression: interferon-gamma as a model system. Prog Nucleic Acid Res Mol Biol 1997;56: 109-127. – reference: Lefevre F, Guillomot M, D'Andrea S, Battegay S, La Bonnardiere C. Interferon-δ: the first member of a novel type I interferon family. Biochimie 1998;80: 779-788. – reference: Ota N, Brett TJ, Murphy TL, Fremont DH, Murphy KM. N-domain-dependent nonphosphorylated STAT4 dimers required for cytokine-driven activation. Nat Immunol 2004;5: 208-215. – reference: Robertsen B, Bergan V, Rokenes T, Larsen R, Albuquerque A. Atlantic salmon interferon genes: cloning, sequence analysis, expression, and biological activity. J Interferon Cytokine Res 2003;23: 601-612. – reference: Fisher PB, Prignoli DR, Hermo H Jr, Weinstein IB, Pestka S. Effects of combined treatment with interferon and mezerein on melanogenesis and growth in human melanoma cells. J Interferon Res 1985;5: 11-22. – reference: Krause CD, et al. Signaling by covalent heterodimers of interferon-gamma. Evidence for one-sided signaling in the active tetrameric receptor complex. J Biol Chem 2000;275: 22995-23004. – reference: Yang CH, et al. Direct association of STAT3 with the IFNAR-1 chain of the human type I interferon receptor. J Biol Chem 1996;271: 8057-8061. – reference: Ozato K, Tsujimura H, Tamura T. Toll-like receptor signaling and regulation of cytokine gene expression in the immune system. Biotechniques 2002; 66-68,70,72. – reference: Paredes J, Krown SE. Interferon-alpha therapy in patients with Kaposi's sarcoma and the acquired immunodeficiency syndrome. Int J Immunopharmacol 1991;13: 77-81. – reference: Oritani K, Kincade PW, Zhang C, Tomiyama Y, Matsuzawa Y. Type I interferons and limitin: a comparison of structures, receptors, and functions. Cytokine Growth Factor Rev 2001;12: 337-348. – reference: Rubinstein M, et al. Human leukocyte interferon: isolation characterization several molecular forms. Arch Biochem Biophys 1981;210: 307-318. – reference: Park YB, Lee SK, Kim DS, Lee J, Lee CH, Song CH. Elevated interleukin-10 levels correlated with disease activity in systemic lupus erythematosus. Clin Exp Rheumatol 1998;16: 283-288. – reference: Hayden FG, Albrecht JK, Kaiser DL, Gwaltney JM Jr. Prevention of natural colds by contact prophylaxis with intranasal alpha 2-interferon. N Engl J Med 1986; 314: 71-75. – reference: Cross JC, Farin CE, Sharif SF, Roberts RM. Characterization of the antiviral activity constitutively produced by murine conceptuses: absence of placental mRNAs for interferon alpha and beta. Mol Reprod Dev 1990;26: 122-128. – reference: Masihi KN. Fighting infection using immunomodulatory agents. Expert Opin Biol Ther 2001;1: 641-653. – reference: Shuai K, Stark GR, Kerr IM, Darnell JE Jr. A single phosphotyrosine residue of Stat91 required for gene activation by interferon-γ. Science 1993;261: 1744-1746. – reference: Galabov A, Savov Z, Vassileva V. Interferon production in arbovirus-infected cell cultures of tortoise (Testudo graeca) kidney. Acta Virol 1973;17: 1-10. – reference: Kirkwood JM, et al. Systemic interferon-alpha (IFN-alpha) treatment leads to Stat3 inactivation in melanoma precursor lesions. Mol Med 1999;5: 11-20. – reference: Langer JA, Rashidbaigi A, Garotta G, Kempner E. Radiation inactivation of human gamma-interferon: cellular activation requires two dimers. Proc Natl Acad Sci USA 1994;91: 5818-5822. – reference: Reboul J, Gardiner K, Monneron D, Uze G, Lutfalla G. Comparative genomic analysis of the interferon/interleukin-10 receptor gene cluster. Genome Res 1999;9: 242-250. – reference: Glezerman M, et al. Placebo-controlled trial of topical interferon in labial and genital herpes. Lancet 1988;1: 150-152. – reference: Taniguchi T, Tanaka N, Ogasawara K, Taki S, Sato M, Takaoka A. Transcription factor IRF-1 and its family members in the regulation of host defense. Cold Spring Harb Symp Quant Biol 1999;64: 465-472. – reference: Senda T, Saitoh S, Mitsui Y. Refined crystal structure of recombinant murine interferon-β at 2.15 Å resolution. J Mol Biol 1995;253: 187-207. – reference: Jung V, et al. Chromosome mapping of biological pathways by fluorescence-activated cell sorting and cell fusion: human interferon gamma receptor as a model system. Somat Cell Mol Genet 1988;14: 583-592. – reference: Sheppard P, et al. IL-28, IL-29 and their class II cytokine receptor IL-28R. Nat Immunol 2003;4: 63-68. – reference: Schindler C, Darnell JE Jr. Transcriptional responses to polypeptide ligands: the JAK-STAT pathway. Annu Rev Biochem 1995;64: 621-651. – reference: Park C, Li S, Cha E, Schindler C. Immune response in Stat2 knockout mice. Immunity 2000;13: 795-804. – reference: Viscomi GC, et al. Antigenic characterization of recombinant, lymphoblastoid, and leukocyte IFN-alpha by monoclonal antibodies. J Interferon Cytokine Res 1999;19: 319-326. – reference: Pianko S, McHutchison JG. Treatment of hepatitis C with interferon and ribavirin. J Gastroenterol Hepatol 2000;15: 581-586. – reference: Lutfalla G, Gardiner K, Proudhon D, Vielh E, Uze G. The structure of the human interferon α/β receptor gene. J Biol Chem 1992;267: 2802-2809. – reference: Evinger M, Rubinstein M, Pestka S. Growth-inhibitory and antiviral activity of purified leukocyte interferon. Ann N Y Acad Sci 1980;350: 399-404. – reference: Ortaldo JR, Mantovani A, Hobbs D, Rubinstein M, Pestka S, Herberman RB. Effects of several species of human leukocyte interferon on cytotoxic activity of NK cells and monocytes. Int J Cancer 1983;31: 285-289. – reference: Farrar MA, Campbell JD, Schreiber RD. Identification of a functionally important sequence in the C terminus of the interferon-gamma receptor. Proc Natl Acad Sci USA 1992;89: 11706-11710. – reference: Staeheli P, Puehler F, Schneider K, Gobel TW, Kaspers B. Cytokines of birds: conserved functions - a largely different look. J Interferon Cytokine Res 2001;21: 993-1010. – reference: Okamoto H, et al. Typing hepatitis C virus by polymerase chain reaction with type-specific primers: application to clinical surveys and tracing infectious sources. J Gen Virol 1992;73: 673-679. – reference: Harrison GA, Young LJ, Watson CM, Miska KB, Miller RD, Deane EM. A survey of type I interferons from a marsupial and monotreme: implications for the evolution of the type I interferon gene family in mammals. Cytokine 2003;21: 105-119. – reference: Berg K. Purification and characterization of murine and human interferons. A review of the literature of the 1970s. Acta Pathol Microbiol Immunol Scand Suppl 1982;279: 1-136. – reference: Dumoutier L, Lejeune D, Hor S, Fickenscher H, Renauld JC. Cloning of a new type II cytokine receptor activating signal transducer and activator of transcription (STAT) 1, STAT2 and STAT3. Biochem J 2003;370: 391-396. – reference: Lutfalla G, et al. Mutant U5A cells are complemented by an interferon-αβ receptor subunit generated by alternative processing of a new member of a cytokine receptor gene cluster. EMBO J 1995;14: 5100-5108. – reference: Randal M, Kossiakoff AA. The 2.0 A structure of bovine interferon-γ; assessment of the structural differences between species. Acta Crystallogr D Biol 2000;56: 14-24. – reference: Chill JH, Quandt SR, Levy R, Schreiber G, Anglister J. The human type I initerferon receptor: NMR structure reveals the molecular basis of ligand binding. Structure 11: 791-802. – reference: Pestka S, Evinger M, McCandliss R, Sloma A, Rubinstein M. Human interferon: the messenger RNA and the proteins. In: Beers RF, Bassett EG, eds. Polypeptide Hormones. New York: Raven Press 1980, 33-48. – reference: Lutfalla G, Crollius HR, Stange-Thomann N, Jaillon O, Mogensen K, Monneron D. Comparative genomic analysis reveals independent expansion of a lineage-specific gene family in vertebrates: the class II cytokine receptors and their ligands in mammals and fish. BMC Genomics 2003;4: 29. – reference: Jung V, Jones C, Kumar CS, Stefanos S, O'Connell S, Pestka S. Expression and reconstitution of a biologically active human interferon-gamma receptor in hamster cells. J Biol Chem 1990;265: 1827-1830. – reference: Altmann SM, Mellon MT, Distel DL, Kim CH. Molecular and functional analysis of an interferon gene from the zebrafish, Danio rerio. J Virol 2003;77: 1992-2002. – reference: Greiner JW, et al. Recombinant interferon enhances monoclonal antibody-targeting carcinoma lesions in vivo. Science 1987;235: 895-898. – reference: Nathan PD, Gore ME, Eisen TG. Unexpected toxicity of combination thalidomide and interferon alpha-2a treatment in metastatic renal cell carcinoma. J Clin Oncol 2002;20: 1429-1430. – reference: Eilers A, Decker T. Activity of Stat family transcription factors is developmentally controlled in cells of the macrophage lineage. Immunobiology 1995;193: 328-333. – reference: Enomoto N, et al. Comparison of full-length sequences of interferon-sensitive and resistant hepatitis C virus 1b. Sensitivity to interferon is conferred by amino acid substitutions in the NS5A region. J Clin Invest 1995;96: 224-230. – reference: Bakhutashvili VI, Merabishvili DG, Gogitashvili RV, Korsantiia BM, Dzotsenidze LL. [Physicochemical and biological properties of human placental amniotic interferon]. Vopr Virusol 1985;30: 693-697. – reference: Ozzello L, DeRosa CM, Habif DV, Cantell K, Pestka S. Up-regulation of a tumor-associated antigen (TAG-72) by interferons alpha and gamma in patients with cutaneous breast cancer recurrences. Int J Oncol 1995;6: 985-991. – reference: Roffi L, et al. Breakthrough during recombinant interferon alfa therapy in patients with chronic hepatitis C virus infection: prevalence, etiology, and management. Hepatology 1995;21: 645-649. – reference: Stein S, Kenny C, Friesen HJ, Shively J, Del Valle U, Pestka S. NH2-terminal amino acid sequence of human fibroblast interferon. Proc Natl Acad Sci USA 1980;77: 5716-5719. – reference: Pestka S, et al. Human interferon: the messenger RNA and the proteins. In: De Weck AL, Kristensen F, Landy M, eds. Biochemical Characterization of Lymphokines. New York: Academic Press, 1980: 315-321. – reference: Stancato LF, et al. Beta interferon and oncostatin M activate Raf-1 and mitogen-activated protein kinase through a JAK1-dependent pathway. Mol Cell Biol 1997;17: 3833-3840. – reference: Randal M, Kossiakoff AA. The structure and activity of a monomeric interferon-γ: α-chain receptor signaling complex. Structure (Camb) 2001;9: 155-163. – reference: Roberts RM, Cross JC, Leaman DW. Unique features of the trophoblast interferons. Pharmacol Ther 1991;51: 329-345. – reference: Herberman RB, Ortaldo JR, Mantovani A, Hobbs DS, Kung H-F, Pestka S. Effect of human recombinant interferon on cytotoxic activity of natural killer (NK) cells and monocytes. Cell Immunol 1982;67: 160-167. – reference: Su L, David M. Distinct mechanisms of STAT phosphorylation via the interferon-alpha/beta receptor. Selective inhibition of STAT3 and STAT5 by piceatannol. J Biol Chem 2000;275: 12661-12666. – reference: Dutcher J, et al. Kidney cancer: the Cytokine Working Group experience (1986-2001): part II. Management of IL-2 toxicity and studies with other cytokines. Med Oncol 2001;18: 209-219. – reference: Schultz U, Kock J, Schlicht HJ, Staeheli P. Recombinant duck interferon: a new reagent for studying the mode of interferon action against hepatitis B virus. Virology 1995;212: 641-649. – reference: Karpusas M, Nolte M, Benton CB, Meier W, Lipscomb WN, Goelz S. The crystal structure of human interferon β at 2.2-Å resolution. Proc Natl Acad Sci USA 1997; 94: 11813-11818. – reference: Masihi KN. Immunomodulators in infectious diseases: panoply of possibilities. Int J Immunopharmacol 2000;22: 1083-1091. – reference: Sun W, Schuchter LM. Metastatic melanoma. Curr Treat Options Oncol 2001;2: 193-202. – reference: Braunstein J, Brutsaert S, Olson R, Schindler C. STATs dimerize in the absence of phosphorylation. J Biol Chem 2003;278: 34133-34140. – reference: Llorente L, et al. Role of interleukin 10 in the B lymphocyte hyperactivity and autoantibody production of human systemic lupus erythematosus. J Exp Med 1995;181: 839-844. – reference: Galabov A, Petrunova S, Savov Z. Molecular weight of virus-induced tortoise interferon in cell cultures. Experientia 1973;29: 900-901. – reference: Nolte KU, Jakschies D, Pestka S, Von Wussow P. Different specificities of SLE-derived and therapy-induced interferon-alpha antibodies. J Interferon Res 1994;14: 197-199. – reference: Abramovich C, Yakobson B, Chebath J, Revel M. A protein-arginine methyltransferase binds to the intracytoplasmic domain of the IFNAR1 chain in the type I interferon receptor. EMBO J 1997;16: 260-266. – reference: Stancato LF, David M, Carter-Su C, Larner AC, Pratt WB. Preassociation of STAT1 with STAT2 and STAT3 in separate signalling complexes prior to cytokine stimulation. J Biol Chem 1996;271: 4134-4137. – reference: Bach EA, Aguet M, Schreiber RD. The IFNγ receptor: a paradigm for cytokine receptor signaling. Annu Rev Immunol 1997;15: 563-591. – reference: Pestka S, Kotenko SV, Muthukumaran G, Izotova L, Cook JR, Garotta G. The interferon γ (IFN-γ) receptor: a paradigm for the multichain cytokine receptor. Cytokine Growth Factor Rev 1997;8: 189-206. – reference: Sakatsume M, et al. Interferon gamma activation of Raf-1 is Jak1-dependent and p21ras-independent. J Biol Chem 1998;273: 3021-3026. – reference: Borden EC, Lindner D, Dreicer R, Hussein M, Peereboom D. Second-generation interferons for cancer: clinical targets. Semin Cancer Biol 2000;10: 125-144. – reference: Soh J, Donnelly RJ, Mariano TM, Cook JR, Schwartz B, Pestka S. Identification of a yeast artificial chromosome clone encoding an accessory factor for the human interferon gamma receptor: evidence for multiple accessory factors. Proc Natl Acad Sci USA 1993;90: 8737-8741. – reference: Suresh M, Karaca K, Foster D, Sharma JM. Molecular and functional characterization of turkey interferon. J Virol 1995;69: 8159-8163. – reference: Touitou R, Cochet C, Joab I. Transcriptional analysis of the Epstein-Barr virus interleukin-10 homologue during the lytic cycle. J Gen Virol 1996;77: 1163-1168. – reference: Cavalieri RL, Havell EA, Vilcek J, Pestka S. Induction and decay of human fibroblast interferon mRNA. Proc Natl Acad Sci USA 1977;74: 4415-4419. – reference: Keay S, Grossberg SE. Interferon inhibits the conversion of 3T3-L1 mouse fibroblasts into adipocytes. Proc Natl Acad Sci USA 1980;77: 4099-4103. – reference: Novick D, Cohen B, Rubenstein M. The human interferon α/β receptor: characterization and molecular cloning. Cell 1994;77: 391-400. – reference: Fountoulakis M, Zulauf M, Lusting A, Garotta G. Stoichiometry of interaction between interferon gamma and its receptor. Eur J Biochem 1992;208: 781-787. – reference: Lutfalla G, Gardiner K, Uze G. A new member of the cytokine receptor gene family maps on chromosome 21 at less than 53 kb from IFNAR. Genomics 1993;16: 366-373. – reference: Raanani P, Ben Bassat I. Immune-mediated complications during interferon therapy in hematological patients. Acta Haematol 2002;107: 133-144. – reference: Diaz MO, et al. Structure of the human type-I interferon gene cluster determined from a YAC clone contig. Genomics 1994;22: 540-552. – reference: Basham TY, Bourgeade MF, Creasey AA, Merigan TC. Interferon increases HLA synthesis in melanoma cells: interferon-resistant and -sensitive cell lines. Proc Natl Acad Sci USA 1982;79: 3265-3269. – reference: Takayanagi H, et al. RANKL maintains bone homeostasis through c-Fos-dependent induction of interferon-beta. Nature 2002;416: 744-749. – reference: Kerbel R, Folkman J. Clinical translation of angiogenesis inhibitors. Nat Rev Cancer 2002;2: 727-739. – reference: Gale MJ Jr, et al. Evidence that hepatitis C virus resistance to interferon is mediated through repression of the PKR protein kinase by the nonstructural 5A protein. Virology 1997;230: 217-227. – reference: Silberberg DH. Specific treatment of multiple sclerosis. Clin Neurosci 1994;2: 271-274. – reference: Nagata S, Mantei N, Weissmann C. The structure of one of the eight or more distinct chromosomal genes for human interferon-a. Nature 1980;287: 401-408. – reference: Hardy MP, Owczarek CM, Jermiin L, Ejdebäck M, Hertzog PJ. Characterization of the type I interferon locus and identification of novel genes. Genomics 2004;84: 331-345. – reference: Tilg H, et al. Treatment of Crohn's disease with recombinant human interleukin 10 induces the proinflammatory cytokine interferon gamma. Gut 2002;50: 191-195. – reference: Rubinstein M, Rubinstein S, Familletti PC, Miller RS, Waldman AA. Human leukocyte interferon purified to homogeneity. Science 1978;202: 1289-1290. – reference: Orange S, Horvath J, Hennessy A. Preeclampsia is associated with a reduced interleukin-10 production from peripheral blood mononuclear cells. Hypertens Pregnancy 2003;22: 1-8. – reference: Rubinstein M, Rubinstein S, Familletti PC, Miller RS, Waldman AA, Pestka S. Human leukocyte interferon: production, purification to homogeneity, and initial characterization. Proc Natl Acad Sci USA 1979;76: 640-644. – reference: Ortaldo JR, et al. A species of human α interferon that lacks the ability to boost human natural killer activity. Proc Natl Acad Sci USA 1984;81: 4926-4929. – reference: Soh J, et al. Expression of a functional human type I interferon receptor in hamster cells: application of functional yeast artificial chromosome (YAC) screening. J Biol Chem 1994;269: 18102-18110. – reference: Bazan JF. Structural design and molecular evolution of a cytokine receptor superfamily. Proc Natl Acad Sci USA 1990;87: 6934-6938. – reference: Fisher PB, Hermo H Jr, Prignoli DR, Weinstein IB, Pestka S. Hybrid recombinant human leukocyte interferon inhibits differentiation in murine B-16 melanoma cells. Biochem Biophys Res Commun 1984;119: 108-115. – reference: Greiner JW, et al. Modulation of tumor associated antigen expression and shedding by recombinant human leukocyte and fibroblast interferons. Pharmacol Ther 1985;31: 209-236. – reference: Cleary CM, Donnelly RJ, Soh J, Mariano TM, Pestka S. Knockout and reconstitution of a functional human type I interferon receptor complex. J Biol Chem 1994;269: 18747-18749. – reference: Pestka S. The purification and manufacture of human interferons. Sci Am 1983;249: 36-43. – reference: Hijikata M, Mishiro S, Miyamoto C, Furuichi Y, Hashimoto M, Ohta Y. Genetic polymorphism of the MxA gene promoter and interferon responsiveness of hepatitis C patients: revisited by analyzing two SNP sites (−123 and −88) in vivo and in vitro. Intervirology 2001;44: 379-382. – reference: Uze G, Lutfalla G, Gresser I. Genetic transfer of a functional human interferon α receptor into mouse cells: cloning and expression of its cDNA. Cell 1990;60: 225-234. – reference: Lembo D, et al. Mouse macrophages carrying both subunits of the human interferon-gamma (IFN-gamma) receptor respond to human IFN-gamma but do not acquire full protection against viral cytopathic effect. J Biol Chem 1996;271: 32659-32666. – reference: Scott GM, Phillpotts RJ, Wallace J, Gauci CL, Greiner J, Tyrrell DA. Prevention of rhinovirus colds by human interferon alpha-2 from Escherichia coli. Lancet 1982;2: 186-188. – reference: Zou J, Clark MS, Secombes CJ. Characterisation, expression and promoter analysis of an interleukin 10 homologue in the puffer fish, Fugu rubripes. Immunogenetics 2003;55: 325-335. – reference: Ortaldo JR, et al. Effects of recombinant and hybrid recombinant human leukocyte interferons on cytotoxic activity of natural killer cells. J Biol Chem 1983;258: 15011-15015. – reference: Shuai K, Schindler C, Prezioso VR, Darnell JE Jr. Activation of transcription by IFN-γ: tyrosine phosphorylation of a 91-kD DNA binding protein. Science 1992;258: 1808-1812. – reference: Greiner JW, Hand PH, Noguchi P, Fisher PB, Pestka S, Schlom J. Enhanced expression of surface tumor-associated antigens on human breast and colon tumor cells after recombinant human leukocyte α-interferon treatment. Cancer Res 1984;44: 3208-3214. – reference: Takayama T, et al. Mammalian and viral IL-10 enhance C-C chemokine receptor 5 but down-regulate C-C chemokine receptor 7 expression by myeloid dendritic cells: impact on chemotactic responses and in vivo homing ability. J Immunol 2001;166: 7136-7143. – reference: Mazzella G, et al. Long-term results with interferon therapy in chronic type B hepatitis: a prospective randomized trial. Am J Gastroenterol 1999;94: 2246-2250. – reference: Maeda S, et al. Construction and identification of bacterial plasmids containing nucleotide sequence for human leukocyte interferon. Proc Natl Acad Sci USA 1980;77: 7010-7013. – reference: Soh J, et al. Identification and sequence of an accessory factor required for activation of the human interferon-γ receptor. Cell 1994;76: 796-803. – reference: Liva SM, Voskuhl RR. Testosterone acts directly on CD4+ T lymphocytes to increase IL-10 production. J Immunol 2001;167: 2060-2067. – reference: Cook JR, Jung V, Schwartz B, Wang P, Pestka S. Structural analysis of the human interferon gamma receptor: a small segment of the intracellular domain is specifically required for class I major histocompatibility complex antigen induction and antiviral activity. Proc Natl Acad Sci USA 1992;89: 11317-11321. – reference: Pestka S. The human interferons - from protein purification and sequence to cloning and expression in bacteria: before, between, beyond. Arch Biochem Biophys 1983;221: 1-37. – reference: Duc-Goiran P, Lebon P, Chany C. Measurement of interferon in human amniotic fluid and placental blood extract. Methods Enzymol 1986;119: 541-551. – reference: Kaempfer R. RNA sensors: novel regulators of gene expression. EMBO Rep 2003;4: 1043-1047. – reference: Maniatis T. Mechanisms of human beta-interferon gene regulation. Harvey Lect 1986;82: 71-104. – reference: Kawamoto S, et al. Antiviral activity of limitin against encephalomyocarditis virus, herpes simplex virus, and mouse hepatitis virus: diverse requirements by limitin and alpha interferon for interferon regulatory factor 1. J Virol 2003;77: 9622-9631. – reference: Dolei A, Capobianchi MR, Ameglio F. Human interferon-γ enhances the expression of class I and class II major histocompatibility complex products in neoplastic cells more effectively than interferon-α and interferon-β. Infect Immun 1983;40: 172-176. – reference: Nguyen H, Ramana CV, Bayes J, Stark GR. Roles of phosphatidylinositol 3-kinase in interferon-gamma-dependent phosphorylation of STAT1 on serine 727 and activation of gene expression. J Biol Chem 2001;276: 33361-33368. – reference: Galabov AS, Velichikova EH. Interferon production in tortoise peritoneal cells. J Gen Virol 1975;28: 259-263. – reference: Taniguchi T, Takaoka A. The interferon-alpha/beta system in antiviral responses: a multimodal machinery of gene regulation by the IRF family of transcription factors. Curr Opin Immunol 2002;14: 111-116. – reference: Fu XY, Schindler C, Improta T, Aebersold R, Darnell JE Jr. The proteins of ISGF-3, the interferon alpha-induced transcriptional activator, define a gene family involved in signal transduction. Proc Natl Acad Sci USA 1992;89: 7840-7843. – reference: Fidler IJ. Regulation of neoplastic angiogenesis. J Natl Cancer Inst Monogr 2001; 10-14. – reference: Lander A, et al. Design, characterization, and structure of a biologically active single-chain mutant of human IFN-gamma. J Mol Biol 2000;299: 169-179. – reference: Thiel DJ, et al. Observation of an unexpected third receptor molecule in the crystal structure of human interferon-γ receptor complex. Structure Fold Des 2000;8: 927-936. – reference: Van Herpen CM, De Mulder PH. Locoregional immunotherapy in cancer patients: review of clinical studies. Ann Oncol 2000;11: 1229-1239. – reference: Kirkwood JM, Ibrahim JG, Sondak VK, Ernstoff MS, Ross M. Interferon alfa-2a for melanoma metastases. Lancet 2002;359: 978-979. – reference: Radhakrishnan R, Walter LJ, Subramaniam PS, Johnson HM, Walter MR. Crystal structure of ovine interferon-τ at 2.1 Å resolution. J Mol Biol 1999;286: 151-162. – reference: Sen GC, Herz R, Davatelis V, Pestka S. Antiviral and protein-inducing activities of recombinant human leukocyte interferons and their hybrids. J Virol 1984;50: 445-450. – reference: Oritani K, Kincade PW, Tomiyama Y. Limitin: an interferon-like cytokine without myeloerythroid suppressive properties. J Mol Med 2001;79: 168-174. – reference: Chung CD, et al. Specific inhibition of Stat3 signal transduction by PIAS3. Science 1997;278: 1803-1805. – reference: Kile BT, Schulman BA, Alexander WS, Nicola NA, Martin HM, Hilton DJ. The SOCS box: a tale of destruction and degradation. Trends Biochem Sci 2002;27: 235-241. – reference: Schindler C, Fu XY, Improta T, Aebersold R, Darnell JE Jr. Proteins of transcription factor ISGF-3: one gene encodes the 91-and 84-kDa ISGF-3 proteins that are activated by interferon α. Proc Natl Acad Sci USA 1992;89: 7836-7839. – reference: Einhorn S, Strander H. Interferon treatment of human malignancies - a short review. Med Oncol Tumor Pharmacother 1993;10: 25-29. – reference: Kotenko SV, Krause CD, Izotova LS, Pollack BP, Wu W, Pestka S. Identification and characterization of a second chain of the interleukin-10 receptor complex. EMBOJ 1997;16: 5894-5903. – reference: Marsters SA, Pennica D, Bach E, Schreiber RD, Ashkenazi A. Interferon gamma signals via a high-affinity multisubunit receptor complex that contains two types of polypeptide chain. Proc Natl Acad Sci USA 1995;92: 5401-5405. – reference: Hemmi S, Bohni R, Stark G, Di Marco F, Aguet M. A novel member of the interferon receptor family complements functionality of the murine interferon γ receptor in human cells. Cell 1994;76: 803-810. – volume: 14 start-page: 111 year: 2002 end-page: 116 article-title: The interferon‐alpha/beta system in antiviral responses: a multimodal machinery of gene regulation by the IRF family of transcription factors publication-title: Curr Opin Immunol – volume: 11 start-page: 39 year: 2000 article-title: IFN‐κ, a novel type I interferon publication-title: Eur Cytokine Netw – volume: 4 start-page: 69 year: 2003 end-page: 77 article-title: IFN‐λs mediate antiviral protection through a distinct class II cytokine receptor complex publication-title: Nat Immunol – volume: 76 start-page: 796 year: 1994 end-page: 803 article-title: Identification and sequence of an accessory factor required for activation of the human interferon‐γ receptor publication-title: Cell – volume: 9 start-page: 242 year: 1999 end-page: 250 article-title: Comparative genomic analysis of the interferon/interleukin‐10 receptor gene cluster publication-title: Genome Res – volume: 79 start-page: 3265 year: 1982 end-page: 3269 article-title: Interferon increases HLA synthesis in melanoma cells: interferon‐resistant and ‐sensitive cell lines publication-title: Proc Natl Acad Sci USA – volume: 275 start-page: 12661 year: 2000 end-page: 12666 article-title: Distinct mechanisms of STAT phosphorylation via the interferon‐alpha/beta receptor. Selective inhibition of STAT3 and STAT5 by piceatannol publication-title: J Biol Chem – volume: 67 start-page: 160 year: 1982 end-page: 167 article-title: Effect of human recombinant interferon on cytotoxic activity of natural killer (NK) cells and monocytes publication-title: Cell Immunol – volume: 84 start-page: 431 year: 1996 end-page: 442 article-title: Targeted disruption of the Stat1 gene in mice reveals unexpected physiologic specificity in the JAK‐STAT signaling pathway publication-title: Cell – volume: 57 start-page: 289 year: 1997 end-page: 303 article-title: Chicken‐embryo fibroblasts produce two types of interferon upon stimulation with Newcastle disease virus publication-title: Vet Immunol Immunopathol – volume: 287 start-page: 401 year: 1980 end-page: 408 article-title: The structure of one of the eight or more distinct chromosomal genes for human interferon‐a publication-title: Nature – volume: 74 start-page: 4415 year: 1977 end-page: 4419 article-title: Induction and decay of human fibroblast interferon mRNA publication-title: Proc Natl Acad Sci USA – volume: 21 start-page: 105 year: 2003 end-page: 119 article-title: A survey of type I interferons from a marsupial and monotreme: implications for the evolution of the type I interferon gene family in mammals publication-title: Cytokine – volume: 424 start-page: 516 year: 2003 end-page: 523 article-title: Integration of interferon‐alpha/beta signalling to p53 responses in tumour suppression and antiviral defence publication-title: Nature – volume: 276 start-page: 33361 year: 2001 end-page: 33368 article-title: Roles of phosphatidylinositol 3‐kinase in interferon‐gamma‐dependent phosphorylation of STAT1 on serine 727 and activation of gene expression publication-title: J Biol Chem – volume: 4 start-page: 1043 year: 2003 end-page: 1047 article-title: RNA sensors: novel regulators of gene expression publication-title: EMBO Rep – volume: 193 start-page: 328 year: 1995 end-page: 333 article-title: Activity of Stat family transcription factors is developmentally controlled in cells of the macrophage lineage publication-title: Immunobiology – volume: 18 start-page: 209 year: 2001 end-page: 219 article-title: Kidney cancer: the Cytokine Working Group experience (1986–2001): part II. Management of IL‐2 toxicity and studies with other cytokines publication-title: Med Oncol – volume: 64 start-page: 621 year: 1995 end-page: 651 article-title: Transcriptional responses to polypeptide ligands: the JAK‐STAT pathway publication-title: Annu Rev Biochem – volume: 1 start-page: 953 year: 1982 end-page: 958 article-title: Cloning and structure of the human immune interferon‐γ chromosomal gene publication-title: EMBO J – volume: 271 start-page: 8057 year: 1996 end-page: 8061 article-title: Direct association of STAT3 with the IFNAR‐1 chain of the human type I interferon receptor publication-title: J Biol Chem – volume: 119 start-page: 108 year: 1984 end-page: 115 article-title: Hybrid recombinant human leukocyte interferon inhibits differentiation in murine B‐16 melanoma cells publication-title: Biochem Biophys Res Commun – volume: 299 start-page: 169 year: 2000 end-page: 179 article-title: Design, characterization, and structure of a biologically active single‐chain mutant of human IFN‐gamma publication-title: J Mol Biol – start-page: 33 year: 1980 end-page: 48 – volume: 56 start-page: 727 year: 1987 end-page: 777 article-title: Interferons and their actions publication-title: Annu Rev Biochem – start-page: 1279 year: 1982 end-page: 1283 – volume: 2 start-page: 271 year: 1994 end-page: 274 article-title: Specific treatment of multiple sclerosis publication-title: Clin Neurosci – volume: 55 start-page: 325 year: 2003 end-page: 335 article-title: Characterisation, expression and promoter analysis of an interleukin 10 homologue in the puffer fish, publication-title: Immunogenetics – volume: 55 start-page: 254 year: 2000 end-page: 287 article-title: The human interferon α species and receptors publication-title: Biopolymers – volume: 5 start-page: 11 year: 1999 end-page: 20 article-title: Systemic interferon‐alpha (IFN‐alpha) treatment leads to Stat3 inactivation in melanoma precursor lesions publication-title: Mol Med – volume: 16 start-page: 5894 year: 1997 end-page: 5903 article-title: Identification and characterization of a second chain of the interleukin‐10 receptor complex publication-title: EMBOJ – volume: 22 start-page: 11 year: 2004 end-page: 14 article-title: Present status and future prospects for adjuvant therapy of melanoma: time to build upon the foundation of high‐dose interferon alfa‐2b publication-title: J Clin Oncol – volume: 76 start-page: 640 year: 1979 end-page: 644 article-title: Human leukocyte interferon: production, purification to homogeneity, and initial characterization publication-title: Proc Natl Acad Sci USA – volume: 14 start-page: 5100 year: 1995 end-page: 5108 article-title: Mutant U5A cells are complemented by an interferon‐αβ receptor subunit generated by alternative processing of a new member of a cytokine receptor gene cluster publication-title: EMBO J – volume: 92 start-page: 386 year: 1984 end-page: 391 article-title: Interferon therapy in juvenile laryngeal papillomatosis publication-title: Otolaryngol Head Neck Surg – volume: 210 start-page: 319 year: 1981 end-page: 329 article-title: Antiproliferative and antiviral activities of human leukocyte interferons publication-title: Arch Biochem Biophys – volume: 98 start-page: 6680 year: 2001 end-page: 6685 article-title: Biologic consequences of Stat1‐independent IFN signaling publication-title: Proc Natl Acad Sci USA – volume: 13 start-page: 795 year: 2000 end-page: 804 article-title: Immune response in Stat2 knockout mice publication-title: Immunity – volume: 40 start-page: 846 year: 1996 end-page: 852 article-title: Interferon beta‐1b inhibits gelatinase secretion and in vitro migration of human T cells: a possible mechanism for treatment efficacy in multiple sclerosis publication-title: Ann Neurol – volume: 10 start-page: 7 year: 1997 end-page: 14 article-title: Interferon antibodies in patients with infectious diseases. Anti‐interferon antibodies publication-title: Biotherapy – volume: 17 start-page: 3833 year: 1997 end-page: 3840 article-title: Beta interferon and oncostatin M activate Raf‐1 and mitogen‐activated protein kinase through a JAK1‐dependent pathway publication-title: Mol Cell Biol – volume: 24 start-page: S9 year: 1997 article-title: The interferon receptors publication-title: Semin Oncol – volume: 15 start-page: 581 year: 2000 end-page: 586 article-title: Treatment of hepatitis C with interferon and ribavirin publication-title: J Gastroenterol Hepatol – volume: 31 start-page: 209 year: 1985 end-page: 236 article-title: Modulation of tumor associated antigen expression and shedding by recombinant human leukocyte and fibroblast interferons publication-title: Pharmacol Ther – volume: 14 start-page: 197 year: 1994 end-page: 199 article-title: Different specificities of SLE‐derived and therapy‐induced interferon‐alpha antibodies publication-title: J Interferon Res – volume: 274 start-page: 661 year: 1997 end-page: 675 article-title: The three‐dimensional high resolution structure of human interferon α‐2a determined by heteronuclear NMR spectroscopy in solution publication-title: J Mol Biol – volume: 15 start-page: 563 year: 1997 end-page: 591 article-title: The IFNγ receptor: a paradigm for cytokine receptor signaling publication-title: Annu Rev Immunol – volume: 258 start-page: 1808 year: 1992 end-page: 1812 article-title: Activation of transcription by IFN‐γ: tyrosine phosphorylation of a 91‐kD DNA binding protein publication-title: Science – volume: 6 start-page: 985 year: 1995 end-page: 991 article-title: Up‐regulation of a tumor‐associated antigen (TAG‐72) by interferons alpha and gamma in patients with cutaneous breast cancer recurrences publication-title: Int J Oncol – volume: 31 start-page: 285 year: 1983 end-page: 289 article-title: Effects of several species of human leukocyte interferon on cytotoxic activity of NK cells and monocytes publication-title: Int J Cancer – volume: 253 start-page: 187 year: 1995 end-page: 207 article-title: Refined crystal structure of recombinant murine interferon‐β at 2.15 Å resolution publication-title: J Mol Biol – volume: 79 start-page: 168 year: 2001 end-page: 174 article-title: Limitin: an interferon‐like cytokine without myeloerythroid suppressive properties publication-title: J Mol Med – volume: 273 start-page: 1717 year: 1996 end-page: 1719 article-title: Regulation of interferon‐gamma‐activated STAT1 by the ubiquitin‐proteasome pathway publication-title: Science – volume: 50 start-page: 191 year: 2002 end-page: 195 article-title: Treatment of Crohn's disease with recombinant human interleukin 10 induces the proinflammatory cytokine interferon gamma publication-title: Gut – volume: 17 start-page: 899 year: 1992 end-page: 914 article-title: Human IFN‐alpha hybrids publication-title: Drugs Future – volume: 2 start-page: 727 year: 2002 end-page: 739 article-title: Clinical translation of angiogenesis inhibitors publication-title: Nat Rev Cancer – volume: 278 start-page: 34133 year: 2003 end-page: 34140 article-title: STATs dimerize in the absence of phosphorylation publication-title: J Biol Chem – volume: 4 start-page: 63 year: 2003 end-page: 68 article-title: IL‐28, IL‐29 and their class II cytokine receptor IL‐28R publication-title: Nat Immunol – volume: 21 start-page: 645 year: 1995 end-page: 649 article-title: Breakthrough during recombinant interferon alfa therapy in patients with chronic hepatitis C virus infection: prevalence, etiology, and management publication-title: Hepatology – volume: 15 start-page: 625 year: 1995 end-page: 631 article-title: Effect of topical interferon‐beta on recurrence rates in genital herpes: a double‐blind, placebo‐controlled, randomized study publication-title: J Interferon Cytokine Res – volume: 1 start-page: 641 year: 2001 end-page: 653 article-title: Fighting infection using immunomodulatory agents publication-title: Expert Opin Biol Ther – volume: 275 start-page: 22995 year: 2000 end-page: 23004 article-title: Signaling by covalent heterodimers of interferon‐gamma. Evidence for one‐sided signaling in the active tetrameric receptor complex publication-title: J Biol Chem – volume: 77 start-page: 1163 year: 1996 end-page: 1168 article-title: Transcriptional analysis of the Epstein–Barr virus interleukin‐10 homologue during the lytic cycle publication-title: J Gen Virol – volume: 11 start-page: 1229 year: 2000 end-page: 1239 article-title: Locoregional immunotherapy in cancer patients: review of clinical studies publication-title: Ann Oncol – volume: 67 start-page: 227 year: 1998 end-page: 264 article-title: How cells respond to interferons publication-title: Annu Rev Biochem – volume: 12 start-page: 337 year: 2001 end-page: 348 article-title: Type I interferons and limitin: a comparison of structures, receptors, and functions publication-title: Cytokine Growth Factor Rev – volume: 65 start-page: 265 year: 1995 end-page: 287 article-title: Interferons alpha, beta and gamma therapy of anogenital human papillomavirus infections publication-title: Pharmacol Ther – volume: 28 start-page: 259 year: 1975 end-page: 263 article-title: Interferon production in tortoise peritoneal cells publication-title: J Gen Virol – volume: 123 start-page: 528 year: 2003 end-page: 535 article-title: Intracellular signal transduction of interferon on the suppression of haematopoietic progenitor cell growth publication-title: Br J Haematol – start-page: 249 year: 1980 end-page: 263 – volume: 258 start-page: 15011 year: 1983 end-page: 15015 article-title: Effects of recombinant and hybrid recombinant human leukocyte interferons on cytotoxic activity of natural killer cells publication-title: J Biol Chem – volume: 11 start-page: 252 year: 1992 article-title: Phase I study IFN alpha BDBB hybrid publication-title: Proc Am Soc Clin Oncol – volume: 59 start-page: 664 year: 1987 end-page: 667 article-title: Therapy of chronic myelogenous leukemia publication-title: Cancer – volume: 1 start-page: 150 year: 1988 end-page: 152 article-title: Placebo‐controlled trial of topical interferon in labial and genital herpes publication-title: Lancet – volume: 107 start-page: 133 year: 2002 end-page: 144 article-title: Immune‐mediated complications during interferon therapy in hematological patients publication-title: Acta Haematol – volume: 39 start-page: 377 year: 1992 end-page: 380 article-title: Interferon therapy for non‐A, non‐B hepatitis: a pilot study and review of the literature publication-title: Hepatogastroenterology – volume: 212 start-page: 641 year: 1995 end-page: 649 article-title: Recombinant duck interferon: a new reagent for studying the mode of interferon action against hepatitis B virus publication-title: Virology – volume: 73 start-page: 673 year: 1992 end-page: 679 article-title: Typing hepatitis C virus by polymerase chain reaction with type‐specific primers: application to clinical surveys and tracing infectious sources publication-title: J Gen Virol – volume: 277 start-page: 1630 year: 1997 end-page: 1635 article-title: STATs and gene regulation publication-title: Science – volume: 107 start-page: 204 year: 1998 end-page: 210 article-title: Sex chromosome linkage of chicken and duck type I interferon genes: further evidence of evolutionary conservation of the Z chromosome in birds publication-title: Chromosoma – volume: 298 start-page: 859 year: 1982 end-page: 863 article-title: Structure of the human immune interferon gene publication-title: Nature – volume: 13 start-page: 77 year: 1991 end-page: 81 article-title: Interferon‐alpha therapy in patients with Kaposi's sarcoma and the acquired immunodeficiency syndrome publication-title: Int J Immunopharmacol – volume: 147 start-page: 258 year: 1957 end-page: 267 article-title: Virus interference. I. The interferon publication-title: Proc R Soc Lond Ser B Biol Sci – volume: 98 start-page: 6674 year: 2001 end-page: 6679 article-title: Stat1‐independent regulation of gene expression in response to IFN‐gamma publication-title: Proc Natl Acad Sci USA – volume: 5 start-page: 208 year: 2004 end-page: 215 article-title: N‐domain‐dependent nonphosphorylated STAT4 dimers required for cytokine‐driven activation publication-title: Nat Immunol – volume: 359 start-page: 978 year: 2002 end-page: 979 article-title: Interferon alfa‐2a for melanoma metastases publication-title: Lancet – volume: 11 start-page: 25 year: 2004 end-page: 26 article-title: ISICR Committee Minutes publication-title: ISICR Newsletter – volume: 30 start-page: 693 year: 1985 end-page: 697 article-title: [Physicochemical and biological properties of human placental amniotic interferon] publication-title: Vopr Virusol – volume: 77 start-page: 1992 year: 2003 end-page: 2002 article-title: Molecular and functional analysis of an interferon gene from the zebrafish, publication-title: J Virol – volume: 81 start-page: 4926 year: 1984 end-page: 4929 article-title: A species of human α interferon that lacks the ability to boost human natural killer activity publication-title: Proc Natl Acad Sci USA – volume: 22 start-page: 540 year: 1994 end-page: 552 article-title: Structure of the human type‐I interferon gene cluster determined from a YAC clone contig publication-title: Genomics – start-page: 599 year: 1981 end-page: 601 – volume: 416 start-page: 744 year: 2002 end-page: 749 article-title: RANKL maintains bone homeostasis through c‐Fos‐dependent induction of interferon‐beta publication-title: Nature – volume: 17 start-page: 1 year: 1973 end-page: 10 article-title: Interferon production in arbovirus‐infected cell cultures of tortoise ( ) kidney publication-title: Acta Virol – volume: 202 start-page: 1289 year: 1978 end-page: 1290 article-title: Human leukocyte interferon purified to homogeneity publication-title: Science – volume: 297 start-page: 2063 year: 2002 end-page: 2066 article-title: Critical role for STAT4 activation by type 1 interferons in the interferon‐gamma response to viral infection publication-title: Science – volume: 91 start-page: 5818 year: 1994 end-page: 5822 article-title: Radiation inactivation of human gamma‐interferon: cellular activation requires two dimers publication-title: Proc Natl Acad Sci USA – volume: 51 start-page: 329 year: 1991 end-page: 345 article-title: Unique features of the trophoblast interferons publication-title: Pharmacol Ther – volume: 1 start-page: 805 year: 2002 end-page: 815 article-title: Seeing the light: preassembly and ligand‐induced changes of the interferon γ receptor complex in cells publication-title: Mol Cell Proteomics – volume: 4 start-page: 29 year: 2003 article-title: Comparative genomic analysis reveals independent expansion of a lineage‐specific gene family in vertebrates: the class II cytokine receptors and their ligands in mammals and fish publication-title: BMC Genomics – volume: 279 start-page: 1 year: 1982 end-page: 136 article-title: Purification and characterization of murine and human interferons. A review of the literature of the 1970s publication-title: Acta Pathol Microbiol Immunol Scand Suppl – volume: 23 start-page: 277 year: 2003 end-page: 292 article-title: Interferons and apoptosis publication-title: J Interferon Cytokine Res – volume: 185 start-page: 227 year: 1985 end-page: 260 article-title: Structural relationship of human interferon alpha genes and pseudogenes publication-title: J Mol Biol – volume: 22 start-page: 1 year: 2003 end-page: 8 article-title: Preeclampsia is associated with a reduced interleukin‐10 production from peripheral blood mononuclear cells publication-title: Hypertens Pregnancy – volume: 13 start-page: 223 year: 2002 end-page: 240 article-title: The family of IL‐10‐related cytokines and their receptors: related, but to what extent? publication-title: Cytokine Growth Factor Rev – volume: 16 start-page: 283 year: 1998 end-page: 288 article-title: Elevated interleukin‐10 levels correlated with disease activity in systemic lupus erythematosus publication-title: Clin Exp Rheumatol – volume: 171 start-page: 285 year: 2003 end-page: 290 article-title: IFN‐alpha induces the human IL‐10 gene by recruiting both IFN regulatory factor 1 and Stat3 publication-title: J Immunol – volume: 24 start-page: S9 year: 1997 article-title: The human interferon‐α species and hybrid proteins publication-title: Semin Oncol – start-page: 315 year: 1980 end-page: 321 – volume: 10 start-page: 125 year: 2000 end-page: 144 article-title: Second‐generation interferons for cancer: clinical targets publication-title: Semin Cancer Biol – volume: 21 start-page: 993 year: 2001 end-page: 1010 article-title: Cytokines of birds: conserved functions – a largely different look publication-title: J Interferon Cytokine Res – volume: 56 start-page: 109 year: 1997 end-page: 127 article-title: Molecular regulation of cytokine gene expression: interferon‐gamma as a model system publication-title: Prog Nucleic Acid Res Mol Biol – volume: 270 start-page: 21606 year: 1995 end-page: 21611 article-title: Cloning and expression of a long form of the β subunit of the interferon αβ receptor that is required for signaling publication-title: J Biol Chem – volume: 11 start-page: 791 end-page: 802 article-title: The human type I initerferon receptor: NMR structure reveals the molecular basis of ligand binding publication-title: Structure – volume: 41 start-page: 489 year: 1985 end-page: 496 article-title: Delimitation and properties of DNA sequences required for the regulated expression of human interferon‐beta gene publication-title: Cell – volume: 14 start-page: 583 year: 1988 end-page: 592 article-title: Chromosome mapping of biological pathways by fluorescence‐activated cell sorting and cell fusion: human interferon gamma receptor as a model system publication-title: Somat Cell Mol Genet – volume: 314 start-page: 71 year: 1986 end-page: 75 article-title: Prevention of natural colds by contact prophylaxis with intranasal alpha 2‐interferon publication-title: N Engl J Med – volume: 271 start-page: 4134 year: 1996 end-page: 4137 article-title: Preassociation of STAT1 with STAT2 and STAT3 in separate signalling complexes prior to cytokine stimulation publication-title: J Biol Chem – volume: 12 start-page: 363 year: 1992 end-page: 368 article-title: Anti‐HIV‐1 activity of recombinant and hybrid species of interferon‐alpha publication-title: J Interferon Res – volume: 23 start-page: 601 year: 2003 end-page: 612 article-title: Atlantic salmon interferon genes: cloning, sequence analysis, expression, and biological activity publication-title: J Interferon Cytokine Res – volume: 77 start-page: 5716 year: 1980 end-page: 5719 article-title: NH2‐terminal amino acid sequence of human fibroblast interferon publication-title: Proc Natl Acad Sci USA – start-page: 353 year: 1983 end-page: 358 – volume: 235 start-page: 895 year: 1987 end-page: 898 article-title: Recombinant interferon enhances monoclonal antibody‐targeting carcinoma lesions in vivo publication-title: Science – volume: 8 start-page: 189 year: 1997 end-page: 206 article-title: The interferon γ (IFN‐γ) receptor: a paradigm for the multichain cytokine receptor publication-title: Cytokine Growth Factor Rev – volume: 286 start-page: 151 year: 1999 end-page: 162 article-title: Crystal structure of ovine interferon‐τ at 2.1 Å resolution publication-title: J Mol Biol – volume: 269 start-page: 18747 year: 1994 end-page: 18749 article-title: Knockout and reconstitution of a functional human type I interferon receptor complex publication-title: J Biol Chem – volume: 264 start-page: 1415 year: 1994 end-page: 1421 article-title: Jak‐STAT pathways and transcriptional activation in response to IFNs and other extracellular signaling proteins publication-title: Science – volume: 269 start-page: 18102 year: 1994 end-page: 18110 article-title: Expression of a functional human type I interferon receptor in hamster cells: application of functional yeast artificial chromosome (YAC) screening publication-title: J Biol Chem – volume: 77 start-page: 4099 year: 1980 end-page: 4103 article-title: Interferon inhibits the conversion of 3T3‐L1 mouse fibroblasts into adipocytes publication-title: Proc Natl Acad Sci USA – volume: 350 start-page: 399 year: 1980 end-page: 404 article-title: Growth‐inhibitory and antiviral activity of purified leukocyte interferon publication-title: Ann N Y Acad Sci – volume: 89 start-page: 7840 year: 1992 end-page: 7843 article-title: The proteins of ISGF‐3, the interferon alpha‐induced transcriptional activator, define a gene family involved in signal transduction publication-title: Proc Natl Acad Sci USA – volume: 208 start-page: 781 year: 1992 end-page: 787 article-title: Stoichiometry of interaction between interferon gamma and its receptor publication-title: Eur J Biochem – volume: 264 start-page: 16507 year: 1989 end-page: 16511 article-title: Unusually large interferon‐alpha‐like mRNAs and high expression of interleukin‐6 in human fetal annexes publication-title: J Biol Chem – volume: 210 start-page: 307 year: 1981 end-page: 318 article-title: Human leukocyte interferon: isolation characterization several molecular forms publication-title: Arch Biochem Biophys – start-page: 58 year: 2002; end-page: 65 article-title: Signal transduction by type I interferons publication-title: Biotechniques – volume: 89 start-page: 11706 year: 1992 end-page: 11710 article-title: Identification of a functionally important sequence in the C terminus of the interferon‐gamma receptor publication-title: Proc Natl Acad Sci USA – volume: 84 start-page: 331 year: 2004 end-page: 345 article-title: Characterization of the type I interferon locus and identification of novel genes publication-title: Genomics – start-page: 362 year: 1981 end-page: 368 – volume: 31 start-page: 1317 year: 2003 end-page: 1322 article-title: Limitin, an interferon‐like cytokine, transduces inhibitory signals on B‐cell growth through activation of Tyk2, but not Stat1, followed by induction and nuclear translocation of Daxx publication-title: Exp Hematol – volume: 166 start-page: 7136 year: 2001 end-page: 7143 article-title: Mammalian and viral IL‐10 enhance C‐C chemokine receptor 5 but down‐regulate C‐C chemokine receptor 7 expression by myeloid dendritic cells: impact on chemotactic responses and in vivo homing ability publication-title: J Immunol – volume: 370 start-page: 391 year: 2003 end-page: 396 article-title: Cloning of a new type II cytokine receptor activating signal transducer and activator of transcription (STAT) 1, STAT2 and STAT3 publication-title: Biochem J – volume: 278 start-page: 1803 year: 1997 end-page: 1805 article-title: Specific inhibition of Stat3 signal transduction by PIAS3 publication-title: Science – volume: 26 start-page: 122 year: 1990 end-page: 128 article-title: Characterization of the antiviral activity constitutively produced by murine conceptuses: absence of placental mRNAs for interferon alpha and beta publication-title: Mol Reprod Dev – volume: 64 start-page: 465 year: 1999 end-page: 472 article-title: Transcription factor IRF‐1 and its family members in the regulation of host defense publication-title: Cold Spring Harb Symp Quant Biol – volume: 19 start-page: 2557 year: 2000 end-page: 2565 article-title: Jak‐Stat signal transduction pathway through the eyes of cytokine class II receptor complexes publication-title: Oncogene – volume: 5 start-page: 11 year: 1985 end-page: 22 article-title: Effects of combined treatment with interferon and mezerein on melanogenesis and growth in human melanoma cells publication-title: J Interferon Res – volume: 221 start-page: 1 year: 1983 end-page: 37 article-title: The human interferons – from protein purification and sequence to cloning and expression in bacteria: before, between, beyond publication-title: Arch Biochem Biophys – volume: 108 start-page: 221 year: 2002 end-page: 232 article-title: Human interferon‐gamma mRNA autoregulates its translation through a pseudoknot that activates the interferon‐inducible protein kinase PKR publication-title: Cell – volume: 44 start-page: 3208 year: 1984 end-page: 3214 article-title: Enhanced expression of surface tumor‐associated antigens on human breast and colon tumor cells after recombinant human leukocyte α‐interferon treatment publication-title: Cancer Res – volume: 17 start-page: S1 year: 1997 end-page: 55 article-title: A review of interferon immunogenicity publication-title: J Interferon Cytokine Res – volume: 87 start-page: 6934 year: 1990 end-page: 6938 article-title: Structural design and molecular evolution of a cytokine receptor superfamily publication-title: Proc Natl Acad Sci USA – volume: 2 start-page: 193 year: 2001 end-page: 202 article-title: Metastatic melanoma publication-title: Curr Treat Options Oncol – start-page: 430 year: 1981 end-page: 435 – volume: 271 start-page: 7635 year: 1996 end-page: 7639 article-title: A family of genes coding for two serologically distinct chicken interferons publication-title: J Biol Chem – volume: 89 start-page: 11317 year: 1992 end-page: 11321 article-title: Structural analysis of the human interferon gamma receptor: a small segment of the intracellular domain is specifically required for class I major histocompatibility complex antigen induction and antiviral activity publication-title: Proc Natl Acad Sci USA – volume: 252 start-page: 698 year: 1990 end-page: 702 article-title: Three dimensional structure of recombinant human initerferon‐γ publication-title: Science – volume: 261 start-page: 1744 year: 1993 end-page: 1746 article-title: A single phosphotyrosine residue of Stat91 required for gene activation by interferon‐γ publication-title: Science – volume: 84 start-page: 4151 year: 1987 end-page: 4155 article-title: Human chromosomes 6 and 21 are required for sensitivity to human interferon gamma publication-title: Proc Natl Acad Sci USA – volume: 41 start-page: 338 year: 1995 end-page: 344 article-title: Structure of the human CRFB4 gene: comparison with its IFNAR neighbor publication-title: J Mol Evol – volume: 454 start-page: 205 year: 1988 end-page: 215 article-title: Structural characterization of recombinant consensus interferon‐α publication-title: J Chromatogr – volume: 83 start-page: 384 year: 1986 end-page: 388 article-title: The gene for the human immune interferon receptor is located on chromosome 6 publication-title: Proc Natl Acad Sci USA – start-page: 3 year: 1986 end-page: 14 – volume: 50 start-page: 445 year: 1984 end-page: 450 article-title: Antiviral and protein‐inducing activities of recombinant human leukocyte interferons and their hybrids publication-title: J Virol – start-page: 10 year: 2001; end-page: 14 article-title: Regulation of neoplastic angiogenesis publication-title: J Natl Cancer Inst Monogr – volume: 76 start-page: 803 year: 1994 end-page: 810 article-title: A novel member of the interferon receptor family complements functionality of the murine interferon γ receptor in human cells publication-title: Cell – volume: 94 start-page: 11813 year: 1997 end-page: 11818 article-title: The crystal structure of human interferon β at 2.2‐Å resolution publication-title: Proc Natl Acad Sci USA – volume: 119 start-page: 541 year: 1986 end-page: 551 article-title: Measurement of interferon in human amniotic fluid and placental blood extract publication-title: Methods Enzymol – volume: 4 start-page: 1453 year: 1996 end-page: 1463 article-title: Zinc mediated dimer of human interferon‐α2b revealed by X‐ray crystallography publication-title: Structure – volume: 84 start-page: 443 year: 1996 end-page: 450 article-title: Targeted disruption of the mouse Stat1 gene results in compromised innate immunity to viral disease publication-title: Cell – volume: 207 start-page: 25 year: 1998 end-page: 32 article-title: Structure of the chicken interferon‐γ gene, and comparison to mammalian homologues publication-title: Gene – volume: 249 start-page: 36 year: 1983 end-page: 43 article-title: The purification and manufacture of human interferons publication-title: Sci Am – volume: 273 start-page: 3021 year: 1998 end-page: 3026 article-title: Interferon gamma activation of Raf‐1 is Jak1‐dependent and p21ras‐independent publication-title: J Biol Chem – volume: 6 start-page: 659 year: 2000 end-page: 666 article-title: Limitin: an interferon‐like cytokine that preferentially influences B‐lymphocyte precursors publication-title: Nat Med – volume: 77 start-page: 9622 year: 2003 end-page: 9631 article-title: Antiviral activity of limitin against encephalomyocarditis virus, herpes simplex virus, and mouse hepatitis virus: diverse requirements by limitin and alpha interferon for interferon regulatory factor 1 publication-title: J Virol – volume: 271 start-page: 32659 year: 1996 end-page: 32666 article-title: Mouse macrophages carrying both subunits of the human interferon‐gamma (IFN‐gamma) receptor respond to human IFN‐gamma but do not acquire full protection against viral cytopathic effect publication-title: J Biol Chem – volume: 276 start-page: 13756 year: 2001 end-page: 13761 article-title: Interferon alpha/beta promotes cell survival by activating nuclear factor kappa B through phosphatidylinositol 3‐kinase and Akt publication-title: J Biol Chem – volume: 40 start-page: 172 year: 1983 end-page: 176 article-title: Human interferon‐γ enhances the expression of class I and class II major histocompatibility complex products in neoplastic cells more effectively than interferon‐α and interferon‐β publication-title: Infect Immun – volume: 9 start-page: 155 year: 2001 end-page: 163 article-title: The structure and activity of a monomeric interferon‐γ: α‐chain receptor signaling complex publication-title: Structure (Camb) – volume: 267 start-page: 2802 year: 1992 end-page: 2809 article-title: The structure of the human interferon α/β receptor gene publication-title: J Biol Chem – volume: 96 start-page: 224 year: 1995 end-page: 230 article-title: Comparison of full‐length sequences of interferon‐sensitive and resistant hepatitis C virus 1b. Sensitivity to interferon is conferred by amino acid substitutions in the NS5A region publication-title: J Clin Invest – volume: 16 start-page: 366 year: 1993 end-page: 373 article-title: A new member of the cytokine receptor gene family maps on chromosome 21 at less than 53 kb from IFNAR publication-title: Genomics – start-page: 255 year: 1986 end-page: 260 – volume: 29 start-page: 900 year: 1973 end-page: 901 article-title: Molecular weight of virus‐induced tortoise interferon in cell cultures publication-title: Experientia – volume: 22 start-page: 1083 year: 2000 end-page: 1091 article-title: Immunomodulators in infectious diseases: panoply of possibilities publication-title: Int J Immunopharmacol – volume: 32 start-page: 1532 year: 1991 article-title: Phase I study of a new recombinant hybrid IFN (alpha1/alpha2) publication-title: Proc Am Soc Clin Oncol – volume: 58 start-page: S40 year: 2002 end-page: S48 article-title: Randomized controlled trails to assess therapies for multiple sclerosis publication-title: Neurology – volume: 230 start-page: 217 year: 1997 end-page: 227 article-title: Evidence that hepatitis C virus resistance to interferon is mediated through repression of the PKR protein kinase by the nonstructural 5A protein publication-title: Virology – volume: 89 start-page: 7836 year: 1992 end-page: 7839 article-title: Proteins of transcription factor ISGF‐3: one gene encodes the 91‐and 84‐kDa ISGF‐3 proteins that are activated by interferon α publication-title: Proc Natl Acad Sci USA – volume: 19 start-page: 319 year: 1999 end-page: 326 article-title: Antigenic characterization of recombinant, lymphoblastoid, and leukocyte IFN‐alpha by monoclonal antibodies publication-title: J Interferon Cytokine Res – volume: 44 start-page: 379 year: 2001 end-page: 382 article-title: Genetic polymorphism of the MxA gene promoter and interferon responsiveness of hepatitis C patients: revisited by analyzing two SNP sites (−123 and −88) in vivo and in vitro publication-title: Intervirology – volume: 167 start-page: 2060 year: 2001 end-page: 2067 article-title: Testosterone acts directly on CD4 T lymphocytes to increase IL‐10 production publication-title: J Immunol – volume: 258 start-page: 9706 year: 1983 end-page: 9709 article-title: Molecular weight of the functional unit of human leukocyte, fibroblast, and immune interferons publication-title: J Biol Chem – volume: 4 start-page: 85 year: 2003 end-page: 87 article-title: A dance between interferon‐alpha/beta and p53 demonstrates collaborations in tumor suppression and antiviral activities publication-title: Cancer Cell – volume: 82 start-page: 71 year: 1986 end-page: 104 article-title: Mechanisms of human beta‐interferon gene regulation publication-title: Harvey Lect – volume: 2 start-page: 186 year: 1982 end-page: 188 article-title: Prevention of rhinovirus colds by human interferon alpha‐2 from publication-title: Lancet – volume: 8 start-page: 927 year: 2000 end-page: 936 article-title: Observation of an unexpected third receptor molecule in the crystal structure of human interferon‐γ receptor complex publication-title: Structure Fold Des – volume: 61 start-page: 239 year: 2003 end-page: 251 article-title: Evolution of the interferon τ genes and their promoters, and maternal‐trophoblast interactions in control of their expression publication-title: Reprod Suppl – volume: 69 start-page: 8159 year: 1995 end-page: 8163 article-title: Molecular and functional characterization of turkey interferon publication-title: J Virol – start-page: 66 year: 2002 end-page: 68 article-title: Toll‐like receptor signaling and regulation of cytokine gene expression in the immune system publication-title: Biotechniques – volume: 92 start-page: 5401 year: 1995 end-page: 5405 article-title: Interferon gamma signals via a high‐affinity multisubunit receptor complex that contains two types of polypeptide chain publication-title: Proc Natl Acad Sci USA – volume: 376 start-page: 230 year: 1995 end-page: 235 article-title: Crystal structure of a complex between interferon‐γ and its soluble high‐affinity receptor publication-title: Nature – volume: 16 start-page: 260 year: 1997 end-page: 266 article-title: A protein‐arginine methyltransferase binds to the intracytoplasmic domain of the IFNAR1 chain in the type I interferon receptor publication-title: EMBO J – volume: 55 start-page: 273 year: 1988 end-page: 280 article-title: Molecular cloning and expression of the human interferon‐γ receptor publication-title: Cell – volume: 271 start-page: 13448 year: 1996 end-page: 13453 article-title: Differential responsiveness of a splice variant of the human type I interferon receptor to interferons publication-title: J Biol Chem – volume: 265 start-page: 1827 year: 1990 end-page: 1830 article-title: Expression and reconstitution of a biologically active human interferon‐gamma receptor in hamster cells publication-title: J Biol Chem – volume: 77 start-page: 391 year: 1994 end-page: 400 article-title: The human interferon α/β receptor: characterization and molecular cloning publication-title: Cell – volume: 276 start-page: 39765 year: 2001 end-page: 39771 article-title: Interferon‐κ, a novel type I interferon expressed in human keratinocytes publication-title: J Biol Chem – volume: 257 start-page: 11497 year: 1982 end-page: 11502 article-title: Specific molecular activities of recombinant and hybrid leukocyte interferons publication-title: J Biol Chem – volume: 274 start-page: 31531 year: 1999 end-page: 31542 article-title: The human homologue of the yeast proteins Skb1 and Hsl7p interacts with Jak kinases and contains protein methyltransferase activity publication-title: J Biol Chem – volume: 77 start-page: 7010 year: 1980 end-page: 7013 article-title: Construction and identification of bacterial plasmids containing nucleotide sequence for human leukocyte interferon publication-title: Proc Natl Acad Sci USA – volume: 60 start-page: 225 year: 1990 end-page: 234 article-title: Genetic transfer of a functional human interferon α receptor into mouse cells: cloning and expression of its cDNA publication-title: Cell – volume: 27 start-page: 235 year: 2002 end-page: 241 article-title: The SOCS box: a tale of destruction and degradation publication-title: Trends Biochem Sci – volume: 181 start-page: 839 year: 1995 end-page: 844 article-title: Role of interleukin 10 in the B lymphocyte hyperactivity and autoantibody production of human systemic lupus erythematosus publication-title: J Exp Med – volume: 22 start-page: 929 year: 2004 end-page: 979 article-title: Interleukin‐10 related cytokines receptors publication-title: Annu Rev Immunol – volume: 80 start-page: 779 year: 1998 end-page: 788 article-title: Interferon‐δ: the first member of a novel type I interferon family publication-title: Biochimie – volume: 94 start-page: 2246 year: 1999 end-page: 2250 article-title: Long‐term results with interferon therapy in chronic type B hepatitis: a prospective randomized trial publication-title: Am J Gastroenterol – volume: 10 start-page: 25 year: 1993 end-page: 29 article-title: Interferon treatment of human malignancies – a short review publication-title: Med Oncol Tumor Pharmacother – volume: 90 start-page: 8737 year: 1993 end-page: 8741 article-title: Identification of a yeast artificial chromosome clone encoding an accessory factor for the human interferon gamma receptor: evidence for multiple accessory factors publication-title: Proc Natl Acad Sci USA – volume: 56 start-page: 14 year: 2000 end-page: 24 article-title: The 2.0 A structure of bovine interferon‐γ; assessment of the structural differences between species publication-title: Acta Crystallogr D Biol – volume: 20 start-page: 1429 year: 2002 end-page: 1430 article-title: Unexpected toxicity of combination thalidomide and interferon alpha‐2a treatment in metastatic renal cell carcinoma publication-title: J Clin Oncol – ident: e_1_2_10_212_2 doi: 10.4049/jimmunol.166.12.7136 – ident: e_1_2_10_37_2 doi: 10.1016/0022-2836(85)90401-2 – ident: e_1_2_10_208_2 doi: 10.1073/pnas.83.2.384 – start-page: 362 volume-title: Methods in Enzymology year: 1981 ident: e_1_2_10_51_2 – ident: e_1_2_10_209_2 doi: 10.1007/BF01535312 – ident: e_1_2_10_215_2 doi: 10.1016/S1359-6101(02)00012-6 – volume: 279 start-page: 1 year: 1982 ident: e_1_2_10_28_2 article-title: Purification and characterization of murine and human interferons. A review of the literature of the 1970s publication-title: Acta Pathol Microbiol Immunol Scand Suppl – ident: e_1_2_10_202_2 doi: 10.1006/jmbi.1995.0544 – ident: e_1_2_10_104_2 doi: 10.1073/pnas.89.24.11706 – ident: e_1_2_10_50_2 doi: 10.1111/j.1749-6632.1980.tb20641.x – ident: e_1_2_10_159_2 doi: 10.1016/S0192-0561(00)00074-6 – volume: 265 start-page: 1827 year: 1990 ident: e_1_2_10_210_2 article-title: Expression and reconstitution of a biologically active human interferon‐gamma receptor in hamster cells publication-title: J Biol Chem doi: 10.1016/S0021-9258(19)39901-6 – ident: e_1_2_10_32_2 doi: 10.1073/pnas.77.10.5716 – ident: e_1_2_10_72_2 doi: 10.1073/pnas.84.12.4151 – ident: e_1_2_10_109_2 doi: 10.1074/jbc.M011006200 – volume: 61 start-page: 239 year: 2003 ident: e_1_2_10_183_2 article-title: Evolution of the interferon τ genes and their promoters, and maternal‐trophoblast interactions in control of their expression publication-title: Reprod Suppl – ident: e_1_2_10_15_2 doi: 10.1038/ni873 – ident: e_1_2_10_204_2 doi: 10.1006/jmbi.1998.2480 – ident: e_1_2_10_121_2 doi: 10.1073/pnas.111163898 – ident: e_1_2_10_89_2 doi: 10.1038/416744a – ident: e_1_2_10_3_2 doi: 10.1146/annurev.bi.56.070187.003455 – ident: e_1_2_10_85_2 doi: 10.1101/sqb.1999.64.465 – ident: e_1_2_10_137_2 doi: 10.1002/1097-0142(19870201)59:3 <664::AID-CNCR2820591316>3.0.CO;2-Y – ident: e_1_2_10_52_2 doi: 10.1016/S0021-9258(17)43764-1 – ident: e_1_2_10_179_2 doi: 10.1007/s004120050298 – ident: e_1_2_10_216_2 doi: 10.1081/PRG-120016788 – ident: e_1_2_10_189_2 doi: 10.1006/viro.1995.1522 – ident: e_1_2_10_31_2 doi: 10.1016/0003-9861(81)90194-6 – ident: e_1_2_10_157_2 doi: 10.1056/NEJM198601093140202 – ident: e_1_2_10_74_2 doi: 10.1073/pnas.89.16.7836 – ident: e_1_2_10_111_2 doi: 10.1074/jbc.273.5.3021 – ident: e_1_2_10_193_2 doi: 10.1038/287401a0 – ident: e_1_2_10_6_2 doi: 10.1016/0003-9861(83)90118-2 – ident: e_1_2_10_91_2 doi: 10.1016/0092-8674(94)90354-9 – volume: 2 start-page: 271 year: 1994 ident: e_1_2_10_163_2 article-title: Specific treatment of multiple sclerosis publication-title: Clin Neurosci – volume: 11 start-page: 39 year: 2000 ident: e_1_2_10_184_2 article-title: IFN‐κ, a novel type I interferon publication-title: Eur Cytokine Netw – ident: e_1_2_10_53_2 doi: 10.1002/ijc.2910310306 – ident: e_1_2_10_178_2 doi: 10.1074/jbc.271.13.7635 – ident: e_1_2_10_130_2 doi: 10.1089/107999003766628124 – ident: e_1_2_10_173_2 doi: 10.1089/107999099314018 – ident: e_1_2_10_132_2 doi: 10.1016/0006-291X(84)91625-5 – ident: e_1_2_10_165_2 doi: 10.1002/ana.410400606 – ident: e_1_2_10_119_2 doi: 10.1126/science.273.5282.1717 – ident: e_1_2_10_127_2 doi: 10.1073/pnas.79.10.3265 – ident: e_1_2_10_221_2 doi: 10.1016/0092-8674(88)90050-5 – ident: e_1_2_10_64_2 doi: 10.1073/pnas.91.13.5818 – volume: 267 start-page: 2802 year: 1992 ident: e_1_2_10_192_2 article-title: The structure of the human interferon α/β receptor gene publication-title: J Biol Chem doi: 10.1016/S0021-9258(18)45950-9 – start-page: 353 volume-title: The Biology of the Interferon System year: 1983 ident: e_1_2_10_61_2 – volume: 24 start-page: S9 year: 1997 ident: e_1_2_10_38_2 article-title: The human interferon‐α species and hybrid proteins publication-title: Semin Oncol – ident: e_1_2_10_211_2 doi: 10.1074/jbc.271.51.32659 – ident: e_1_2_10_17_2 doi: 10.1016/j.ygeno.2004.03.003 – ident: e_1_2_10_45_2 – ident: e_1_2_10_2_2 doi: 10.1098/rspb.1957.0048 – ident: e_1_2_10_9_2 doi: 10.1016/S0300-9084(99)80030-3 – ident: e_1_2_10_55_2 doi: 10.1016/0008-8749(82)90208-8 – ident: e_1_2_10_198_2 doi: 10.1007/s001090100206 – ident: e_1_2_10_136_2 doi: 10.1016/0192-0561(91)90128-T – ident: e_1_2_10_118_2 doi: 10.1016/S0968-0004(02)02085-6 – ident: e_1_2_10_158_2 doi: 10.1016/S0140-6736(82)91031-5 – ident: e_1_2_10_10_2 doi: 10.1016/0163-7258(91)90064-S – ident: e_1_2_10_149_2 doi: 10.1172/JCI118025 – ident: e_1_2_10_144_2 doi: 10.1023/A:1008335318764 – ident: e_1_2_10_35_2 doi: 10.1073/pnas.77.12.7010 – ident: e_1_2_10_78_2 doi: 10.1042/BJ20021935 – ident: e_1_2_10_224_2 doi: 10.1093/emboj/16.19.5894 – ident: e_1_2_10_16_2 – ident: e_1_2_10_22_2 doi: 10.1073/pnas.74.10.4415 – ident: e_1_2_10_100_2 doi: 10.1038/376230a0 – ident: e_1_2_10_145_2 doi: 10.1111/j.1572-0241.1999.01300.x – ident: e_1_2_10_195_2 doi: 10.1007/BF01946357 – start-page: 10 year: 2001 ident: e_1_2_10_134_2 article-title: Regulation of neoplastic angiogenesis publication-title: J Natl Cancer Inst Monogr – volume: 39 start-page: 377 year: 1992 ident: e_1_2_10_148_2 article-title: Interferon therapy for non‐A, non‐B hepatitis: a pilot study and review of the literature publication-title: Hepatogastroenterology – volume: 50 start-page: 445 year: 1984 ident: e_1_2_10_161_2 article-title: Antiviral and protein‐inducing activities of recombinant human leukocyte interferons and their hybrids publication-title: J Virol doi: 10.1128/jvi.50.2.445-450.1984 – ident: e_1_2_10_86_2 doi: 10.1038/sj.onc.1203524 – ident: e_1_2_10_218_2 doi: 10.1136/gut.50.2.191 – ident: e_1_2_10_14_2 doi: 10.1038/ni875 – ident: e_1_2_10_65_2 doi: 10.1016/S1359-6101(97)00009-9 – ident: e_1_2_10_146_2 doi: 10.1046/j.1440-1746.2000.02082.x – ident: e_1_2_10_217_2 doi: 10.4049/jimmunol.167.4.2060 – ident: e_1_2_10_133_2 doi: 10.1089/jir.1985.5.11 – ident: e_1_2_10_41_2 – ident: e_1_2_10_110_2 doi: 10.2144/Oct0207 – volume: 11 start-page: 25 year: 2004 ident: e_1_2_10_199_2 article-title: ISICR Committee Minutes publication-title: ISICR Newsletter – ident: e_1_2_10_122_2 doi: 10.1016/j.exphem.2003.08.011 – volume: 264 start-page: 16507 year: 1989 ident: e_1_2_10_20_2 article-title: Unusually large interferon‐alpha‐like mRNAs and high expression of interleukin‐6 in human fetal annexes publication-title: J Biol Chem doi: 10.1016/S0021-9258(19)84735-X – ident: e_1_2_10_68_2 doi: 10.1016/S0021-9258(17)32423-7 – ident: e_1_2_10_79_2 doi: 10.1128/JVI.77.17.9622-9631.2003 – ident: e_1_2_10_25_2 doi: 10.1016/S0079-6603(08)61004-1 – ident: e_1_2_10_95_2 doi: 10.1016/S0092-8674(00)81289-1 – ident: e_1_2_10_180_2 doi: 10.1089/107999001317205123 – ident: e_1_2_10_191_2 doi: 10.1073/pnas.87.18.6934 – volume: 10 start-page: 25 year: 1993 ident: e_1_2_10_142_2 article-title: Interferon treatment of human malignancies – a short review publication-title: Med Oncol Tumor Pharmacother doi: 10.1007/BF02987765 – volume-title: Topley and Wilson Microbiology and Microbial Infection ident: e_1_2_10_143_2 – ident: e_1_2_10_203_2 doi: 10.1073/pnas.94.22.11813 – ident: e_1_2_10_182_2 doi: 10.1016/S1074-7613(00)00077-7 – volume: 9 start-page: 242 year: 1999 ident: e_1_2_10_187_2 article-title: Comparative genomic analysis of the interferon/interleukin‐10 receptor gene cluster publication-title: Genome Res doi: 10.1101/gr.9.3.242 – volume: 16 start-page: 283 year: 1998 ident: e_1_2_10_220_2 article-title: Elevated interleukin‐10 levels correlated with disease activity in systemic lupus erythematosus publication-title: Clin Exp Rheumatol – ident: e_1_2_10_39_2 doi: 10.1038/scientificamerican0883-36 – ident: e_1_2_10_106_2 doi: 10.1074/jbc.M304531200 – ident: e_1_2_10_200_2 doi: 10.1016/S0969-2126(96)00152-9 – ident: e_1_2_10_181_2 doi: 10.1016/S1043-4666(03)00029-2 – ident: e_1_2_10_18_2 doi: 10.1002/mrd.1080260205 – ident: e_1_2_10_76_2 doi: 10.1146/annurev.bi.64.070195.003201 – ident: e_1_2_10_97_2 doi: 10.1111/j.1432-1033.1992.tb17248.x – ident: e_1_2_10_84_2 doi: 10.1016/S0952-7915(01)00305-3 – ident: e_1_2_10_164_2 doi: 10.1212/WNL.58.8_suppl_4.S40 – ident: e_1_2_10_120_2 doi: 10.1073/pnas.111164198 – start-page: 255 volume-title: Methods in Enzymology year: 1986 ident: e_1_2_10_63_2 – volume: 17 start-page: 1 year: 1973 ident: e_1_2_10_196_2 article-title: Interferon production in arbovirus‐infected cell cultures of tortoise (Testudo graeca) kidney publication-title: Acta Virol – ident: e_1_2_10_92_2 doi: 10.1016/0092-8674(94)90355-7 – volume: 17 start-page: S1 year: 1997 ident: e_1_2_10_171_2 article-title: A review of interferon immunogenicity publication-title: J Interferon Cytokine Res – ident: e_1_2_10_201_2 doi: 10.1006/jmbi.1997.1396 – start-page: 1279 volume-title: NK Cells and Other Natural Effector Cells year: 1982 ident: e_1_2_10_56_2 – ident: e_1_2_10_102_2 doi: 10.1016/S0969-2126(01)00567-6 – ident: e_1_2_10_175_2 doi: 10.1128/JVI.77.3.1992-2002.2003 – ident: e_1_2_10_46_2 doi: 10.1073/pnas.81.15.4926 – ident: e_1_2_10_135_2 doi: 10.1038/nrc905 – ident: e_1_2_10_150_2 doi: 10.1006/viro.1997.8493 – ident: e_1_2_10_108_2 doi: 10.1074/jbc.M105070200 – ident: e_1_2_10_71_2 doi: 10.1002/j.1460-2075.1995.tb00192.x – start-page: 315 volume-title: Biochemical Characterization of Lymphokines year: 1980 ident: e_1_2_10_47_2 – ident: e_1_2_10_214_2 doi: 10.1007/s00251-003-0580-y – ident: e_1_2_10_81_2 doi: 10.1074/jbc.275.17.12661 – ident: e_1_2_10_117_2 doi: 10.1126/science.278.5344.1803 – ident: e_1_2_10_169_2 doi: 10.1200/JCO.2004.10.952 – start-page: 430 volume-title: Methods in Enzymology year: 1981 ident: e_1_2_10_33_2 – ident: e_1_2_10_226_2 doi: 10.1006/geno.1993.1199 – ident: e_1_2_10_147_2 doi: 10.1002/hep.1840210307 – ident: e_1_2_10_98_2 doi: 10.1073/pnas.92.12.5401 – ident: e_1_2_10_26_2 doi: 10.1016/S0092-8674(02)00616-5 – ident: e_1_2_10_29_2 doi: 10.1126/science.725605 – ident: e_1_2_10_213_2 doi: 10.1099/0022-1317-77-6-1163 – volume: 6 start-page: 985 year: 1995 ident: e_1_2_10_129_2 article-title: Up‐regulation of a tumor‐associated antigen (TAG‐72) by interferons alpha and gamma in patients with cutaneous breast cancer recurrences publication-title: Int J Oncol – ident: e_1_2_10_228_2 doi: 10.1006/jmbi.2000.3734 – ident: e_1_2_10_11_2 doi: 10.1038/76233 – volume: 24 start-page: S9 year: 1997 ident: e_1_2_10_66_2 article-title: The interferon receptors publication-title: Semin Oncol – ident: e_1_2_10_36_2 – ident: e_1_2_10_87_2 doi: 10.1074/jbc.271.8.4134 – ident: e_1_2_10_162_2 doi: 10.1089/jir.1992.12.363 – ident: e_1_2_10_8_2 doi: 10.1146/annurev.biochem.67.1.227 – volume: 82 start-page: 71 year: 1986 ident: e_1_2_10_24_2 article-title: Mechanisms of human beta‐interferon gene regulation publication-title: Harvey Lect – ident: e_1_2_10_96_2 doi: 10.1016/S0171-2985(11)80562-0 – ident: e_1_2_10_190_2 doi: 10.1016/S0165-2427(97)00019-6 – ident: e_1_2_10_140_2 doi: 10.1385/MO:18:3:209 – ident: e_1_2_10_194_2 doi: 10.1099/0022-1317-28-2-259 – ident: e_1_2_10_167_2 doi: 10.1200/JCO.2002.20.5.1429 – ident: e_1_2_10_34_2 doi: 10.1016/0003-9861(81)90195-8 – ident: e_1_2_10_7_2 doi: 10.1002/1097-0282(2000)55:4<254::AID-BIP1001>3.0.CO;2-1 – ident: e_1_2_10_30_2 doi: 10.1073/pnas.76.2.640 – ident: e_1_2_10_27_2 doi: 10.1038/sj.embor.7400005 – ident: e_1_2_10_40_2 doi: 10.1006/geno.1994.1427 – ident: e_1_2_10_197_2 doi: 10.1016/S1359-6101(01)00009-0 – ident: e_1_2_10_115_2 doi: 10.1093/emboj/16.2.260 – volume: 44 start-page: 3208 year: 1984 ident: e_1_2_10_124_2 article-title: Enhanced expression of surface tumor‐associated antigens on human breast and colon tumor cells after recombinant human leukocyte α‐interferon treatment publication-title: Cancer Res – ident: e_1_2_10_227_2 doi: 10.1126/science.1902591 – ident: e_1_2_10_141_2 doi: 10.1006/scbi.2000.0315 – ident: e_1_2_10_225_2 doi: 10.1007/BF01215180 – ident: e_1_2_10_174_2 doi: 10.1016/S0378-1119(97)00600-8 – ident: e_1_2_10_170_2 doi: 10.1007/BF02678212 – start-page: 3 volume-title: Methods in Enzymology year: 1986 ident: e_1_2_10_5_2 – start-page: 66 year: 2002 ident: e_1_2_10_13_2 article-title: Toll‐like receptor signaling and regulation of cytokine gene expression in the immune system publication-title: Biotechniques doi: 10.2144/Oct0208 – volume: 11 start-page: 252 year: 1992 ident: e_1_2_10_59_2 article-title: Phase I study IFN alpha BDBB hybrid publication-title: Proc Am Soc Clin Oncol – ident: e_1_2_10_126_2 doi: 10.1126/science.3580039 – ident: e_1_2_10_160_2 doi: 10.1517/14712598.1.4.641 – ident: e_1_2_10_77_2 doi: 10.1146/annurev.immunol.22.012703.104622 – ident: e_1_2_10_99_2 doi: 10.1074/jbc.M909607199 – ident: e_1_2_10_83_2 doi: 10.4049/jimmunol.171.1.285 – ident: e_1_2_10_166_2 doi: 10.1016/S0092-8674(00)81288-X – start-page: 33 volume-title: Polypeptide Hormones. year: 1980 ident: e_1_2_10_48_2 – ident: e_1_2_10_70_2 doi: 10.1074/jbc.270.37.21606 – ident: e_1_2_10_93_2 doi: 10.1126/science.1281555 – volume: 258 start-page: 9706 year: 1983 ident: e_1_2_10_62_2 article-title: Molecular weight of the functional unit of human leukocyte, fibroblast, and immune interferons publication-title: J Biol Chem doi: 10.1016/S0021-9258(17)44554-6 – volume: 269 start-page: 18747 year: 1994 ident: e_1_2_10_69_2 article-title: Knockout and reconstitution of a functional human type I interferon receptor complex publication-title: J Biol Chem doi: 10.1016/S0021-9258(17)32231-7 – volume: 257 start-page: 11497 year: 1982 ident: e_1_2_10_54_2 article-title: Specific molecular activities of recombinant and hybrid leukocyte interferons publication-title: J Biol Chem doi: 10.1016/S0021-9258(18)33788-8 – ident: e_1_2_10_107_2 doi: 10.1038/ni1032 – ident: e_1_2_10_152_2 doi: 10.1159/000050075 – ident: e_1_2_10_131_2 doi: 10.1073/pnas.77.7.4099 – ident: e_1_2_10_154_2 doi: 10.1016/S0140-6736(88)92723-7 – ident: e_1_2_10_42_2 – ident: e_1_2_10_88_2 doi: 10.1007/BF03402135 – ident: e_1_2_10_139_2 doi: 10.1007/s11864-001-0033-5 – ident: e_1_2_10_172_2 doi: 10.1089/jir.1994.14.197 – ident: e_1_2_10_80_2 doi: 10.1126/science.1074900 – ident: e_1_2_10_207_2 doi: 10.1016/S1359-6101(97)00009-9 – ident: e_1_2_10_82_2 doi: 10.1074/jbc.271.14.8057 – ident: e_1_2_10_105_2 doi: 10.1074/mcp.M200065-MCP200 – ident: e_1_2_10_75_2 doi: 10.1073/pnas.89.16.7840 – ident: e_1_2_10_44_2 – ident: e_1_2_10_103_2 doi: 10.1073/pnas.89.23.11317 – volume: 11 start-page: 791 ident: e_1_2_10_230_2 article-title: The human type I initerferon receptor: NMR structure reveals the molecular basis of ligand binding publication-title: Structure doi: 10.1016/S0969-2126(03)00120-5 – ident: e_1_2_10_125_2 doi: 10.1016/0163-7258(85)90023-3 – ident: e_1_2_10_151_2 doi: 10.1099/0022-1317-73-3-673 – ident: e_1_2_10_60_2 doi: 10.1016/S0021-9673(00)88614-8 – ident: e_1_2_10_156_2 doi: 10.1177/019459988409200403 – ident: e_1_2_10_90_2 doi: 10.1073/pnas.90.18.8737 – ident: e_1_2_10_101_2 doi: 10.1016/S0969-2126(00)00184-2 – ident: e_1_2_10_114_2 doi: 10.1016/S1535-6108(03)00193-4 – ident: e_1_2_10_205_2 doi: 10.1074/jbc.271.23.13448 – ident: e_1_2_10_94_2 doi: 10.1126/science.7690989 – ident: e_1_2_10_21_2 doi: 10.1016/0076-6879(86)19074-4 – ident: e_1_2_10_222_2 doi: 10.1146/annurev.immunol.15.1.563 – ident: e_1_2_10_229_2 doi: 10.1107/S0907444999014304 – ident: e_1_2_10_138_2 doi: 10.1016/S0140-6736(02)08001-7 – ident: e_1_2_10_112_2 doi: 10.1128/MCB.17.7.3833 – ident: e_1_2_10_153_2 doi: 10.1016/0163-7258(94)00063-9 – ident: e_1_2_10_219_2 doi: 10.1084/jem.181.3.839 – ident: e_1_2_10_185_2 doi: 10.1002/j.1460-2075.1982.tb01277.x – ident: e_1_2_10_168_2 doi: 10.1159/000057631 – volume: 32 start-page: 1532 year: 1991 ident: e_1_2_10_58_2 article-title: Phase I study of a new recombinant hybrid IFN (alpha1/alpha2) publication-title: Proc Am Soc Clin Oncol – ident: e_1_2_10_12_2 doi: 10.1074/jbc.M102502200 – ident: e_1_2_10_206_2 doi: 10.1126/science.8197455 – ident: e_1_2_10_176_2 doi: 10.1186/1471-2164-4-29 – ident: e_1_2_10_177_2 doi: 10.1089/107999003322485107 – volume: 69 start-page: 8159 year: 1995 ident: e_1_2_10_188_2 article-title: Molecular and functional characterization of turkey interferon publication-title: J Virol doi: 10.1128/jvi.69.12.8159-8163.1995 – ident: e_1_2_10_67_2 doi: 10.1016/0092-8674(90)90738-Z – volume: 30 start-page: 693 year: 1985 ident: e_1_2_10_19_2 article-title: [Physicochemical and biological properties of human placental amniotic interferon] publication-title: Vopr Virusol – ident: e_1_2_10_57_2 doi: 10.1358/dof.1992.017.10.195933 – ident: e_1_2_10_73_2 doi: 10.1126/science.277.5332.1630 – ident: e_1_2_10_116_2 doi: 10.1074/jbc.274.44.31531 – ident: e_1_2_10_123_2 doi: 10.1046/j.1365-2141.2003.04650.x – ident: e_1_2_10_49_2 – ident: e_1_2_10_155_2 doi: 10.1089/jir.1995.15.625 – volume: 40 start-page: 172 year: 1983 ident: e_1_2_10_128_2 article-title: Human interferon‐γ enhances the expression of class I and class II major histocompatibility complex products in neoplastic cells more effectively than interferon‐α and interferon‐β publication-title: Infect Immun doi: 10.1128/iai.40.1.172-176.1983 – ident: e_1_2_10_23_2 doi: 10.1016/S0092-8674(85)80022-2 – ident: e_1_2_10_186_2 doi: 10.1038/298859a0 – ident: e_1_2_10_43_2 – ident: e_1_2_10_223_2 doi: 10.1016/0092-8674(94)90154-6 – start-page: 599 volume-title: Methods in Enzymology year: 1981 ident: e_1_2_10_4_2 – ident: e_1_2_10_113_2 doi: 10.1038/nature01850 |
| SSID | ssj0017324 |
| Score | 2.43361 |
| SecondaryResourceType | review_article |
| Snippet | Recombinant interferon‐α (IFN‐α) was approved by regulatory agencies in many countries in 1986. As the first biotherapeutic approved, IFN‐α paved the way for... Recombinant interferon-alpha (IFN-alpha) was approved by regulatory agencies in many countries in 1986. As the first biotherapeutic approved, IFN-alpha paved... Recombinant interferon- (IFN-) was approved by regulatory agencies in many countries in 1986. As the first biotherapeutic approved, IFN- paved the way for the... |
| SourceID | proquest pubmed crossref wiley istex |
| SourceType | Aggregation Database Index Database Enrichment Source Publisher |
| StartPage | 8 |
| SubjectTerms | Animals Evolution, Molecular Hepatitis, Viral, Human - drug therapy Humans Interferon Type I - physiology Interferon-alpha - physiology Interferon-gamma - physiology Interferons - genetics Interferons - isolation & purification Interferons - physiology Interferons - therapeutic use Molecular Structure Multiple Sclerosis, Relapsing-Remitting - drug therapy Protein Structure, Tertiary Receptors, Interferon - physiology Signal Transduction - physiology |
| Title | Interferons, interferon-like cytokines, and their receptors |
| URI | https://api.istex.fr/ark:/67375/WNG-72JKT0GB-4/fulltext.pdf https://onlinelibrary.wiley.com/doi/abs/10.1111%2Fj.0105-2896.2004.00204.x https://www.ncbi.nlm.nih.gov/pubmed/15546383 https://www.proquest.com/docview/17377146 https://www.proquest.com/docview/67083238 |
| Volume | 202 |
| hasFullText | 1 |
| inHoldings | 1 |
| isFullTextHit | |
| isPrint | |
| link | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwrV1NS-RAEC1EEbyo62d2Xc1BPBlJp7vTmaMu6yd6EEVvTXemAxLJyDgDuid_gr9xf4lVnUxkREHES0hDKiTdVV2vk9evADadMegXQkQS0ykuUAoRWYQFkchSXI0IITuGNgqfnqWHl-L4Wl43_CfaC1PrQ7Qf3Cgy_HxNAW7s_ViQU3HHCBcMnmlAItgJHglPEnWL8NF5qyTFFE9qme_GZIzU8_6NxjLVFHX6w3swdBzV-rS0Pwfl6IVqNkq5MxzYnfzfG63H73njeZht0Gu4W7vbD5hw1QJM1_UsHxehpjAWro-uvB3etI3_T8-3N6UL88dBrySe_XZoqm7of1KEOOW6O6r5swSX-38v_hxGTX2GKBeci4gXxiOcghU43co8zhy2skLhiBsW28yq1Eouu9YgKutahBMdleSCdWzBCbosw2TVq9wqhAmzqSQhGJ7HwqUuw9QqHZNdkQjLpAtAjcZC5414OdXQuNWvixjqHE2dQ6U1hfadox8CYK3lXS3g8QmbLT_crYHpl0SAU1JfnR1olRyfXMQHe1oEsDHyB41hSf9aTOV6w3uNDqcUZqGPr0gVol8ETAGs1I70-njEHOQZD0B6d_j0c-uj03M8-flFu18wM5KxjNkaTA76Q_cbIdfArvtgegEe-heb |
| linkProvider | Wiley-Blackwell |
| linkToHtml | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwrV1Lb9swDCaGBkN32aPdw-u6-lD0VBeWJVnOcR3Wpo_kUKRYb4LkyECQwCmyBGh66k_Yb9wvGSk7LlJ0QDH0YliAaUgUKX6UKBJg1xmDciFEJNGcooNSiMgiLIhElqI3IoRsG7oo3O2lnUtxeiWv6nJAdBemyg_RbLiRZvj1mhScNqRXtJyqO0boMfhQA8qCneATAWWLCnx7_-qiySXFFE-qRN81zUpYz-N_WrFVLWL7zWNAdBXXesN09AbGyyFV8Sijg_nMHuS3D7I9PtOY38LrGsCG3yqJewcvXLkBL6uSlotNqKIYCzdFad4Ph03jz93v8XDkwnwxm4wo1H4_NOUg9OcUIa667prK_ryHy6Mf_e-dqC7REOWCcxHxwniQU7ACV1yZx5nDVlYonHTDYptZlVrJ5cAaBGYDi4iirZJcsLYtOKGXD7BWTkr3CcKEWZy1hKc8j4VLXYbWVTomByIRlkkXgFpOhs7r_OVURmOs7_0YYo4m5lB1TaE9c_RNAKyhvK5yeDyBZs_Pd0NgpiOKgVNS_-wda5WcnvXj40MtAthZCoRGzaTjFlO6yfyXRolTCg3Rv79IFQJgxEwBfKwk6b57FDzIMx6A9PLw5H7rk-4Fvnz-T7odWO_0u-f6_KR3tgWvllktY_YF1mbTudtGBDazX71m_QWtORu2 |
| linkToPdf | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwrV1LT9wwEB4hEFUvLX2npSWHqieC4tiOs8fyWF5lVSFQuVl24kgoKLva7krQU38Cv5FfwoyTDdoKJIR6iWIpE8X2jOebePwNwFdnDOqFEJFEd4oBSikii7AgElmK0YgQsmfooPDRIN07FQdn8qzNf6KzMA0_RPfDjSzDr9dk4KOinDNyKu4YYcDgMw2IBDvBK-LJJZHGGWn49nFHJcUUTxqe71ZmLqvn_jfNuaolGvXL-3DoPKz1fqn_EqpZj5p0lGpjOrEb-Z9_yB7_T5dX4EULX8Pvjb69ggVXv4blpqDl1RtochhLN0ZdXg_Pu8bN3-uL88qF-dVkWFGi_Xpo6iL0uxQhrrluREV_3sJpf-dkay9qCzREueBcRLw0HuKUrMT1VuZx5rCVlQqn3LDYZlalVnJZWIOwrLCIJ3oqyQXr2ZITdnkHi_Wwdh8gTJhNJTHB8DwWLnUZ-lbpmCxEIiyTLgA1mwudt-zlVETjQt9FMTQ4mgaHamsK7QdHXwbAOslRw-DxCJlvfro7ATOuKANOSf1rsKtVcnB4Eu9uahHA2kwfNNolbbaY2g2nvzUqnFLohh5-IlUIfxExBfC-UaS7z6PUQZ7xAKRXh0d_t94_Osabj0-UW4NnP7f7-sf-4PATPJ9RWsZsFRYn46n7jPBrYr94u7oFRY0abg |
| openUrl | ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Interferons%2C+interferon%E2%80%90like+cytokines%2C+and+their+receptors&rft.jtitle=Immunological+reviews&rft.au=Pestka%2C+Sidney&rft.au=Krause%2C+Christopher+D.&rft.au=Walter%2C+Mark+R.&rft.date=2004-12-01&rft.issn=0105-2896&rft.eissn=1600-065X&rft.volume=202&rft.issue=1&rft.spage=8&rft.epage=32&rft_id=info:doi/10.1111%2Fj.0105-2896.2004.00204.x&rft.externalDBID=n%2Fa&rft.externalDocID=10_1111_j_0105_2896_2004_00204_x |
| thumbnail_l | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=0105-2896&client=summon |
| thumbnail_m | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=0105-2896&client=summon |
| thumbnail_s | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=0105-2896&client=summon |